Join Clinical trials for endocrine-disorders

All Categories Medical Conditions » Endocrine/Hormonal Disorders

Oxidative Stress and Bisphenol A (BPA) Impact With Polycystic Ovary Syndrome (PCOS)

Conditions: Oxidative Stress; Endocrine-Disrupting Chemicals; Polycystic Ovary Syndrome
Intervention:
Sponsors: Taipei Medical University WanFang Hospital; Ming-I Hsu
Recruiting - verified May 2012
The Genetic Investigation of Reproductive Disorders

Conditions: Kallmann Syndrome; Hypogonadotropic Hypogonadism; Hypothalamic Amenorrhea; Polycystic Ovarian Syndrome; Precocious Puberty
Intervention:
Sponsors: Centre Hospitalier Universitaire Vaudois; Centre Hospitalier Universitaire Vaudois; Swiss National Science Foundation
Recruiting - verified May 2012
Effects of 5-day Statin Withdrawal on Endothelial Progenitor Cells and Inflammatory Markers in Type 2 Diabetic Patients

Conditions: Type 2 Diabetes Mellitus; Atherosclerosis; Dyslipidemia
Intervention: Other: Statin withdrawal
Sponsors: University of Padova; University of Padova
Not yet recruiting - verified May 2012
The Association of Ferrtin and Homocysteine Etc. With RI and MS in Polycystic Ovary Syndrome (PCOS)

Condition: Polycystic Ovary Syndrome
Intervention:
Sponsors: Taipei Medical University WanFang Hospital; Taipei Medical University WanFang Hospital
Recruiting - verified May 2012
Veterans Service Organizations and MHV

Conditions: Hypertension; Hyperlipidemia; Coronary Artery Disease; Diabetes Mellitus
Intervention: Other: Education
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; The American Legion, Department of Wisconsin
Not yet recruiting - verified May 2012
Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections

Condition: Thyroid-associated Ophthalmopathy
Intervention: Drug: subconjunctival triamcinolone injection
Sponsors: Yonsei University; Yonsei University
Recruiting - verified May 2012
Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ)

Condition: Ovarian Cancer
Intervention: Drug: pazopanib in combination with weekly topotecan
Sponsors: Charite University, Berlin, Germany; JSehouli; GlaxoSmithKline
Not yet recruiting - verified May 2012
The Effect of Liraglutide on the Treatment of Coronary Artery Disease and Type 2 Diabetes

Conditions: Coronary Artery Disease; Diabetes Mellitus, Type 2
Interventions: Drug: Liraglutide; Drug: Placebo
Sponsors: Haugaard, Steen Bendix, M.D., DMSc; Haugaard, Steen Bendix, M.D., DMSc
Recruiting - verified May 2012
Exercise Study of Function and Pathology for Women With X-linked Adrenoleukodystrophy

Condition: X-linked Adrenoleukodystrophy
Intervention: Behavioral: exercise training
Sponsors: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; European Leukodystrophy Association
Recruiting - verified May 2012
Testing the Effect of the InsuPad Device in Daily Life Conditions

Conditions: Diabetics Mellitus Type 1; Diabetes Mellitus Type 2
Intervention: Device: InsuPad
Sponsors: Insuline Medical Ltd.; Insuline Medical Ltd.
Not yet recruiting - verified May 2012
EGF Ointment for Erlotinib Skin Lesion

Conditions: Non-small Cell Lung Cancer; Pancreatic Cancer
Intervention: Drug: Epidermal growth factor (EGF) ointment
Sponsors: Dong-A University Hospital; Dong-A University Hospital
Recruiting - verified May 2012
Mirtazapine Plus Gemcitabine Versus Gemcitabine in Metastasis Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: Mirtazapine plus gemcitabine; Drug: Gemcitabine, placebo
Sponsors: Tianjin Medical University Cancer Institute and Hospital; Tianjin Medical University Cancer Institute and Hospital
Not yet recruiting - verified May 2012
Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children

Condition: Pediatric Growth Hormone Deficiency
Interventions: Drug: MOD-4023; Drug: Somatropin
Sponsors: Prolor Biotech, Inc.; Prolor Biotech, Inc.
Recruiting - verified May 2012
Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE)

Condition: Proliferative Diabetic Retinopathy (PDR)
Interventions: Drug: Ranibizumab; Procedure: Laser photocoagulation; Procedure: Ranibizumab & laser photocoagulation
Sponsors: Novartis; Novartis Pharmaceuticals; Cologne Image Reading Center & Laboratory (CIRCL); Spranger Laboratories
Not yet recruiting - verified May 2012
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®

Conditions: Diabetic Retinopathy; HIV
Interventions: Drug: Tesamorelin; Drug: Placebo-Control
Sponsors: EMD Serono; EMD Serono
Not yet recruiting - verified May 2012
Induction Chemotherapy With Gemcitabine and Cisplatin Followed by CCRT for Unresectable Pancreatic Carcinoma

Condition: Pancreatic Carcinoma Non-resectable
Intervention: Radiation: Induction Chemotherapy with CCRT
Sponsors: National Cancer Center, Korea; National Cancer Center, Korea
Recruiting - verified May 2012
A Randomized, Double-blind, Placebo- and Active-controlled Study of the Electric Current Effects of ABT-639 on the Spontaneous Activity of Pain Sensory Receptors in Patients With Diabetic Peripheral Neuropathy.

Condition: Diabetic Neuropathic Pain
Interventions: Drug: ABT-639; Drug: Placebo; Drug: Lidocaine
Sponsors: Abbott; Abbott
Not yet recruiting - verified April 2012
Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer
Interventions: Other: Neuroimaging & Neuropsychological Evaluation; Other: Neuroimaging & Neuropsychological Evaluation
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Weill Medical College of Cornell University
Recruiting - verified May 2012
A Pilot Study on the Effects of ILARIS® on Patients With Proliferative Diabetic Retinopathy (PDRP)

Condition: Proliferative Diabetic Retinopathy
Intervention: Drug: CANAKINUMAB (ILARIS®)
Sponsors: Triemli Hospital; PD Dr. med. Stephan Michels; Novartis; Center for Clinical Research, University and University Hospital Zurich
Recruiting - verified April 2012
A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic Retinopathy

Condition: Proliferative Diabetic Retinopathy
Interventions: Drug: Macugen; Drug: Sham
Sponsors: Greater Houston Retina Research; Greater Houston Retina Research
Recruiting - verified April 2012
Pancreatic Tumor Cell Vaccine (GVAX), Low Dose Cyclophosphamide, Fractionated Stereotactic Body Radiation Therapy (SBRT), and FOLFIRINOX Chemotherapy in Patients With Resected Adenocarcinoma of the Pancreas

Condition: Pancreatic Cancer
Interventions: Drug: Cyclophosphamide; Biological: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1/GM-Neo vaccine; Radiation: Stereotactic Body Radiation (SBRT); Drug: FOLFIRINOX
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting - verified May 2012
Human Placental-Derived Stem Cell Transplantation

Conditions: Mucopolysaccharidosis I; Mucopolysaccharidosis VI; Adrenoleukodystrophy; Niemann-Pick Disease; Metachromatic Leukodystrophy; Wolman Disease; Krabbe's Disease; Gaucher's Disease; Fucosidosis; Batten Disease; Severe Aplastic Anemia; Diamond-Blackfan Anemia; Amegakaryocytic Thrombocytopenia; Myelodysplastic Syndrome; Acute Myelogenous Leukemia; Acute Lymphocytic Leukemia
Intervention: Drug: Human Placental Derived Stem Cell
Sponsors: New York Medical College; New York Medical College
Not yet recruiting - verified April 2012
Effect of Early Management on PAin and DEpression in Patients With PancreatoBiliary Cancer, EPADE-PB

Conditions: Pancreatic Cancer; Biliary Tract Cancer; Cancer Pain; Depression
Intervention: Other: Early Palliative care integrated with usual oncologic care
Sponsors: National Cancer Center, Korea; National Cancer Center, Korea
Recruiting - verified April 2012
Diagnosing Thyroid Cancer Using a Blood Test

Condition: Differentiated Thyroid Cancer
Intervention:
Sponsors: Newcastle-upon-Tyne Hospitals NHS Trust; Newcastle-upon-Tyne Hospitals NHS Trust
Recruiting - verified April 2012
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer

Conditions: brca1 Mutation Carrier; brca2 Mutation Carrier; Pancreatic Cancer
Interventions: Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: veliparib
Sponsors: National Cancer Institute (NCI); Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Not yet recruiting - verified April 2012
Pancreatic Enzyme Supplementation in Patients With Unresectable Pancreatic Cancer (PESUP)

Condition: Pancreatic Cancer
Intervention: Drug: Norzyme
Sponsors: National Cancer Center, Korea; National Cancer Center, Korea; Pharmbio Korea Co., Ltd.
Recruiting - verified April 2012
Cancer and Mindfulness-Based Cancer Recovery After Chemotherapy

Conditions: Cancer Survivor; Breast Cancer; Colorectal Cancer; Gynecological Cancer; Ovarian Cancer; Uterine Cancer
Intervention: Behavioral: Mindfulness Based Cancer Recovery
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Not yet recruiting - verified May 2012
A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer

Condition: Metastatic Pancreas Cancer
Interventions: Drug: 5FU, leucovorin, oxaliplatin; Drug: Gemcitabine
Sponsors: Alberta Health Services; Alberta Health Services
Not yet recruiting - verified April 2012
Ketoconazole as Inhibitor of the Enzyme CYP17 in Locally Advanced or Disseminated Granulosa Cell Tumour of Ovary

Condition: Granulosa Cell Tumour of the Ovary
Intervention: Drug: Ketoconazole
Sponsors: Grupo Español de Tumores Huérfanos e Infrecuentes; Grupo Español de Tumores Huérfanos e Infrecuentes
Not yet recruiting - verified April 2012
Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA)

Conditions: Cancer.; Melanoma.; Ovarian Cancer.; Lung Cancer.
Interventions: Biological: NY-ESO-1 combined with MPLA; Biological: NY-ESO-1 combined with MPLA vaccine
Sponsors: Instituto de Investigação em Imunologia; Instituto de Investigação em Imunologia; Butantan Institute
Not yet recruiting - verified April 2012
A Survivorship Care Plan for Gynaecological Cancer Patients

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Cervical Cancer; Endometrial Cancer; Esophageal Cancer; Fallopian Tube Cancer; Gastric Cancer; Ovarian Cancer; Sarcoma; Vaginal Cancer; Vulvar Cancer
Intervention:
Sponsors: Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of Surrey
Recruiting - verified April 2012
Treating Cancer With Anti-mesothelin Modified Lymphocytes

Conditions: Metastatic Cancer; Pancreatic Cancer; Mesothelioma
Interventions: Drug: Fludarabine; Drug: Cycolphosphamide; Biological: Aldesleukin
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012
FOLFIRINOX + RT for Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: FOLFIRINOX; Drug: Capecitabine; Radiation: Proton Radiation; Procedure: Surgery
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Cancer Institute (NCI)
Not yet recruiting - verified May 2012
Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Drug: vargatef; Drug: placebo
Sponsors: ARCAGY/ GINECO GROUP; ARCAGY/ GINECO GROUP
Not yet recruiting - verified April 2012
The ADHERENCE Index - the Indicator of Effective Coping With the Requirements of the Disease of Children and Adolescents With Type 1 Diabetes

Condition: Type 1 Diabetes
Intervention: Other: Observational study
Sponsors: Institution of Mother and Child, Warsaw, Poland; Institution of Mother and Child, Warsaw, Poland
Recruiting - verified April 2012
Renal Denervation in Diabetic Nephropathy

Conditions: Diabetic Nephropathy; Persistent Proteinuria With Type II Diabetes
Interventions: Procedure: Percutaneous renal denervation and TMNS; Drug: Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris
Not yet recruiting - verified March 2012
Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets

Conditions: Liver Cancer; Pancreatic Cancer
Interventions: Drug: FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin); Device: TheraSpheres
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Nordion (Canada) Inc.
Recruiting - verified April 2012
Effect of Bariatric Surgery "Digestive Adaptations III" on Cardiovascular Risk

Conditions: Diabetes Mellitus; Metabolic Syndrome; Obesity; Atherosclerosis
Intervention:
Sponsors: University of Sao Paulo; University of Sao Paulo; Fundação de Amparo à Pesquisa do Estado de São Paulo
Not yet recruiting - verified April 2012
PRevention of End Stage Kidney Disease by Darbepoetin Alfa In Chronic Kidney Disease Patients With nondiabeTic Kidney Disease

Conditions: Chronic Kidney Disease; Diabetes
Interventions: Drug: darbepoetin alfa; Drug: darbepoetin alfa
Sponsors: Translational Research Informatics Center, Kobe, Hyogo, Japan; Translational Research Informatics Center, Kobe, Hyogo, Japan; Showa University School of Medicine
Recruiting - verified April 2012
Phase Ib Trial of Folate Binding Protein Vaccine in Ovarian Cancer

Conditions: Ovarian Cancer; Endometrial Cancer
Interventions: Biological: E39 peptide vaccine; Other: Clinical tracking for disease progression/recurrence
Sponsors: San Antonio Military Medical Center; COL George Peoples, MD, FACS
Recruiting - verified April 2012
The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy

Conditions: Thyroid-associated Ophthalmopathy; Dry Eye Syndrome
Interventions: Drug: Methylprednisolone; Drug: Esomeprazole
Sponsors: Medical University of Vienna; Medical University of Vienna
Not yet recruiting - verified April 2012
Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer

Condition: Pancreatic Ductal Adenocarcinoma
Intervention: Drug: Doxorubicin-EMCH
Sponsors: CytRx; CytRx
Not yet recruiting - verified May 2012
An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease

Condition: Cushing's Disease
Intervention: Drug: Pasireotide sub-cutaneous formulation
Sponsors: Novartis; Novartis Pharmaceuticals
Available - verified April 2012
A Pilot Study of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes

Condition: Diabetic Nephropathies
Interventions: Drug: Allopurinol; Drug: Placebo
Sponsors: Joslin Diabetes Center; Alessandro Doria; Steno Diabetes Center; University of Michigan; University of Minnesota - Clinical and Translational Science Institute
Not yet recruiting - verified April 2012
Central Hypothyroidism and Cardiovascular Risk

Condition: Hypopituitarism
Intervention: Other: levothyroxine
Sponsors: Rigshospitalet, Denmark; Rigshospitalet, Denmark
Recruiting - verified April 2012
Impact of Sleep Apnea on Diabetic Foot Wound

Conditions: Diabetic Foot; Sleep Apnea
Intervention: Device: Positive airway pressure therapy
Sponsors: AGIR à Dom; AGIR à Dom
Recruiting - verified May 2012
Efficacy of Metformin and Diane-35 on PCOS Patients,a Randomized, Controlled, Prospective Clinical Trial

Conditions: Polycystic Ovary Syndrome; Insulin Resistance
Interventions: Drug: Metformin; Drug: Ethinylestradiol and Cyproterone Acetate
Sponsors: Chongqing Medical University; Chongqing Medical University
Recruiting - verified April 2012
A Glomerular Filtration Rate (GFR) Measuring Study of RTA 402 in Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes Mellitus

Conditions: Chronic Kidney Disease; Type 2 Diabetes
Intervention: Drug: RTA 402
Sponsors: Kyowa Hakko Kirin Company, Limited; Kyowa Hakko Kirin Company, Limited
Recruiting - verified May 2012
A Study of RTA 402 in Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes Mellitus

Conditions: Chronic Kidney Disease; Type 2 Diabetes
Intervention: Drug: RTA 402
Sponsors: Kyowa Hakko Kirin Company, Limited; Kyowa Hakko Kirin Company, Limited
Recruiting - verified April 2012
Investigation of Optimal Dosing Conditions for NN9924 in Healthy Male Subjects

Conditions: Diabetes; Diabetes Mellitus, Type 2; Healthy
Interventions: Drug: NN9924; Drug: NN9924; Drug: NN9924; Drug: NN9924; Drug: NN9924; Drug: NN9924; Drug: NN9924; Drug: NN9924
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2012
Radius Loading in Primary Hyperparathyroidism

Conditions: Hyperparathyroidism, Primary; Bone Diseases, Metabolic; Osteoporosis, Postmenopausal; Bone Loss, Postmenopausal
Interventions: Other: Forearm exercise program; Other: Walking program
Sponsors: Columbia University; Columbia University; National Institutes of Health (NIH); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified April 2012
Baseline Physiology Studies in Carriers of Gene Variant X Conferring Major Risk of CVD-prone Metabolic Disorders

Conditions: Hyperlipidemia; Diabetes Mellitus; Metabolic Syndrome; Arterial Hypertension; Obesity
Intervention: Other: first phase insulin secretion (FPIR), Hyperinsulinemic euglycemic clamp (HEC), glucose tracer, and palmitate tracer
Sponsors: University of Aarhus; University of Aarhus; Lundbeck Foundation; Aarhus University Hospital; Vejle Hospital; Sydvestjysk Hospital; Steno Diabetes Center; University of Copenhagen
Not yet recruiting - verified April 2012
Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema

Conditions: Diabetic Macular Edema.; Non-proliferative Diabetic Retinopathy; Proliferative Diabetic Retinopathy
Interventions: Drug: dexamethasone intravitreal implant; Drug: intravitreal bevacizumab
Sponsors: Retina Macula Institute; Retina Macula Institute; Allergan
Recruiting - verified April 2012
Phase 2 Study to Evaluate Safety & Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis

Conditions: Diabetes Mellitus; Diabetes Mellitus Complications; Gastroparesis
Interventions: Drug: RM-131; Drug: Placebo
Sponsors: Rhythm Pharmaceuticals, Inc.; Rhythm Pharmaceuticals, Inc.
Recruiting - verified May 2012
Anti-3-[18F]FACBC Imaging of Parathyroid Adenomas

Condition: Parathyroid Disease
Intervention: Drug: FACBC
Sponsors: Emory University; David M. Schuster, MD
Not yet recruiting - verified April 2012
A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effects of Residual Renal Function (RFF) in Patients With End-Stage Renal Disease and Type 2 Diabetes Mellitus on Peritoneal Dialysis

Conditions: End-Stage Renal Disease; Type 2 Diabetes Mellitus
Interventions: Drug: Bardoxolone Methyl 20 mg; Drug: Placebo
Sponsors: Reata Pharmaceuticals, Inc.; Reata Pharmaceuticals, Inc.
Not yet recruiting - verified April 2012
Study of Psychological and Motor Effects of Testosterone in Adolescents With XXY/Klinefelter Syndrome

Conditions: Klinefelter Syndrome; XXY Syndrome
Interventions: Drug: Testosterone gel 1%; Drug: Placebo gel
Sponsors: University of Colorado, Denver; University of Colorado, Denver; Colorado Clinical & Translational Sciences Institute; Children's Hospital Colorado; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified April 2012
Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors

Conditions: Acromegaly; Nonfunctioning Pituitary Tumor
Intervention:
Sponsors: Emory University; Emory University
Recruiting - verified March 2012
Effect of Sodium Bicarbonate on Urinary Markers of Renal Injury in Diabetic CKD

Conditions: Chronic Renal Insufficiency; Diabetes Mellitus
Interventions: Drug: Sodium bicarbonate; Drug: Placebo
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Not yet recruiting - verified April 2012
Evaluation of the Effect of Intensive Diabetes Control Through Non-Surgical Intensive Lifestyle Modifications and Weight Reduction on Diabetic Peripheral Neuropathy

Conditions: Diabetic Polyneuropathy; Weight Loss
Intervention: Other: Weight Achievement and Intensive Treatment (Why WAIT)
Sponsors: Joslin Diabetes Center; Joslin Diabetes Center; NeuroMetrix, Inc.
Not yet recruiting - verified March 2012
Change of Fructose to Fat in South Asians

Conditions: Elevated Triglycerides; Diabetes; Cardiovascular Disease; Dyslipidemia
Intervention: Other: Fructose + Glucose Beverage
Sponsors: The Rogosin Institute; The Rogosin Institute; Weill Medical College of Cornell University
Recruiting - verified March 2012
Effects of Purple Vegetables on Cardiovascular Disease (CVD) Risk Factors

Conditions: Hypertension; Hypercholesterolemia; Type II Diabetes; Obesity; Inflammation
Intervention: Other: vegetable
Sponsors: University of Guelph; University of Guelph; Ontario Ministry of Agriculture, Food and Rural Affairs
Not yet recruiting - verified March 2012
Clinical Evaluation Of Needle-based Confocal Laser Endomicroscopy in The Lymph Nodes Along With Masses and Cystic Tumors of the Pancreas

Conditions: Pancreatic Cyst; Pancreatic Neoplasms; Pancreatic Adenoma; Pancreatic Cancer; Pancreatic Islet Cell Tumors; Lymph Node; Lymphadenopathy
Interventions: Procedure: EUS-FNA; Device: nCLE
Sponsors: Mauna Kea Technologies; Mauna Kea Technologies
Not yet recruiting - verified May 2012
Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas

Condition: Pancreatic Cancer
Interventions: Drug: Oxaliplatin; Drug: Irinotecan; Drug: 5-FU; Drug: Gemcitabine; Radiation: Radiation Therapy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified March 2012
Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Disseminated Neuroblastoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Plasma Cell Neoplasm; Poor Prognosis Metastatic Gestational Trophoblastic Tumor; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Neuroblastoma; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage II Ovarian Epithelial Cancer; Stage II Ovarian Germ Cell Tumor; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Malignant Testicular Germ Cell Tumor; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Ovarian Epithelial Cancer; Stage III Ovarian Germ Cell Tumor; Stage III Small Lymphocytic Lymphoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Breast Cancer; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Small Lymphocytic Lymphoma
Interventions: Procedure: management of therapy complications; Procedure: musculoskeletal complications management/prevention
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Not yet recruiting - verified May 2012
Autologous T Cells Expressing Enhanced TCRs Specific for MAGEA3/A6/B18 or NYESO-1/LAGE in Patients With Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Biological: T cells; Biological: T cells
Sponsors: University of Pennsylvania; University of Pennsylvania; Roswell Park Cancer Institute; Adaptimmune Ltd.
Recruiting - verified April 2012
Double Bypass Versus Stent-treatment in Irresectable Pancreatic Cancer

Conditions: Pancreatic Cancer; Periampullary Tumor
Interventions: Procedure: Hepaticojejunostomy and gastroenterostomy; Procedure: Stent strategy
Sponsors: Göteborg University; Göteborg University
Recruiting - verified March 2012
A Clinical Trial to Study the Effects of GRC 17536 in Patients With Painful Diabetic Neuropathy (Painful Extremities Due to Peripheral Nerve Damage in Diabetic Patients)

Condition: Painful Diabetic Neuropathy
Interventions: Drug: GRC 17536; Drug: GRC 17536; Drug: Placebo
Sponsors: Glenmark Pharmaceuticals Ltd. India; Glenmark Pharmaceuticals Ltd. India; Glenmark Pharmaceuticals SA
Not yet recruiting - verified March 2012
The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
Interventions: Biological: TroVax®; Biological: Placebo
Sponsors: University College, London; University College, London; Oxford BioMedica; Cancer Research UK
Not yet recruiting - verified March 2012
Combination Therapy With Myo-inositol and Folic Acid Versus Myo-inositol Alone

Conditions: Polycystic Ovary Syndrome; Hirsutism; Menstrual Irregularity
Interventions: Drug: myo-inositol 1500 gr; Drug: myo-inositol 2000 gr + folic acid 200 mcg
Sponsors: Catholic University of the Sacred Heart; Catholic University of the Sacred Heart
Recruiting - verified March 2012
STA9090: Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer

Conditions: Pancreatic Cancer; Rectal Cancer
Intervention: Drug: capecitabine +ganetespib
Sponsors: Emory University; Emory University; Synta Pharmaceuticals Corp.
Not yet recruiting - verified March 2012
Prospective Study of Clinically Nonfunctioning Pituitary Adenomas

Conditions: Pituitary Adenoma; Pituitary Tumor
Intervention:
Sponsors: Columbia University; Columbia University; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified March 2012
Behavioral Activation Therapy for Rural Veterans With Diabetes and Depression

Conditions: Diabetes Mellitus; Depression
Interventions: Behavioral: Healthy Outcomes through Patient Empowerment (HOPE); Behavioral: Enhanced Usual Care
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Not yet recruiting - verified April 2012
Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes

Conditions: Renal Insufficiency, Chronic; Diabetes Mellitus, Type 2
Intervention: Drug: Bardoxolone Methyl
Sponsors: Reata Pharmaceuticals, Inc.; Reata Pharmaceuticals, Inc.
Recruiting - verified May 2012
Surgical Trial Comparing LIGASURE Assisted Recto-Sigmoid Resection and Omentectomy Compared to Stand

Condition: Epithelial Ovarian Cancer
Interventions: Other: Standard Surgical resection; Device: LIGASURE
Sponsors: University of Utah; University of Utah
Recruiting - verified March 2012
Pilot Assessment of the Effects of Bardoxolone Methyl on Renal Perfusion, Systemic Haemodynamics and Cardiac Function in Patients With Chronic Kidney Disease and Type 2 Diabetes

Conditions: Renal Insufficiency, Chronic; Diabetes Mellitus, Type 2
Intervention: Drug: Bardoxolone Methyl
Sponsors: Reata Pharmaceuticals, Inc.; Reata Pharmaceuticals, Inc.
Recruiting - verified May 2012
Evaluating the Dietary Supplement Anatabloc in Thyroid Health-ASAP (Antabloc Supplementation Autoimmune Prevention)

Condition: Thyroiditis, Autoimmune
Interventions: Dietary Supplement: Anatabloc Supplement; Dietary Supplement: Placebo
Sponsors: Rock Creek Pharmaceuticals, Inc.; Rock Creek Pharmaceuticals, Inc.
Recruiting - verified April 2012
Rapid, Non-invasive, Regional Functional Imaging of the Retina. (Diabetic Retinopathy Diagnosis Device)

Conditions: Diabetes; Retinal Disorders
Intervention:
Sponsors: University of California, Los Angeles; University of California, Los Angeles; Neuro Kinetics; Jules Stein Eye Institute; National Eye Institute (NEI)
Recruiting - verified March 2012
Empowering Primary Care Providers and Patients to Improve Chronic Disease Outcomes: The EMPOWER Participatory Action Research (EMPOWER - PAR)

Conditions: Hypertension; Type 2 Diabetes Mellitus
Intervention: Other: EMPOWER-PAR
Sponsors: Ministry of Health, Malaysia; Ministry of Health, Malaysia
Not yet recruiting - verified March 2012
Salvage Ovarian FANG Vaccine + Bevacizumab

Condition: Stage IIIC Ovarian Cancer
Interventions: Biological: FANG™ Vaccine; Drug: Bevacizumab
Sponsors: Gradalis, Inc.; Gradalis, Inc.
Recruiting - verified March 2012
Study to Evaluate MK-6096 in the Treatment of Painful Diabetic Neuropathy (PDN) in Adults (MK-6096-021)

Condition: Diabetic Neuropathy, Painful
Interventions: Drug: MK-6096; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012
Fallopian Tube Removal as a Method of Ovarian Cancer Prevention: A Descriptive Study

Condition: Ovarian Cancer
Intervention:
Sponsors: University of Washington; University of Washington
Recruiting - verified February 2012
Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic Cancer

Condition: Pancreatic Carcinoma.
Interventions: Drug: Gemzar; Drug: Revlimid
Sponsors: Karolinska University Hospital; Maria Liljefors; Karolinska University Hospital; Karolinska Institutet; Celgene Corporation
Recruiting - verified March 2012
Trial of Fenretinide/LXS Plus Ketoconazole in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma

Condition: Recurrent Ovarian Cancer
Intervention: Drug: Ketoconazole and HPR/LXS
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center; South Plains Oncology Consortium
Not yet recruiting - verified February 2012
Medico-economic Evaluation Comparing the Use of Ultrasonic Scissors to the Conventional Techniques of Haemostasis in Thyroid Surgery by Cervicotomy

Condition: Thyroid Tumor
Interventions: Device: Ultrasonic Scissors (Ethicon); Device: Bipolar Electrosurgical instruments (Medtronic) (SLS- Clips)
Sponsors: Nantes University Hospital; Nantes University Hospital
Recruiting - verified February 2012
Changes in Vitreous Temperature During Phacoemulsification

Condition: Proliferative Diabetic Retinopathy
Intervention: Device: Phacoemlsification
Sponsors: Asociación para Evitar la Ceguera en México; Asociación para Evitar la Ceguera en México
Recruiting - verified March 2012
Effect of DPP-IV Inhibitor on Glycemic Control and Autonomic Neuropathy in Adult Patients With Diabetes Mellitus

Condition: Type 2 Diabetes Mellitus
Intervention: Drug: Sitagliptin, 50 mg once per day per os
Sponsors: Nagaoka Red Cross Hospital; Nagaoka Red Cross Hospital
Recruiting - verified February 2012
Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 Diabetes

Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Technosphere Insulin Inhalation Powder; Drug: Rapid Acting Analog
Sponsors: Mannkind Corporation; Mannkind Corporation
Recruiting - verified May 2012
Saxagliptin and Atherosclerosis

Conditions: Coronary Artery Disease; Diabetes Mellitus Type 2
Interventions: Drug: Saxagliptin; Drug: Placebo
Sponsors: Oslo University Hospital; Oslo University Hospital
Recruiting - verified April 2012
Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Conditions: brca1 Mutation Carrier; brca2 Mutation Carrier; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: veliparib; Genetic: DNA analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Assessing the Efficacy and Safety of Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer

Condition: Stage IV Pancreatic Cancer
Intervention: Drug: Ascorbic Acid
Sponsors: Thomas Jefferson University; Thomas Jefferson University
Recruiting - verified March 2012
Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma

Condition: Pancreatic Cancer
Interventions: Drug: Placebo; Drug: Caprelsa (vandetanib)
Sponsors: University of Liverpool; University of Liverpool; AstraZeneca
Recruiting - verified May 2012
Acromegaly Combination Treatment Study

Condition: Acromegaly
Interventions: Drug: Pegvisomant; Drug: Somatostatin Receptor Ligand (SRL)
Sponsors: Cedars-Sinai Medical Center; Cedars-Sinai Medical Center
Recruiting - verified February 2012
Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) in Ovarian Cancer Recurrence

Condition: First Recurrence of Ovarian Cancer
Interventions: Procedure: Secondary citoreduction; Procedure: Hyperthermic intra-peritoneal chemotherapy (HIPEC)
Sponsors: Catholic University of the Sacred Heart; Catholic University of the Sacred Heart
Recruiting - verified February 2012
A Clinical Outcomes Study to Measure Reduction in Pain and Numbness During Administration of an Amino Acid Formulation in Subjects Diagnosed With Peripheral Neuropathy

Conditions: Diabetic Neuropathy; Chemotherapy Induced Neuropathy; HIV Neuropathy; Trauma Induced Neuropathy
Intervention: Drug: Neuron012703 (Medical Food)
Sponsors: Targeted Medical Pharma; Targeted Medical Pharma
Not yet recruiting - verified February 2012
Propranolol for Diabetic Retinopathy

Condition: Proliferative Diabetic Retinopathy
Intervention: Drug: Propranolol
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison
Recruiting - verified February 2012
Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery

Conditions: Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IV Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: vismodegib; Drug: sirolimus; Procedure: positron emission tomography; Procedure: computed tomography; Other: pharmacological study; Other: laboratory biomarker analysis; Radiation: fludeoxyglucose F 18
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified April 2012
Global SYMPLICITY Registry

Conditions: Hypertension; Diabetes Mellitus; Heart Failure; Chronic Kidney Disease; Sleep Apnea
Intervention: Device: Medtronic Renal Denervation System
Sponsors: Medtronic Vascular; Medtronic Vascular
Recruiting - verified April 2012
A Study to Evaluate the Efficacy and Safety of a Single Application of QUTENZA Compared to That of Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)

Conditions: Diabetic Peripheral Neuropathy; Pain
Interventions: Drug: QUTENZA; Drug: Placebo
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified May 2012
Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436

Condition: Papillary Thyroid Carcinoma
Intervention: Drug: GSK2118436
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; GlaxoSmithKline
Not yet recruiting - verified April 2012
Metabolic Efficiency of Combined Pancreatic Islet and Lung Transplant for the Treatment of End-Stage Cystic Fibrosis

Conditions: Cystic Fibrosis; Diabetes Related Cystic Fibrosis
Intervention: Procedure: Combined pancreatic islet and lung transplantation
Sponsors: University Hospital, Strasbourg, France; University Hospital, Strasbourg, France
Not yet recruiting - verified February 2012
Function of Regulatory T Cells Improved by Dexamethasone in Graves' Patients

Condition: Graves' Disease
Intervention: Drug: Dexamethasone
Sponsors: Nanjing Medical University; Xiao-Ming Mao
Recruiting - verified March 2012
Hydrocortisone Replacement in Patients With Secondary Adrenal Insufficiency (SUPREME CORT)

Condition: Adrenal Insufficiency
Intervention: Drug: Hydrocortisone
Sponsors: University Medical Centre Groningen; University Medical Centre Groningen
Recruiting - verified March 2012
Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer

Conditions: Ovarian Cancer; Cancer of Ovary; Cancer of the Ovary; Ovary Neoplasms; Primary Peritoneal Carcinoma
Intervention: Drug: Fenretinide/LXS + Ketoconazole
Sponsors: South Plains Oncology Consortium; South Plains Oncology Consortium
Recruiting - verified February 2012
Endoscopic Ultrasound (EUS) Guided Ethanol With Paclitaxel Ablation for Pancreatic Mucinous Cystic Neoplasm

Conditions: Mucinous Cystic Tumor With Moderate Dysplasia; Mucinous Cystadenoma of Pancreas; Mucinous Cystadenocarcinoma of Pancreas; Benign Neoplasm of Pancreas
Intervention: Drug: Ethanol and Paclitaxel Injection
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute; University of Western Ontario, Canada
Not yet recruiting - verified February 2012
Donor Atorvastatin Calcium in Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Donor Peripheral Blood Stem Cell Transplant

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Disseminated Neuroblastoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; High Risk Metastatic Gestational Trophoblastic Tumor; Juvenile Myelomonocytic Leukemia; Low Risk Metastatic Gestational Trophoblastic Tumor; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Plasma Cell Neoplasm; Previously Treated Childhood Rhabdomyosarcoma; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Gestational Trophoblastic Tumor; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Neuroblastoma; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Small Lymphocytic Lymphoma; Recurrent Wilms Tumor and Other Childhood Kidney Tumors; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage II Ovarian Epithelial Cancer; Stage II Ovarian Germ Cell Tumor; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Childhood Small Noncleaved Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Malignant Testicular Germ Cell Tumor; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Ovarian Epithelial Cancer; Stage III Ovarian Germ Cell Tumor; Stage III Small Lymphocytic Lymphoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Breast Cancer; Stage IV Childhood Hodgkin Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Childhood Small Noncleaved Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: atorvastatin calcium; Procedure: peripheral blood stem cell transplantation; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012
A Community Pharmacy-based Program to Improve Management of Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Behavioral: Community pharmacist-led diabetes education program; Other: Usual care
Sponsors: Tehran University of Medical Sciences; Tehran University of Medical Sciences; Research Center for Rational Use of Drugs
Recruiting - verified April 2012
Early Rehabilitation of Cancer Patients

Conditions: Breast Cancer; Colorectal Cancer; Lymphoma; Prostate Cancer; Testicle Cancer
Intervention: Other: Stressmanagement
Sponsors: Haukeland University Hospital; Haukeland University Hospital; University of Bergen; Uppsala University; University of Agder
Recruiting - verified January 2012
Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers

Conditions: Ovarian Cancer; Endometrial Cancer; Uterine Cervical Cancer
Interventions: Drug: Filgrastim; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Belgian Gynaecological Oncology Group; Belgian Gynaecological Oncology Group
Recruiting - verified March 2012
EUS-Guided ERCP Multicenter Registry

Conditions: Cholangiocarcinoma; Pancreatic Cancer; Bile Duct Cancer; Biliary Stricture; Biliary Obstruction; Stent Obstruction; Proximal Duct Stricture; Distal Duct Stricture; Ampullary Cancer; Biliary Sphincter Stenosis; Impacted Stones; Chronic Pancreatitis; Peri-ampullary Diverticula; Altered Anatomy
Intervention: Procedure: Endoscopic Ultrasound (EUS) guided Endoscopic retrograde cholangiopancreatography (ERCP)
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Recruiting - verified January 2012
A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study for the Pain of Diabetic Peripheral Neuropathy

Condition: Painful Diabetic Neuropathy
Interventions: Drug: SKL11197; Drug: Placebo
Sponsors: SK Life Science; SK Life Science
Recruiting - verified March 2012
Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1

Conditions: Metastatic Pancreatic Cancer; ERCC1
Intervention: Drug: gemcitabine and oxaliplatin
Sponsors: University of Hawaii; University of Hawaii
Recruiting - verified January 2012
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

Conditions: Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Adult Primary Hepatocellular Carcinoma; Chondrosarcoma; Clear Cell Sarcoma of the Kidney; Conjunctival Kaposi Sarcoma; Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; Hormone-resistant Prostate Cancer; Limited Stage Small Cell Lung Cancer; Localized Resectable Adult Primary Liver Cancer; Male Breast Cancer; Mast Cell Sarcoma; Ovarian Sarcoma; Recurrent Adult Brain Tumor; Recurrent Adult Primary Liver Cancer; Recurrent Adult Soft Tissue Sarcoma; Recurrent Bladder Cancer; Recurrent Breast Cancer; Recurrent Colon Cancer; Recurrent Esophageal Cancer; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Gastric Cancer; Recurrent Kaposi Sarcoma; Recurrent Melanoma; Recurrent Non-small Cell Lung Cancer; Recurrent Osteosarcoma; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Prostate Cancer; Recurrent Rectal Cancer; Recurrent Renal Cell Cancer; Recurrent Small Cell Lung Cancer; Recurrent Uterine Sarcoma; Small Intestine Leiomyosarcoma; Stage I Colon Cancer; Stage I Rectal Cancer; Stage I Uterine Sarcoma; Stage IA Breast Cancer; Stage IA Gastric Cancer; Stage IA Ovarian Epithelial Cancer; Stage IA Ovarian Germ Cell Tumor; Stage IB Breast Cancer; Stage IB Gastric Cancer; Stage IB Ovarian Epithelial Cancer; Stage IB Ovarian Germ Cell Tumor; Stage IC Ovarian Epithelial Cancer; Stage IC Ovarian Germ Cell Tumor; Stage II Breast Cancer; Stage II Uterine Sarcoma; Stage IIA Colon Cancer; Stage IIA Gastric Cancer; Stage IIA Non-small Cell Lung Cancer; Stage IIA Ovarian Epithelial Cancer; Stage IIA Ovarian Germ Cell Tumor; Stage IIA Rectal Cancer; Stage IIB Colon Cancer; Stage IIB Esophageal Cancer; Stage IIB Gastric Cancer; Stage IIB Melanoma; Stage IIB Non-small Cell Lung Cancer; Stage IIB Ovarian Epithelial Cancer; Stage IIB Ovarian Germ Cell Tumor; Stage IIB Rectal Cancer; Stage IIC Colon Cancer; Stage IIC Melanoma; Stage IIC Ovarian Epithelial Cancer; Stage IIC Ovarian Germ Cell Tumor; Stage IIC Rectal Cancer; Stage III Uterine Sarcoma; Stage IIIA Breast Cancer; Stage IIIA Colon Cancer; Stage IIIA Esophageal Cancer; Stage IIIA Gastric Cancer; Stage IIIA Melanoma; Stage IIIA Non-small Cell Lung Cancer; Stage IIIA Ovarian Epithelial Cancer; Stage IIIA Ovarian Germ Cell Tumor; Stage IIIA Rectal Cancer; Stage IIIB Breast Cancer; Stage IIIB Colon Cancer; Stage IIIB Esophageal Cancer; Stage IIIB Gastric Cancer; Stage IIIB Melanoma; Stage IIIB Ovarian Epithelial Cancer; Stage IIIB Ovarian Germ Cell Tumor; Stage IIIB Rectal Cancer; Stage IIIC Breast Cancer; Stage IIIC Colon Cancer; Stage IIIC Esophageal Cancer; Stage IIIC Gastric Cancer; Stage IIIC Melanoma; Stage IIIC Ovarian Epithelial Cancer; Stage IIIC Ovarian Germ Cell Tumor; Stage IIIC Rectal Cancer; Stage IV Bladder Cancer; Stage IV Esophageal Cancer; Stage IV Gastric Cancer; Stage IV Melanoma; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Prostate Cancer; Stage IV Renal Cell Cancer; Stage IV Uterine Sarcoma; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sirolimus; Other: laboratory biomarker analysis; Biological: DEC-205-NY-ESO-1 fusion protein vaccine
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified March 2012
Gondanatropin Levels in Puberty and Fertility

Conditions: Endocrine Disease; Infertility; Hypogonadism; Amenorrhea; Adolescents
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Massachusetts General Hospital, Boston, MA
Recruiting - verified November 2011
Retinal Adaptation to Intensified Insulin Therapy and Bariatric Surgery in Patients With Diabetes

Conditions: Diabetes Mellitus; Diabetic Retinopathy
Interventions: Other: Insulin pump; Other: Multiple daily insulin injections; Procedure: Bariatric surgery; Other: Medical therapy for type 2 diabetes
Sponsors: Glostrup University Hospital, Copenhagen; Glostrup University Hospital, Copenhagen
Recruiting - verified January 2012
Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer

Conditions: Metastatic Pancreatic Cancer; Pancreatic Cancer
Intervention: Drug: Folfirinox
Sponsors: Yale University; Yale University
Recruiting - verified January 2012
HELP-Apheresis in Diabetic Ischemic Foot Treatment (H.A.D.I.F)

Conditions: Foot Ulcers; Arteriosclerosis Obliterans; Diabetes Mellitus; LDL-apheresis
Intervention: Device: LDL-apheresis
Sponsors: Universita di Verona; Universita di Verona
Recruiting - verified February 2012
Comparison of Cilotax Stent and Everolimus -Eluting Stent With Diabetes Mellitus (ESSENCE-DM III)

Condition: Coronary Artery Disease
Interventions: Device: percutaneous coronary stenting implantation (Cilotax); Device: percutaneous coronary stenting implantation (Xience Prime)
Sponsors: CardioVascular Research Foundation, Korea; Duk-Woo Park; CARDIOTEC CO., LTD.
Recruiting - verified March 2012
Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma

Conditions: Primary Peritoneal Carcinoma; Ovarian Carcinoma; Fallopian Tube Carcinoma
Intervention: Drug: neoadjuvant chemotherapy
Sponsors: University of Kentucky; University of Kentucky
Recruiting - verified May 2012
Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer

Conditions: Pancreatic Neoplasms; Pancreatic Cancer
Intervention: Drug: Gemcitabine with escalating ascorbic acid
Sponsors: University of Iowa; University of Iowa; Susan L Bader Foundation of Hope; The Holden Comprehensive Cancer Center; The National Cancer Institute (NCI)
Not yet recruiting - verified May 2012
Eating Disorders in Type 1 Diabetes: Mechanisms of Comorbidity

Conditions: Type 1 Diabetes; Eating Disorder
Intervention:
Sponsors: Duke University; Duke University; National Institute of Diabetes & Digestive & Kidney Diseases
Recruiting - verified January 2012
Cvac as Maintenance Treatment in Patients With EOC in Complete Remission Following First-Line Chemotherapy

Condition: Epithelial Ovarian Cancer
Interventions: Biological: Placebo Study Agent; Biological: Cvac
Sponsors: Prima BioMed Ltd; Prima BioMed Ltd
Recruiting - verified May 2012
First Human Dose Trial of NNC0195-0092 in Healthy Subjects

Conditions: Adult Growth Hormone Deficiency; Growth Hormone Deficiency in Children; Healthy
Interventions: Drug: NNC0195-0092; Drug: placebo; Drug: NNC0195-0092; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified April 2012
A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Condition: Well-differentiated Pancreatic Neuroendocrine Tumor
Intervention: Drug: sunitinib
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified April 2012
Intra-op Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand

Condition: Ovarian Cancer
Intervention: Drug: EC-17
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified January 2012
Bioequivalence of Two Products (Norditropin® Versus Nutropin AQ®) in Healthy Adult Volunteers

Conditions: Growth Hormone Deficiency; Healthy
Interventions: Drug: somatropin; Drug: somatropin
Sponsors: Novo Nordisk; Novo Nordisk
Not yet recruiting - verified March 2012
Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable

Condition: Pancreatic Cancer
Interventions: Drug: Gemcitabine; Radiation: Radiotherapy; Drug: Tarceva; Drug: Oxaliplatin
Sponsors: Institut Català d'Oncologia; Institut Català d'Oncologia
Recruiting - verified February 2012
Prevalence of Peripheral Neuropathy in Children and Adolescents With Type I Diabetes Mellitus: a Prospective Study

Conditions: Diabetes Mellitus Type I; Diabetic Peripheral Neuropathy; Nerve Conduction Study Not Performed
Intervention:
Sponsors: Landeskrankenhaus Feldkirch; Landeskrankenhaus Feldkirch
Recruiting - verified January 2012
New Thyroid Fine Needle Aspiration Biopsy Apparatus

Condition: Thyroid Cancer
Intervention: Procedure: biopsy
Sponsors: SB Istanbul Education and Research Hospital; SB Istanbul Education and Research Hospital; Bezmialem Vakif University
Recruiting - verified January 2012
Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors

Conditions: Gastrinoma; Glucagonoma; Insulinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Recurrent Pancreatic Cancer; Somatostatinoma; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: temozolomide; Biological: bevacizumab
Sponsors: Stanford University; Stanford University; National Cancer Institute (NCI)
Not yet recruiting - verified January 2012
A Pilot Study of the Effects of Contrast Enhanced Endoscopic Ultrasound on Determining Vascular Involvement in Pancreatic Lesions

Condition: Pancreatic Tumors
Intervention: Drug: Definity Contrast
Sponsors: University of Vermont; University of Vermont
Not yet recruiting - verified February 2012
The Clinical and Laboratory Characteristics of Recurrent Drug- Related Hyponatremia

Conditions: Hyponatremia; SIADH
Intervention:
Sponsors: Hadassah Medical Organization; Hadassah Medical Organization
Not yet recruiting - verified January 2012
Healthy Eating for Reproductive Health (HERHealth)

Conditions: Polycystic Ovarian Syndrome; Infertility; Obesity; Overweight
Interventions: Behavioral: Low-fat, Low-Glycemic Index, Vegan diet; Behavioral: Low Calorie
Sponsors: University of South Carolina; University of South Carolina; American Dietetic Association
Recruiting - verified March 2012
A Study Using 18F-FAZA and PET Scans to Study Hypoxia in Pancreatic Cancer

Conditions: Pancreatic Cancer; Hypoxia
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Canadian Cancer Society
Recruiting - verified March 2012
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

Conditions: Metastatic Pancreatic Adenocarcinoma; Pancreatic Cancer; Metastatic Pancreatic Cancer
Intervention: Drug: 90Y-hPAM4
Sponsors: Immunomedics, Inc.; Immunomedics, Inc.
Recruiting - verified May 2012
A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment

Condition: Metastatic Pancreatic Cancer
Intervention: Drug: TL-118
Sponsors: Tiltan Pharma Ltd.; Tiltan Pharma Ltd.
Recruiting - verified February 2012
Integrated Molecular Profiling in Advanced Cancers Trial

Conditions: Breast Cancer; Non-small Cell Lung Cancer; Colorectal Cancer; Ovarian Cancer
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Princess Margaret Hospital, Canada
Recruiting - verified March 2012
Ferric Carboxymaltose in Type 2 Diabetes Mellitus (T2DM) Patients on Oral Antidiabetic Medication

Conditions: Type 2 Diabetes Mellitus (Non-insulin-dependent); Iron Deficiency Anemia
Interventions: Drug: ferric carboxymaltose; Drug: NaCl (0,9%)
Sponsors: GWT-TUD GmbH; GWT-TUD GmbH; Vifor Pharma
Not yet recruiting - verified May 2012
Asian Phase 2 Study for Treatment of Pain Associated With Diabetic Peripheral Neuorpathy

Conditions: Pain; Diabetic Peripheral Neuropathy
Interventions: Drug: DS-5565; Drug: DS-5565; Drug: DS-5565; Drug: Placebo; Drug: Pregabalin capsules
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Co., Ltd.
Recruiting - verified February 2012
Beta-Blocker / Ovarian

Conditions: Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer
Interventions: Drug: Propranolol; Drug: Chemotherapy; Procedure: Surgery; Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohorts in KRAS Wild Type Metastatic Colorectal and Pancreatic Cancer

Conditions: Advanced Solid Tumors; Metastatic Colorectal Cancer; Metastatic Pancreatic Cancer
Interventions: Drug: BKM120; Drug: mFOLFOX6
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center
Not yet recruiting - verified January 2012
A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer

Conditions: Advanced Adenocarcinoma; Metastatic Adenocarcinoma
Interventions: Drug: Hydroxychloroquine (HCQ); Drug: Gemcitabine
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified January 2012
A Clinical Trial of Tarceva(Erlotinib), Gemcitabine and Oxaliplatin Combination Chemotherapy in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer

Condition: Pancreatic Cancer
Intervention: Drug: Tarceva(Erlotinib), Gemcitabine, Oxaliplatin
Sponsors: Soonchunhyang University Hospital; Soonchunhyang University Hospital
Recruiting - verified January 2012
Inherited Reproductive Disorders

Conditions: Endocrine Diseases; Genetic Disorder; Infertility; Hypogonadism; Amenorrhea
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Massachusetts General Hospital
Recruiting - verified November 2011
Effect of the Adjunctive IVB Before PRP

Condition: Diabetic Retinopathy
Intervention: Drug: bevacizumab
Sponsors: Kyungpook National University; Kyungpook National University
Recruiting - verified January 2012
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Conditions: Recurrent Fallopian Tube Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Cavity Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Epithelial Cancer; Stage IIA Primary Peritoneal Cavity Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Epithelial Cancer; Stage IIB Primary Peritoneal Cavity Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Epithelial Cancer; Stage IIC Primary Peritoneal Cavity Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Epithelial Cancer; Stage IIIA Primary Peritoneal Cavity Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Epithelial Cancer; Stage IIIB Primary Peritoneal Cavity Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Epithelial Cancer; Stage IIIC Primary Peritoneal Cavity Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Primary Peritoneal Cavity Cancer
Interventions: Biological: ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine; Drug: sirolimus; Other: laboratory biomarker analysis; Biological: sargramostim
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer

Conditions: Head and Neck Cancer; Kidney Cancer; Liver Cancer; Sarcoma
Interventions: Drug: sorafenib tosylate; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Prospective Open-Label Pilot Clinical Study Evaluating the Efficacy of Paricalcitol On Erythropoietin Consumption in Calcitriol-Resistant Patients

Conditions: Stage 5 Chronic Kidney Diseases; Moderate to Severe Secondary Hyperparathyroidism
Intervention: Drug: Paricalcitol
Sponsors: Abbott; Abbott
Not yet recruiting - verified April 2012
A Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f® and Luveris® Starting on Day 1 Versus Day 6 in Women Undergoing Assisted Reproductive Technique

Conditions: Infertility; Fertility; Follicle Stimulating Hormone Deficiency
Interventions: Drug: Lutropin alfa; Drug: Lutropin alpha
Sponsors: Merck KGaA; Merck KGaA; Merck Serono Middle East FZ LLC
Not yet recruiting - verified December 2011
A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With Chronic Kidney Disease and Type 2 Diabetes

Conditions: Chronic Kidney Disease; Type 2 Diabetes
Interventions: Drug: 20 mg bardoxolone methyl; Drug: Placebo
Sponsors: Reata Pharmaceuticals, Inc.; Reata Pharmaceuticals, Inc.
Recruiting - verified February 2012
NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer

Condition: Pancreas Cancer
Interventions: Drug: Neoadjuvant chemotherapy; Procedure: surgery and Adjuvant chemotherapy
Sponsors: Institut Paoli-Calmettes; Institut Paoli-Calmettes
Recruiting - verified January 2012
Family Genetics Health Education and Healthy Behaviors

Conditions: Diabetes; Cancer; Heart Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified October 2011
Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma

Condition: Adrenocortical Carcinoma
Intervention: Drug: Dovitinib
Sponsors: Spanish Oncology Genito-Urinary Group; Spanish Oncology Genito-Urinary Group
Not yet recruiting - verified January 2012
Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial

Conditions: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma
Interventions: Drug: Paclitaxel(intravenous) + Carboplatin(intravenous); Drug: Paclitaxel(intravenous) + Carboplatin(intraperitoneal)
Sponsors: Gynecologic Oncology Trial & Investigation Consortium; Gynecologic Oncology Trial & Investigation Consortium; Japanese Gynecologic Oncology Group
Recruiting - verified January 2012
Hypoparathyroidism in Denmark

Condition: Hypoparathyroidism
Intervention:
Sponsors: University of Aarhus; University of Aarhus
Recruiting - verified March 2012
Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

Condition: Diabetic Peripheral Neuropathy
Interventions: Drug: DS-5565 tablet; Drug: pregabalin capsule; Drug: Placebo
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified March 2012
NEI Intramural Biorepository for Retinal Diseases

Conditions: Age-Related Macular Degeneration; Diabetic Retinopathy; Von Hippel-Lindau Syndrome; Retinal Disease; Retinal Vein Occlusion
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Eye Institute (NEI)
Recruiting - verified May 2012
Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy

Conditions: Fallopian Tube Cancer; Fatigue; Neuropathy; Neurotoxicity; Ovarian Cancer; Pain; Primary Peritoneal Cavity Cancer
Interventions: Dietary Supplement: acetyl-L-carnitine hydrochloride; Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel; Other: placebo
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified April 2012
Study of MM-398 Versus 5-Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer

Condition: Metastatic Pancreatic Cancer
Interventions: Drug: MM-398; Drug: 5 Fluorouracil; Drug: Leucovorin
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals
Recruiting - verified April 2012
The Effects of Sevelamer Carbonate on Diabetic Nephropathy

Condition: Diabetic Nephropathy
Interventions: Drug: Sevelamer Carbonate; Drug: calcium carbonate
Sponsors: Mount Sinai School of Medicine; Gary Striker
Not yet recruiting - verified December 2011
Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer

Conditions: Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Malignant Tumor of Peritoneum; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor
Interventions: Radiation: stereotactic body radiation therapy; Procedure: positron emission tomography; Procedure: computed tomography; Other: questionnaire administration; Radiation: fludeoxyglucose F 18
Sponsors: Stanford University; Stanford University
Recruiting - verified April 2012
Pilot Study of Meat-Borne Carcinogens and Pancreatic Cancer

Condition: Pancreatic Cancer
Intervention: Radiation: MeIQx
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Not yet recruiting - verified January 2012
Medtronic Treat to Range (TTR) Closed-Loop Control

Conditions: Diabetes Mellitus; Type 1 Diabetes; Metabolic and Nutritional Disorders
Intervention: Device: TTR controller (Medtronic)
Sponsors: Stanford University; Stanford University; Medtronic
Recruiting - verified December 2011
EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: EGEN-001; Drug: pegylated liposomal doxorubicin hydrochloride; Genetic: RNA analysis; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified April 2012
ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer

Condition: Metastatic Pancreatic Cancer
Intervention: Drug: Veliparib and 5-FU and Oxaliplatin and Leucovorin
Sponsors: Georgetown University; Georgetown University; Abbott
Recruiting - verified December 2011
A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy

Condition: Type 2 Diabetic Nephropathy
Interventions: Drug: PF-03882845; Drug: PF-03882845; Drug: PF-03882845; Drug: Spironolactone; Other: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

Condition: Proliferative Diabetic Retinopathy
Interventions: Other: Prompt Panretinal Photocoagulation; Drug: 0.5-mg Ranibizumab; Other: Deferred panretinal photocoagulation
Sponsors: Diabetic Retinopathy Clinical Research Network; Diabetic Retinopathy Clinical Research Network; National Eye Institute (NEI); Genentech
Recruiting - verified March 2012
Clinical Evaluation of NeoPlex4 Assay and NeoPlex System

Conditions: Adrenal Hyperplasia, Congenital; Congenital Hypothyroidism; Cystic Fibrosis
Intervention:
Sponsors: Luminex Molecular Diagnostics; Luminex Corporation
Recruiting - verified January 2012
Pathophysiological Implications of the Incretin Hormones in Patients With Liver Disease With and Without Diabetes

Conditions: Non Alcoholic Fatty Liver Disease; Type 2 Diabetes; Liver Cirrhosis
Interventions: Other: OGTT; Other: IIGI
Sponsors: University Hospital, Gentofte, Copenhagen; University Hospital, Gentofte, Copenhagen
Recruiting - verified December 2011
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients

Conditions: Type 2 Diabetes Mellitus; Chronic Kidney Disease
Interventions: Drug: CTP-499; Drug: Placebo
Sponsors: Concert Pharmaceuticals; Concert Pharmaceuticals
Recruiting - verified March 2012
Lipid Metabolic Status in Thyroid Carcinoma

Conditions: Thyroid Carcinoma; Dyslipidemias; Risk Reduction Behavior; Hormone Replacement
Intervention:
Sponsors: Prof. Dr. I. Chiricuta Institute of Oncology; Prof. Dr. I. Chiricuta Institute of Oncology; Iuliu Hatieganu University of Medicine and Pharmacy
Recruiting - verified December 2011
Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients

Condition: Pancreatic Cancer
Intervention: Drug: LDE225+gemcitabine
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer

Condition: Thyroid Cancer
Interventions: Drug: 300mg vandetanib; Drug: 150mg vandetanib
Sponsors: AstraZeneca; AstraZeneca
Not yet recruiting - verified April 2012
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer

Condition: Ovarian Cancer Recurrent
Interventions: Drug: EP-100; Drug: Paclitaxel
Sponsors: Esperance Pharmaceuticals Inc; Esperance Pharmaceuticals Inc
Recruiting - verified May 2012
VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer

Condition: Stage IV Pancreatic Cancer
Interventions: Biological: VXM01; Biological: Placebo
Sponsors: Vaximm GmbH; Vaximm GmbH
Recruiting - verified December 2011
Surgical Approach for Primary Hyperparathyroidism in the Elderly

Condition: Multigland Disease in Primary Hyperparathyroidism
Intervention: Procedure: unilateral neck exploration
Sponsors: Rambam Health Care Campus; Rambam Health Care Campus
Recruiting - verified December 2011
A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression

Condition: Ovarian Epithelial Carcinoma
Intervention: Drug: PD0332991
Sponsors: Jonsson Comprehensive Cancer Center; Jonsson Comprehensive Cancer Center
Recruiting - verified March 2012
LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer

Condition: Pancreatic Cancer
Intervention: Drug: LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Dana-Farber Cancer Institute
Recruiting - verified December 2011
Metformin and Transient Hyperglycemia

Conditions: Acute Lymphoblastic Leukemia; Hyperglycemia; Insulin Resistance; Diabetes Mellitus
Intervention: Drug: Metformin
Sponsors: Children's Hospital Los Angeles; Children's Hospital Los Angeles
Recruiting - verified December 2011
Understanding Patient Perspectives on the Risks of Ionizing Radiation Used for Medical Imaging

Conditions: Breast Cancer; Colon Cancer; Lung Cancer; Neuroblastoma; Testicular Cancer
Interventions: Behavioral: Focus Group Sessions; Behavioral: Focus Group Sessions; Behavioral: Focus Group Sessions; Behavioral: Focus Group Sessions; Behavioral: Focus Group Sessions; Behavioral: Focus Group Sessions
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012
Effect of Weight and Insulin Sensitivity on Reproductive Function in PCOS

Condition: Polycystic Ovary Syndrome
Interventions: Drug: Metformin; Behavioral: Dietary Restriction; Behavioral: Exercise Training
Sponsors: Pennington Biomedical Research Center; Pennington Biomedical Research Center; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified February 2012
A Clinical Trial for AMN: Validation of Biomarkers of Oxidative Stress, Efficacy and Safety of a Mixture of Antioxidants

Condition: Adrenomyeloneuropathy
Interventions: Drug: N-acetylcysteine; Drug: lipoic acid; Drug: vitamin E
Sponsors: Onofre, Aurora Pujol, M.D.; Onofre, Aurora Pujol, M.D.; Ministerio de Sanidad, Politica Social e Igualdad; Fundacion Hesperia
Recruiting - verified May 2012
Effects of N-acetylcysteine on Low T3 Syndrome

Conditions: Acute Myocardial Infarction; Euthyroid Sick Syndrome; Ischemic Heart Disease
Intervention: Drug: N-acetylcysteine
Sponsors: Federal University of Rio Grande do Sul; Federal University of Rio Grande do Sul; Hospital de Clinicas de Porto Alegre; Programa de pós-graduação em endocrinologia
Recruiting - verified December 2011
Evaluation of Clinical Outcomes and Costs of a Lifestyle Intervention in Obese Infertile Women

Conditions: Female Infertility; Polycystic Ovary Syndrome; Obesity
Intervention: Behavioral: Interdisciplinary lifestyle intervention
Sponsors: Universitaire de Sherbrooke; Universitaire de Sherbrooke; Fonds de la Recherche en Santé du Québec
Recruiting - verified November 2011
Pilot Study to Determine Effects of Salsalate in Type 1 Diabetes and Painful Peripheral Neuropathy

Conditions: Peripheral Neuropathy; Type 1 Diabetes
Intervention: Drug: Salsalate
Sponsors: University of Michigan; University of Michigan
Recruiting - verified December 2011
A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency

Condition: 21-hydroxylase Deficiency
Intervention: Drug: Abiraterone acetate
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified April 2012
Cinacalcet in Paediatric Secondary Hyperparathyroidism (SHPT) Due to Chronic Kidney Disease (CKD)

Condition: Secondary Hyperparathyroidism
Intervention: Drug: Cinacalcet HCl
Sponsors: Istituto Giannina Gaslini; ENRICO VERRINA
Recruiting - verified November 2011
A Study of Oral Rucaparib in Patients With gBRCA Mutation Breast or Ovarian Cancer, or Other Solid Tumor

Conditions: Metastatic Solid Tumor; Breast Cancer; Ovarian Cancer
Intervention: Drug: Rucaparib
Sponsors: Clovis Oncology, Inc.; Clovis Oncology, Inc.
Recruiting - verified May 2012
Intravitreal Ozurdex After Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy

Condition: Proliferative Diabetic Retinopathy
Interventions: Drug: Intravitreal dexamethasone implant; Procedure: Vitrectomy
Sponsors: St. Erik Eye Hospital; Anders Kvanta
Recruiting - verified November 2011
Vitrous Analysis in Proliferative Diabetic Retinopathy

Condition: Proliferative Diabetic Retinopathy
Intervention:
Sponsors: St. Erik Eye Hospital; Anders Kvanta
Recruiting - verified November 2011
A Study to Evaluate the Long-term Safety of Repeated QUTENZA Administration for Treatment of Pain Caused by Nerve Damage in Diabetic Patients

Condition: Painful Diabetic Peripheral Neuropathy (PDPN)
Intervention: Drug: QUTENZA
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified March 2012
Diffusion-weighted Imaging Study in Cancer of the Ovary

Conditions: Ovarian Cancer; Peritoneal Metastases
Intervention:
Sponsors: Institute of Cancer Research, United Kingdom; Institute of Cancer Research, United Kingdom; Cancer Research UK; Royal Marsden NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Imperial College Healthcare NHS Trust; Northumbria Healthcare NHS Foundation Trust
Not yet recruiting - verified March 2012
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer

Condition: Stage IV Pancreatic Cancer
Interventions: Drug: Gemcitabine; Drug: nab-paclitaxel; Drug: FOLFIRINOX; Genetic: Immunohistochemistry (IHC) Analysis; Drug: Metformin
Sponsors: Pancreatic Cancer Research Team; Pancreatic Cancer Research Team
Recruiting - verified March 2012
Step Monitoring to Improve ARTERial Health

Conditions: Type 2 Diabetes; Hypertension
Interventions: Behavioral: Step count prescription; Behavioral: Usual care
Sponsors: McGill University Health Center; McGill University Health Center; Canadian Institutes of Health Research (CIHR)
Recruiting - verified April 2012
Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505

Conditions: Type 2 Diabetes; Diabetes Mellitus, Type 2; Metabolic Diseases; Cardiovascular Diseases; Obese; Dyslipidemia
Interventions: Drug: GFT505 120mg - old formulation; Drug: GFT505 120mg - new formulation; Drug: GFT505 180mg - new formulation; Drug: GFT505 240mg - new formulation; Drug: GFT505 300mg - new formulation; Drug: Placebo
Sponsors: Genfit; Genfit; SGS Aster S.A.S.; NATURALPHA
Recruiting - verified January 2012
Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN)

Condition: Diabetic Peripheral Neuropathy
Interventions: Drug: Pregabalin; Other: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy

Condition: Painful Diabetic Neuropathies
Interventions: Genetic: Low Dose: 16 mg VM202; Genetic: High Dose: 32 mg VM202; Genetic: Placebo (Normal Saline)
Sponsors: ViroMed Co., Ltd.; ViroMed Co., Ltd.; VM Biopharma
Not yet recruiting - verified February 2012
Does Serum-DXM Increase Diagnostic Accuracy of the Overnight DXM Suppression Test in the Work-up of Cushing's Syndrome?

Conditions: Cushing's Syndrome; Adrenal Incidentalomas; Alcoholism; Obesity
Intervention:
Sponsors: Haukeland University Hospital; Haukeland University Hospital
Recruiting - verified May 2012
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Biological: ganitumab; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: oxaliplatin; Other: placebo; Other: questionnaire administration
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012
Glucose Counterregulation in Long Standing Type 1 Diabetes

Conditions: Hypoglycemia Unawareness; Type 1 Diabetes; Healthy
Intervention: Device: Real Time Continuous Glucose Monitor (RT-CGM)
Sponsors: University of Pennsylvania; University of Pennsylvania; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified November 2011
Improving Mental Health in Diabetes: A Guided Self-Help Study

Conditions: Type 2 Diabetes; Anxiety; Depression
Intervention: Behavioral: CBT-based Guided Self-Help
Sponsors: University of Edinburgh; University of Edinburgh
Not yet recruiting - verified November 2011
Comparison Between Two Fertility Protocols in Obese Polycystic Ovary Syndrome Patients

Conditions: Obese; Infertility; Polycystic Ovary Syndrome
Interventions: Procedure: IVM (In Vitro Maturation) Treatment; Procedure: IVF (In Vitro Fertilization) Antagonist Protocol
Sponsors: Hillel Yaffe Medical Center; Hillel Yaffe Medical Center
Not yet recruiting - verified April 2012
Longitudinal Study of Bone Disease in Children With Mucopolysaccharidoses (MPS) I, II, and VI

Condition: Mucopolysaccharidoses
Intervention:
Sponsors: University of Minnesota - Clinical and Translational Science Institute; Lynda Polgreen; Children's Hospital & Research Center Oakland; University of Utah
Recruiting - verified November 2011
Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema

Conditions: Diabetic Retinopathy; Macular Edema
Interventions: Drug: Ranibizumab; Drug: Ranibizumab
Sponsors: Retina Vitreous Associates of Florida; Retina Vitreous Associates of Florida; Genentech
Recruiting - verified November 2011
Prediction of Ovarian Malignancy in the Presence of Sonographic Pelvic Mass

Condition: Ovarian Neoplasm
Intervention:
Sponsors: HaEmek Medical Center, Israel; HaEmek Medical Center, Israel; Women and Infants Hospital of Rhode Island
Recruiting - verified November 2011
Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy

Conditions: Adenocarcinoma of the Pancreas; Metastatic Disease
Intervention: Drug: AUY922
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Novartis Pharmaceuticals
Not yet recruiting - verified January 2012
Geriatric Assessment and Nursing Telephone Intervention in Elderly Women With Ovarian Cancer

Conditions: Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer
Interventions: Behavioral: geriatric assessment and telephone call from nurse; Other: geriatric assessment and no call from nurse
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Condition: Pancreatic Cancer
Interventions: Drug: GS-6624; Drug: GS-6624; Drug: Placebo; Drug: Gemcitabine; Drug: Gemcitabine; Drug: Gemcitabine; Drug: Gemcitabine; Drug: GS-6624
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012
Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma

Condition: Pancreatic Cancer
Interventions: Drug: Chemotherapy; Drug: Chemotherapy and ChemoRadiotherapy
Sponsors: University of Florida; University of Florida
Recruiting - verified February 2012
Safety Study of Intranasal Insulin in Type 1 Diabetes and Diabetic Peripheral Neuropathy

Condition: Diabetic Peripheral Neuropathy
Interventions: Drug: Novolin Toronto insulin; Drug: Normal saline
Sponsors: University of Calgary; University of Calgary
Recruiting - verified November 2011
Insulin Resistance Before and During Pregnancy in Women With Polycystic Ovary Syndrome

Conditions: Polycystic Ovary Syndrome; Insulin Resistance; Insulin Sensitivity; Obesity; Pregnancy
Intervention:
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University; National Center on Minority Health and Health Disparities (NCMHD)
Recruiting - verified November 2011
Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel; Drug: pazopanib hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of DMOT4039A in Patients With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer

Conditions: Ovarian Cancer; Pancreatic Cancer
Intervention: Drug: DMOT4039A
Sponsors: Genentech; Genentech
Recruiting - verified April 2012
New Biomarkers Evaluating Ovarian Cancer

Condition: Adnexal Mass
Intervention:
Sponsors: Fujirebio Diagnostics, Inc.; Fujirebio Diagnostics, Inc.
Not yet recruiting - verified November 2011
Selenium Supplementation in Pregnancy

Conditions: Pregnancy; Infertility; Auto-immune Thyroiditis
Interventions: Dietary Supplement: Selenium; Other: Sugar Pill Placebo; Other: Selenium + L-Thyroxine (LT4); Other: Sugar Pill Placebo + L-Thyroxine (LT4)
Sponsors: University of Roma La Sapienza; University of Roma La Sapienza
Not yet recruiting - verified February 2012
Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation

Condition: Recurrent, Epithelial Ovarian Cancer
Intervention: Drug: Veliparib
Sponsors: Vejle Hospital; Vejle Hospital; Abbott
Recruiting - verified December 2011
The Reduced Thyroid Function of the Premature Newborn: Relation With Molecular Changes in the Placenta and Maternal Thyroid Hormone Status and Neurodevelopmental Implications

Condition: Thyroid Metabolism
Intervention:
Sponsors: Universitaire Ziekenhuizen Leuven; Universitaire Ziekenhuizen Leuven
Recruiting - verified July 2011
A Study to Evaluate the Safety and Tolerability of ABT-614 and Its Effect on Kidney Function in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Protein in Their Urine

Conditions: Type 2 Diabetics; Chronic Kidney Disease; Protein in Urine
Interventions: Drug: ABT-614; Drug: Placebo Comparator
Sponsors: Abbott; Abbott
Recruiting - verified December 2011
Dairy Lipids, Proteins, and the Metabolic Syndrome - "DairyHealth"

Conditions: Metabolic Syndrome; Type 2 Diabetes; Cardiovascular Disease; Abdominal Obesity
Interventions: Dietary Supplement: High content of SMC-SFA; Dietary Supplement: Whey; Dietary Supplement: Low content of SMC-SFA; Dietary Supplement: Casein
Sponsors: University of Aarhus; University of Aarhus; Aarhus University Hospital; Arla Foods; Wageningen University; University of Dublin, Trinity College
Recruiting - verified February 2012
Dietetic and Hygiene Measures in Metabolic Neuropathies: the Neurodiet Study

Conditions: Peripheral Nervous System Diseases; Diabetic Polyneuropathy; Metabolic Syndrome X
Interventions: Behavioral: hygienic-dietetic measures; Behavioral: hygienic-dietetic measures
Sponsors: Henri Mondor University Hospital; Henri Mondor University Hospital
Not yet recruiting - verified November 2011
Everolimus in Refractory Testicular Germ Cell Cancer

Condition: Germ Cell Tumor
Intervention: Drug: Everolimus
Sponsors: National Cancer Institute, Slovakia; National Cancer Institute, Slovakia
Recruiting - verified March 2012
Efficacy Of CACIPLIQ20 On Diabetic Ulcers In Patients Wearing An Nonremovable, Windowed, Fiberglass Cast Boot

Conditions: Foot Ulcer; Diabetes Mellitus; Diabetic Neuropathy
Interventions: Device: CACIPLIQ20 and Nonremovable, Windowed, Fiberglass Cast Boot; Device: Placebo and Nonremovable, Windowed, Fiberglass Cast Boot
Sponsors: Organ, Tissue, Regeneration, Repair and Replacement; Organ, Tissue, Regeneration, Repair and Replacement
Recruiting - verified November 2011
Copeptin as a Diagnostic Marker in the Management of Neurosurgical Patients With Disturbance of Water Homeostasis

Condition: Pituitary Adenoma
Intervention:
Sponsors: University Hospital, Basel, Switzerland; University Hospital, Basel, Switzerland; Kantonsspital Aarau
Recruiting - verified October 2011
Epidemiology of Ovarian Cancer in Taiwan

Condition: Ovarian Cancer
Intervention:
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital
Recruiting - verified April 2011
Evaluation of Optimal Initial Treatment Duration of Bevacizumab in Combination With Standard Chemotherapy in Patients With Ovarian Cancer

Conditions: Genital Diseases, Female; Ovarian Diseases; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms
Interventions: Biological: Bevacizumab; Biological: Bevacizumab; Drug: Paclitaxel; Drug: Carboplatin; Other: specialized pathology review (Germany only)
Sponsors: AGO Study Group; AGO Study Group; ARCAGY/ GINECO GROUP; Nordic Society for Gynaecologic Oncology
Recruiting - verified November 2011
Activity, Tolerability, Safety of Temsirolimus in Women With Ovarian Cancer Who Progressed During Previous Platinum Chemotherapy or Within 6 Months After Therapy or Advanced Endometrial Carcinoma

Conditions: Genital Diseases, Female; Ovarian Diseases; Ovarian Neoplasms; Endometrial Neoplasms
Intervention: Drug: Temsirolimus
Sponsors: AGO Study Group; AGO Study Group
Recruiting - verified March 2012
Efficacy Study of Neoadjuvant Chemotherapy to Treat Advanced Ovarian Cancer

Condition: Advanced Ovarian Cancer
Interventions: Drug: Neoadjuvant chemotherapy; Drug: Carboplatin
Sponsors: Asan Medical Center; Asan Medical Center; Sanofi-Aventis
Recruiting - verified October 2011
An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism

Conditions: Parathyroid Carcinoma; Hypercalcemia; Primary Hyperparathyroidism
Intervention: Drug: Cinacalcet HCl
Sponsors: Kyowa Hakko Kirin Company, Limited; Kyowa Hakko Kirin Company, Limited
Recruiting - verified November 2011
Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: Gemcitabine; Drug: Taxotere; Drug: Xeloda; Drug: Cisplatin
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified December 2011
Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Conditions: Carcinoid Tumor; Pancreatic Neuroendocrine Tumor
Intervention: Drug: Cabozantinib
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Not yet recruiting - verified November 2011
Effects of Hormone Stimulation on Brain Scans for Cushing's Disease

Condition: Pituitary Neoplasm
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified August 2011
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia

Conditions: Adult Acute Lymphoblastic Leukemia; Adult Acute Myeloid Leukemia; Adult Burkitt Lymphoma; Adult Diffuse Large Cell Lymphoma; Adult Diffuse Mixed Cell Lymphoma; Adult Diffuse Small Cleaved Cell Lymphoma; Adult Hodgkin Lymphoma; Adult Immunoblastic Large Cell Lymphoma; Adult Lymphoblastic Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Breast Cancer; Chronic Eosinophilic Leukemia; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Cutaneous T-cell Non-Hodgkin Lymphoma; Disseminated Neuroblastoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3 Follicular Lymphoma; Malignant Testicular Germ Cell Tumor; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Multiple Myeloma; Mycosis Fungoides/Sezary Syndrome; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Neutropenia; Nodal Marginal Zone B-cell Lymphoma; Ovarian Epithelial Cancer; Ovarian Germ Cell Tumor; Plasma Cell Neoplasm; Poor Prognosis Metastatic Gestational Trophoblastic Tumor; Primary Myelofibrosis; Prolymphocytic Leukemia; Small Lymphocytic Lymphoma; Splenic Marginal Zone Lymphoma
Intervention: Drug: cefepime hydrochloride
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified November 2011
Postoperative Proton Radiotherapy With Chemo for Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Radiation: Proton Therapy; Drug: Gemcitabine
Sponsors: University of Florida; University of Florida
Recruiting - verified March 2012
Testosterone and Alendronate in Hypogonadal Men

Conditions: Hypogonadism; Osteopenia; Osteoporosis
Interventions: Drug: Testosterone; Drug: Alendronate; Drug: Placebo Alendronate; Drug: Placebo Testosterone
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Endo Pharmaceuticals; Merck
Recruiting - verified March 2012
Comparison of Two Needles (ProCore vs EchoTip) for the Diagnosis of Pancreatic Solid Mass Under EUS

Conditions: Pancreatic Tumor; Fine Needle Aspiration; Endoscopic Ultrasonography
Intervention: Procedure: Puncture with fine needle aspiration under endoscopic ultrasonographic control
Sponsors: Société Française d'Endoscopie Digestive; VANBIERVLIET
Recruiting - verified October 2011
Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study)

Condition: Graves´ Disease
Interventions: Drug: Diclofenac; Drug: Methimazole; Drug: L-thyroxin; Drug: Propranolol; Drug: Metoprolol
Sponsors: Region Skane; Mikael Lantz
Recruiting - verified October 2011
An Open-Label, Multicenter, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies

Conditions: Malignant Solid Tumour; Breast Cancer; Ovarian Cancer; Colorectal Cancer
Intervention: Drug: NKTR-102
Sponsors: Nektar Therapeutics; Nektar Therapeutics
Available - verified April 2012
Surgical Complications Related to Primary or Interval Debulking in Ovarian Neoplasm

Condition: Stage IIIC Ovarian Cancer
Interventions: Procedure: Laparoscopy; Procedure: Cytoreduction
Sponsors: Catholic University of the Sacred Heart; Catholic University of the Sacred Heart
Recruiting - verified October 2011
Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: Neoadjuvant chemoradiation; Procedure: Upfront surgery
Sponsors: Seoul National University Hospital; Seoul National University Hospital
Recruiting - verified February 2012
Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery

Conditions: Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer
Interventions: Biological: ipilimumab; Drug: gemcitabine hydrochloride; Other: laboratory biomarker analysis
Sponsors: Northwestern University; Northwestern University; Robert H. Lurie Cancer Center
Not yet recruiting - verified November 2011
Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma

Condition: Adenocarcinoma Pancreas
Interventions: Other: Gemcitabine; Drug: CP-870,893
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Not yet recruiting - verified March 2012
Health Coaching to Effect Lifestyle Behaviour Change

Conditions: Prediabetes; Prehypertension
Intervention: Behavioral: Health Coaching
Sponsors: Memorial University of Newfoundland; Marshal Godwin; Canadian Institutes of Health Research (CIHR)
Not yet recruiting - verified October 2011
Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain

Condition: Painful Diabetic Peripheral Neuropathy
Interventions: Drug: pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Evaluation of Image-guided Brushing of Pancreatic Cyst Wall in Diagnosis of Cystic Pancreatic Tumors

Condition: Pancreatic Tumors
Interventions: Procedure: EUS Guided Fine Needle Aspiration; Procedure: EUS Guided EchoBrush Sampling
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; American Cancer Society
Recruiting - verified April 2012
Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018)

Conditions: Stage 5 Chronic Kidney Disease (CKD); Secondary Hyperparathyroidism (SHPT); Hemodialysis (HD)
Interventions: Drug: Lunacalcipol 180; Drug: Lunicalcipol 270
Sponsors: Cytochroma Inc.; Cytochroma Inc.
Not yet recruiting - verified October 2011
Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer

Condition: Stage IV Pancreatic Cancer
Interventions: Drug: Gemcitabine; Drug: PEGPH20+ gemcitabine
Sponsors: Halozyme Therapeutics; Halozyme Therapeutics
Recruiting - verified March 2012
Efficacy & Safety of ODSH (2-0, 3-0 Desulfated Heparin) in Patients With Metastatic Pancreatic Cancer Treated With Gemcitabine & Abraxane

Condition: Metastatic Pancreatic Cancer
Interventions: Drug: Abraxane ( Nab-paclitaxel); Drug: Abraxane ( Nab-paclitaxel); Drug: Gemcitabine; Drug: Gemcitabine; Drug: ODSH ( 2-O, 3-O Desulfated Heparin); Drug: ODSH ( 2-O, 3-O Desulfated Heparin); Drug: Abraxane ( nab-paclitaxel); Drug: Gemcitabine
Sponsors: ParinGenix; ParinGenix; TGen Drug Development Services
Recruiting - verified April 2012
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Conditions: CD27 Expressing B-cell Malignancies; CD27 Expressing Solid Tumors; Chronic Lymphocytic Leukemia; Burkett's Lymphoma; Mantle Cell Lymphoma; Primary Lymphoma of the Central Nervous System; Marginal Zone B Cell Lymphoma; Solid Tumor; Metastatic Melanoma; Renal (Clear) Cell Carcinoma; Hormone-refractory Prostate Adenocarcinoma; Ovarian Cancer; Colorectal Adenocarcinoma; Non-small Cell Lung Cancer
Intervention: Drug: CDX-1127
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2012
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis

Conditions: Gastroparesis; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: 10mg TZP-102; Drug: 20mg TZP-102
Sponsors: Tranzyme, Inc.; Tranzyme, Inc.
Recruiting - verified April 2012
Study of Individualized Selection of Chemotherapy in Patients With Advanced Pancreatic Carcinoma According to Therapeutic Targets

Condition: Advanced Pancreatic Carcinoma
Interventions: Drug: gemcitabine, or gemcitabine and capecitabine, or gemcitabine and erlotinib, or FOLFIRINOX, or FOLFOX, or FOLFIRI.; Drug: Gemcitabine, Gemcitabine-Capecitabine, Gemcitabine-Erlotinib, FOLFOXIRI, FOLFOX, FOLFIRI
Sponsors: Centro Nacional de Investigaciones Oncologicas CARLOS III; Centro Nacional de Investigaciones Oncologicas CARLOS III; Hospital Universitario Fuenlabrada; Apices Soluciones S.L.; Grupo Hospital de Madrid
Recruiting - verified April 2012
Study To Assess the Dietary Carbohydrate Content of Indian Diabetic Population

Conditions: Metabolic Disease; Diabetes Mellitus
Interventions: Other: No drug; Other: No drug
Sponsors: Bayer; Bayer
Not yet recruiting - verified May 2012
Vitamin E δ-Tocotrienol Multiple Dose in Healthy Subjects

Condition: Pancreatic Cancer
Intervention: Drug: Vitamin E δ-Tocotrienol
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI); BioGene Life Science
Recruiting - verified March 2012
Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: pegylated liposomal doxorubicin hydrochloride; Drug: veliparib
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Acupuncture to Treat Insulin Resistance in Women With and Without Polycystic Ovary Syndrome

Conditions: Polycystic Ovary Syndrome; Insulin Resistance
Intervention: Other: Acupuncture
Sponsors: Göteborg University; Göteborg University
Recruiting - verified October 2011
Metabolomic Embryo Profiles of Obese in Vitro Fertilization (IVF) Patients and Their Relationship With Polycystic Ovary Syndrome (PCO)

Conditions: Infertility; Obesity
Intervention: Other: Culture medium metabolomic analysis
Sponsors: Instituto Valenciano de Infertilidad, Spain; Instituto Valenciano de Infertilidad, Spain
Recruiting - verified February 2012
Salusin-alpha - a New Factor in the Pathogenesis of Lipid Abnormalities in Hemodialysis Patients

Conditions: Renal Failure Chronic Requiring Hemodialysis; Metabolic Syndrome; Diabetes Mellitus Type 2; Hyperlipidemia
Intervention: Drug: Atorvastatin
Sponsors: Poznan University of Medical Sciences; Poznan University of Medical Sciences
Recruiting - verified October 2011
Cinacalcet Versus Parathyroidectomy in Peritoneal Dialysis Patients

Conditions: Kidney Failure; Secondary Hyperparathyroidism; Vascular Diseases
Intervention: Drug: Cinacalcet
Sponsors: The University of Hong Kong; The University of Hong Kong
Recruiting - verified October 2011
A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy

Conditions: Diabetic Nephropathy; Type 2 Diabetes Mellitus
Interventions: Drug: Placebo; Drug: CCX140-B; Drug: CCX140-B
Sponsors: ChemoCentryx; ChemoCentryx
Recruiting - verified May 2012
Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

Conditions: Pancreatic Alpha Cell Carcinoma; Pancreatic Beta Islet Cell Carcinoma; Pancreatic Delta Cell Carcinoma; Pancreatic G-cell Carcinoma; Recurrent Islet Cell Carcinoma
Interventions: Drug: temozolomide; Drug: pazopanib hydrochloride
Sponsors: Northwestern University; Northwestern University; Robert H. Lurie Cancer Center; National Comprehensive Cancer Network; GlaxoSmithKline
Recruiting - verified November 2011
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers

Conditions: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
Interventions: Drug: MM-121 (SAR256212) + Paclitaxel; Drug: Paclitaxel
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals; Sanofi-Aventis
Recruiting - verified May 2012
Matrix Metalloproteinases in Atherosclerosis of Chronic Kidney Disease

Condition: Diabetic Nephropathy
Intervention:
Sponsors: Aristotle University Of Thessaloniki; Aristotle University Of Thessaloniki; AHEPA University Hospital
Not yet recruiting - verified September 2011
Predictors of Tumor Response and of Radiation Therapy Side Effects in Patients With Gastrointestinal Cancers

Conditions: Esophageal Cancer; Stomach Cancer; Pancreatic Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified May 2012
PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)

Conditions: Choroidal Neovascularization; Diabetic Retinopathy; Diabetic Macular Edema
Interventions: Drug: PF-04523655 (Stratum I); Drug: PF-04523655 and ranibizumab; Drug: ranibizumab; Drug: PF-04523655 (Stratum II)
Sponsors: Quark Pharmaceuticals; Quark Pharmaceuticals
Recruiting - verified April 2012
AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer

Conditions: Breast Cancer; Ovarian Cancer
Interventions: Drug: AZ2281; Drug: Carboplatin
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2011
Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199

Conditions: Fallopian Tube Cancer; Hereditary Breast/Ovarian Cancer (brca1, brca2); Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Other: medical chart review; Other: study of socioeconomic and demographic variables; Procedure: disease screening; Procedure: evaluation of cancer risk factors; Procedure: genitourinary surgical procedure; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified September 2011
Assessing the Risk of Developing Type II Diabetes Using Serum Biomarkers in Patients Diagnosed With Obstructive Sleep Apnea

Conditions: Obstructive Sleep Apnea; Diabetes Mellitus
Intervention: Behavioral: PreDx Diabetes Risk Score
Sponsors: Mike O'Callaghan Federal Hospital; Mike O'Callaghan Federal Hospital
Recruiting - verified April 2012
Counterregulatory Hormone Production in Adrenal Insufficiency and Diabetes Type I

Conditions: Addison's Disease; Adrenal Insufficiency; Diabetes Mellitus Type I
Intervention: Procedure: Spiroergometry
Sponsors: University of Wuerzburg; University of Wuerzburg
Recruiting - verified October 2011
Pharmacokinetics of Hydrocortisone After Subcutaneous Administration in Chronic Adrenal Insufficiency

Condition: Primary Adrenal Insufficiency
Interventions: Drug: Hydrocortisone intramuscular first; Drug: Hydrocortisone subcutaneously first
Sponsors: University of Wuerzburg; Bruno Allolio
Not yet recruiting - verified October 2011
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: Paclitaxel; Drug: AMG 386 Placebo; Drug: Carboplatin
Sponsors: Amgen; Amgen
Recruiting - verified April 2012
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Conditions: Anemia; Breast Cancer; Cancer; Colorectal Cancer; Lung Cancer; Ovarian Cancer; Prostate Cancer; Solid Tumors
Intervention:
Sponsors: Amgen; Amgen
Recruiting - verified April 2012
ABC294640 in Treating Patients With Advanced Solid Tumors

Conditions: Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Drug: sphingosine kinase-2 inhibitor ABC294640
Sponsors: Medical University of South Carolina; Medical University of South Carolina; Apogee Biotechnology Corporation; National Cancer Institute (NCI)
Recruiting - verified November 2011
Vitamin E δ-Tocotrienol (VEDT) Single Dose in Healthy Subjects

Condition: Pancreatic Cancer
Intervention: Drug: Vitamin E δ-Tocotrienol
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI); BioGene Life Science
Recruiting - verified March 2012
Genome-wide Association Study of Pituitary Tumors

Condition: Pituitary Adenomas
Intervention:
Sponsors: Huashan Hospital; Huashan Hospital
Recruiting - verified September 2011
Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer

Conditions: Cancer of Pancreas; Cancer of the Pancreas; Neoplasms, Pancreatic; Pancreas Cancer; Pancreas Neoplasms
Interventions: Drug: Folfirinox; Radiation: Stereotactic Body Radiotherapy (SBRT)
Sponsors: Emory University; Emory University
Recruiting - verified April 2012
Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers

Condition: Growth Hormone Deficiency
Interventions: Drug: Somatropin; Drug: Placebo
Sponsors: HanAll BioPharma Co., Ltd.; HanAll BioPharma Co., Ltd.
Recruiting - verified September 2011
Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment

Conditions: Malignant Struma Ovarii; Papillary Thyroid Cancer; Hurthle Cell Thyroid Cancer; Follicular Thyroid Cancer; Tall Cell Variant Thyroid Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified August 2011
Collection of Blood From Cancer Patients for Genetic Analysis

Conditions: Prostate Cancer; Breast Cancer; Lung Cancer; Ovarian Cancer; Lymphoma
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Not yet recruiting - verified March 2012
Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer

Conditions: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma
Intervention: Procedure: Acute Normovolemic Hemodilution
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012
Safety and Tolerability of Cinacalcet in Pediatric Subjects With Chronic Kidney Disease and Secondary Hyperparathyroidism

Conditions: Chronic Kidney Disease; Hyperparathyroidism, Secondary
Intervention: Drug: Cinacalcet HCl
Sponsors: Amgen; Amgen
Not yet recruiting - verified September 2011
A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria

Conditions: Diabetic Nephropathy; Type 2 Diabetes Mellitus
Interventions: Drug: Placebo; Drug: CCX140-B
Sponsors: ChemoCentryx; ChemoCentryx
Recruiting - verified September 2011
The Effects of Work Schedule and Sleep Patterns on Caregivers' Health

Conditions: Obesity; Diabetes; Cancer; Metabolic Syndrome; Sleep Deprivation
Intervention:
Sponsors: Oregon Health and Science University; Oregon Health and Science University
Not yet recruiting - verified September 2011
FES-PET to Determine ER-expression in Epithelial Ovarian Cancer

Condition: Epithelial Ovarian Cancer
Intervention: Other: Diagnostic intervention: Positron Emission Tomography with 16-alpha-[18-fluoro]-17betaestradiol
Sponsors: University Medical Centre Groningen; University Medical Centre Groningen
Recruiting - verified September 2011
Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient-Controlled Analgesia For Liver and/or Pancreas

Conditions: Liver Cancer; Pancreatic Cancer
Interventions: Procedure: Intravenous Patient-Controlled Analgesia (IVPCA); Procedure: Thoracic Epidural Analgesia (TEA); Behavioral: Questionnaires; Behavioral: Pain Assessment
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
A Prospective Phase I Study of Cyclotron-produced Tc-99m Pertechnetate (CPERT) in Patients With Thyroid Cancer

Condition: Thyroid Neoplasms
Interventions: Drug: CPERT; Drug: GPERT
Sponsors: Alberta Health Services; Alberta Health Services; Natural Resources, Canada; Edmonton PET Centre
Recruiting - verified April 2012
TKM 080301 for Primary or Secondary Liver Cancer

Conditions: Colorectal Cancer With Hepatic Metastases; Pancreas Cancer With Hepatic Metastase; Gastric Cancer With Hepatic Metastase; Breast Cancer With Hepatic Metastase; Ovarian Cancer With Hepatic Metastase
Intervention: Drug: TKM-080301
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified February 2012
Ex Vivo Evaluation of the Interest of the Association of Platinum With a Molecule BH3-mimetic ABT-737 in Samples of Ovarian Tumors

Condition: Ovarian Cancer
Intervention: Other: culture ex vivo with exposure to different therapeutic agents alone or in combination.
Sponsors: Centre Francois Baclesse; Centre Francois Baclesse; GRECAN
Recruiting - verified May 2012
Nexium Capsules Clinical Experience Investigation

Condition: Gastric Ulcer, Duodenal Ulcer, Anastomotic Ulcer, Reflux Oesophagitis,"Non-erosive Reflux Disease, Zollinger-Ellison Syndrome
Intervention:
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified April 2012
Safety of Active Immunotherapy in Subjects With Ovarian Cancer

Condition: Ovarian Epithelial Cancer
Interventions: Biological: Procure; Biological: Procure
Sponsors: Life Research Technologies GmbH; Life Research Technologies GmbH
Recruiting - verified October 2011
Prospective Follow-up of a Cohort of Pre-diabetics in the North of France (DiabeNord)

Condition: Prediabetes
Intervention: Other: Prediabetes screening and prospective follow-up over 5 years
Sponsors: Genfit; Genfit
Recruiting - verified September 2011
Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin

Conditions: Pancreatic Neoplasms; Cholangiocarcinoma
Intervention: Drug: Gemcitabine with TheraSphere
Sponsors: Emory University; Hyun Kevin Kim; Emory University
Recruiting - verified April 2012
Studying Biomarkers in Samples From Younger Patients With Malignant Germ Cell Tumor Progression

Conditions: Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Ovarian Cancer; Testicular Germ Cell Tumor
Interventions: Genetic: DNA methylation analysis; Genetic: mutation analysis; Genetic: nucleic acid sequencing; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: medical chart review
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified September 2011
Mindfulness-based Personalized Health Planning for Reducing Risk Factors of Heart Disease and Diabetes

Condition: Prediabetes
Interventions: Behavioral: Lifestyle Intervention; Behavioral: Structured and Guided Education
Sponsors: Duke University; Duke University; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified December 2011
Safety and Efficacy Study of Ultrasonic Coagulation Device and Bipolar Energy Sealing System

Condition: Thyroid Cancer
Interventions: Device: Ultrasonic coagulation device (Harmonic ACE); Device: bipolar energy sealing system (LigaSure Precise)
Sponsors: Seoul St. Mary's Hospital; Seoul St. Mary's Hospital
Recruiting - verified March 2012
Value of 25 Mcg Cortrosyn Stimulation Test

Condition: Adrenal Insufficiency
Interventions: Procedure: ACTH stimulation test; Procedure: 250 ug ACTH stimulation test; Procedure: 25 ug Cortrosyn stimulation test; Procedure: Insulin tolerance test; Procedure: 1 ug cortrosyn test
Sponsors: The Cleveland Clinic; The Cleveland Clinic
Recruiting - verified March 2012
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Conditions: Febrile Neutropenia; Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Prostate Cancer; Multiple Myeloma; Bladder Cancer; B-cell Lymphoma
Intervention:
Sponsors: Sandoz; Sandoz
Recruiting - verified October 2011
Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone in Hyperandrogenemic Adolescent Girls

Conditions: Polycystic Ovary Syndrome; Hyperandrogenism
Interventions: Drug: Metformin; Drug: Progesterone; Drug: estrace
Sponsors: University of Virginia; University of Virginia; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified August 2011
Suppression of Daytime and Nighttime Luteinizing Hormone Frequency by Progesterone in Early Pubertal Girls With and Without Hyperandrogenemia

Conditions: Polycystic Ovary Syndrome; Hyperandrogenism
Interventions: Drug: Progesterone; Drug: Placebo
Sponsors: University of Virginia; University of Virginia; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified August 2011
Effects of Vitamin D on Renal Blood Flow, Proteinuria and Inflammation in Patients With Chronic Kidney Disease

Conditions: Chronic Kidney Disease; Secondary Hyperparathyroidism
Intervention: Drug: Contrast Enhanced Ultrasonography
Sponsors: University of Virginia; University of Virginia
Recruiting - verified January 2012
Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone

Conditions: Polycystic Ovary Syndrome; Hyperandrogenism
Interventions: Drug: Flutamide; Drug: Progesterone; Drug: estrace (estradiol)
Sponsors: University of Virginia; University of Virginia; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified September 2011
Mifepristone for Metabolic Syndrome

Conditions: Endocrine Disease; Diabetes
Intervention: Drug: Mifepristone
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified June 2011
18 Fluoro-deoxy-glucose Positrons Emission Tomography Combined With Computed Tomography (18-FDG TEP-CT ) in the Diagnosis of the Degeneration of Intraductal Papillary Mucinous Tumor of the Pancreas

Condition: Tumor
Intervention: Other: 18 fluoro-deoxy-glucose positrons emission tomography combined with computed tomography
Sponsors: Nantes University Hospital; Nantes University Hospital
Recruiting - verified August 2011
Fractional Urate Excretion in Nonedematous Hyponatremia

Conditions: Cerebral Hyponatremia; SIADH; Cerebral Salt-wasting Syndrome; Reset Hypothalamic Osmostat
Intervention: Drug: Tolvaptan in euvolemic hyponatremia
Sponsors: Winthrop University Hospital; Winthrop University Hospital
Not yet recruiting - verified August 2011
Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina

Conditions: Angina Pectoris; Coronary Artery Disease; Type 2 Diabetes Mellitus
Intervention: Drug: Ranolazine
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012
Diet and Systemic Inflammation

Conditions: Low-grade Chronic Inflammation; Intestinal Permeability; Type 2 Diabetes Mellitus; Cardiovascular Disease; Obesity
Interventions: Other: Fructose-sweetened beverages; Other: Glucose-sweetened beverages; Other: High-fructose corn syrup-sweetened beverages
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Heart, Lung, and Blood Institute (NHLBI); University of Washington
Recruiting - verified December 2011
The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases

Conditions: Gastro-enteropancreatic Neuroendocrine Tumor; Secondary Malignant Neoplasm of Liver
Intervention: Other: magnetic resonance imaging (MRI)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified December 2011
Intensive Blood Pressure and LDL Lowering in Diabetic Patients With Coronary Artery Disease

Conditions: Type 2 Diabetes; Coronary Artery Disease; Hypertension; Dyslipidemia
Interventions: Other: intensive control; Other: standard control
Sponsors: Kyoto University, Graduate School of Medicine; Takeshi Morimoto; University of the Ryukyus
Recruiting - verified August 2011
Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib and GSK1120212 in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer

Conditions: Solid Tumors; Advanced Thyroid Cancer
Intervention: Drug: Combination of pazopanib and GSK1120212
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Comprehensive Cancer Network; GlaxoSmithKline
Recruiting - verified May 2012
Patient Reported Symptoms in Ovarian Cancer (PRECISION)

Condition: Ovarian Cancer
Intervention:
Sponsors: Genentech; Genentech
Not yet recruiting - verified August 2011
Study of Ruxolitinib in Pancreatic Cancer Patients

Condition: Metastatic Pancreatic Adenocarcinoma
Interventions: Drug: Number 1 - Capecitabine and ruxolitinib; Drug: Number 2 - Capecitabine and placebo
Sponsors: Incyte Corporation; Incyte Corporation
Recruiting - verified May 2012
Effect of Longer-term Adrenal Suppression Using Low Dose Hydrocortisone on Androgen Overproduction

Conditions: Hyperandrogenemia; Obesity; Polycystic Ovary Syndrome
Interventions: Drug: Hydrocortisone; Drug: dexamethasone; Drug: Cosyntropin; Drug: r-hCG (Ovidrel)
Sponsors: University of Virginia; University of Virginia
Not yet recruiting - verified August 2011
Effect of Spironolactone on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess

Conditions: Obesity; Hyperandrogenemia; Polycystic Ovary Syndrome
Interventions: Drug: Spironolactone; Drug: Dexamethasone; Drug: Cosyntropin; Drug: r-hCG (Ovidrel)
Sponsors: University of Virginia; University of Virginia
Not yet recruiting - verified August 2011
Effect of Metformin on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess

Conditions: Obesity; Hyperandrogenemia; Polycystic Ovary Syndrome
Interventions: Drug: Metformin; Drug: Dexamethasone; Drug: Cosyntropin; Drug: r-hCG (Ovidrel)
Sponsors: University of Virginia; University of Virginia
Not yet recruiting - verified August 2011
Efficacy and Safety of High Intensity Focused Ultrasound (HIFU) Device to Treat Secondary Hyperparathyroidism

Conditions: Secondary Hyperparathyroidism; End Stage Renal Disease; Parathyroid Hyperplasia
Intervention: Device: Ultrasonic ablation device
Sponsors: Theraclion; Theraclion
Recruiting - verified August 2011
Effects of Sandostatin LAR® in Acromegaly

Condition: Acromegaly
Intervention: Drug: Sandostatin LAR
Sponsors: Columbia University; Columbia University; Novartis
Recruiting - verified August 2011
Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess

Conditions: Hyperandrogenemia; Obesity; Polycystic Ovary Syndrome
Interventions: Drug: Hydrocortisone; Drug: dexamethasone; Drug: Cosyntropin (ACTH)
Sponsors: University of Virginia; University of Virginia
Not yet recruiting - verified August 2011
Evaluation of Adrenal Androgens in Normal and Obese Girls After Suppression and Stimulation

Conditions: Hyperandrogenemia; Polycystic Ovary Syndrome; Obesity
Interventions: Drug: Dexamethasone; Drug: Cortrosyn
Sponsors: University of Virginia; University of Virginia; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); University of California, San Diego
Recruiting - verified August 2011
Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess

Conditions: Hyperandrogenemia; Obesity; Polycystic Ovary Syndrome
Interventions: Drug: Leuprolide; Drug: Dexamethasone; Drug: recombinant human chorionic gonadotropin
Sponsors: University of Virginia; University of Virginia
Not yet recruiting - verified August 2011
First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children : the PREDICT Pharmacogenetics Validation Study

Conditions: Idiopathic Growth Hormone Deficiency; Turner Syndrome
Intervention: Other: Blood sampling
Sponsors: Merck KGaA; Merck KGaA; Merck Serono S.A., Geneva
Recruiting - verified May 2012
Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)

Conditions: Colorectal Cancer; Cancer of Pancreas; Pancreatic Neoplasm; Malignant Neoplasm of Large Intestine; Malignant Tumor of Colon; Colon Carcinoma; Cancer of Colon; Pancreatic Cancer
Interventions: Drug: FOLFOX6; Biological: EGFRBi armed ATC Infusions
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute
Recruiting - verified September 2011
Ovarian Contribution to Androgen Production in Adolescent Girls

Conditions: Polycystic Ovary Syndrome; Obesity; Hyperandrogenism
Interventions: Drug: Dexamethasone; Drug: r-hCG (Ovidrel)
Sponsors: University of Virginia; University of Virginia; University of California, San Diego
Recruiting - verified August 2011
TRANSforming InTerprofessional Cardiovascular Prevention in Primary Care

Conditions: Diabetes Mellitus, Type 2; Hypertension; Dyslipidemias; Cholesterol, LDL; Comorbitdity
Interventions: Other: Facilitation; Other: Passive diffusion (usual implementation strategy)
Sponsors: Fonds de la Recherche en Santé du Québec; Fonds de la Recherche en Santé du Québec; Université de Montréal
Recruiting - verified August 2011
Pilot Program to Personalize Care & Improve Quality of Life for Women With Recurrent Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Other: Pre-study Questionnaire; Other: Educational Presentations; Other: CAM Therapies; Other: Post-study Questionnaire
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; University of South Florida
Recruiting - verified January 2012
Comparison Between aPDT and Systemic Doxycycline on Non-surgical Periodontal Therapy in Type 2 Diabetics

Conditions: Periodontal Disease; Type 2 Diabetes
Interventions: Drug: Systemic Doxycycline and Sham aPDT; Drug: aPDT + Doxycycline Placebo
Sponsors: University of Sao Paulo; University of Sao Paulo; Fundação de Amparo à Pesquisa do Estado de São Paulo
Recruiting - verified May 2012
Periprocedural Glycemic Control in Patients Undergoing Coronary Angiography

Conditions: Diabetes Mellitus; Coronary Artery Disease
Intervention: Other: hold hypoglycemic meds
Sponsors: New York University School of Medicine; New York University School of Medicine
Recruiting - verified August 2011
Gemcitabine Hydrochloride in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

Condition: Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride; Genetic: mutation analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Other: pharmacological study; Procedure: adjuvant therapy
Sponsors: National Cancer Institute (NCI); Federation Francophone de Cancerologie Digestive
Recruiting - verified August 2011
Hashimotos Thyroiditis and Thyroid Cancer

Conditions: Thyroid Cancer; Hashimotos Thyroiditis
Intervention:
Sponsors: The University of Texas, Galveston; The University of Texas, Galveston
Recruiting - verified September 2011
A Clinical Trial in Patients With BRCA Defective Tumours

Conditions: Breast Cancer; Ovarian Cancer
Interventions: Drug: 6-Mercaptopurine; Drug: Methotrexate
Sponsors: University of Oxford; University of Oxford
Recruiting - verified September 2011
Cancer Vaccines CRS-207 and GVAX Pancreas for Metastatic Pancreatic Adenocarcinoma

Condition: Pancreatic Cancer
Interventions: Drug: GVAX Pancreas, Cyclophosphamide and CRS-207; Drug: GVAX Pancreas and Cyclophosphamide
Sponsors: Aduro BioTech, Inc.; Aduro BioTech, Inc.; Johns Hopkins University
Recruiting - verified May 2012
Risk Prediction in Type II Diabetics With Ischemic Heart Disease

Conditions: Type-2 Diabetes Mellitus; Ischemic Heart Disease
Intervention:
Sponsors: Thebiosignals.com; Thebiosignals.com
Recruiting - verified August 2011
Phase 1-2 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
Interventions: Biological: DPX-Survivac; Drug: low dose cyclophosphamide (oral)
Sponsors: ImmunoVaccine Technologies, Inc.; ImmunoVaccine Technologies, Inc.
Recruiting - verified December 2011
Amatuximab for High Mesothelin Cancers

Conditions: Carcinoma, Pancreatic Ductal; Mesothelioma; Ovarian Neoplasms; Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Amatuximab (MORab-009)
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified April 2012
OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas

Condition: Pancreatic Cancer, Metastatic
Interventions: Drug: Gemcitabine, Erlotinib, OSI-906; Drug: Gemcitabine, Erlotinib
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Not yet recruiting - verified May 2012
Distal Pancreatectomy With Partial Splenectomy for Pancreatic Tumors

Condition: Tumor of Exocrine Pancreas
Intervention: Procedure: Distal pancreatectomy with partial splenectomy
Sponsors: University of Missouri-Columbia; University of Missouri-Columbia
Not yet recruiting - verified August 2011
Pharmacogenetics of Ace Inhibitor-Associated Angioedema

Conditions: Hypertension; Diabetes Type 2
Interventions: Drug: BNP, GLP-1, sitagliptin/placebo; Drug: Substance P, BK, sitagliptin/placebo
Sponsors: Vanderbilt University; Vanderbilt University
Not yet recruiting - verified August 2011
The Effect of Vitamin D Supplementation on Cardiovascular Risk Factors Among Hispanics and African Americans With Type 2 Diabetes Mellitus

Condition: Type 2 Diabetes
Intervention: Drug: Cholecalciferol
Sponsors: Florida International University; Florida International University
Recruiting - verified August 2011
Efficacy and Safety of Octreolin for Acromegaly

Condition: Acromegaly
Intervention: Drug: Active oral octreotide study drug therapy
Sponsors: Chiasma, Inc.; Chiasma, Inc.
Recruiting - verified April 2012
Biomarker Directed Adjuvant Chemotherapy for Resected Pancreas Cancer

Condition: Pancreas Cancer
Interventions: Drug: gemcitabine; Drug: 5-fluorouracil
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified April 2012
Feasibility and Safety Study in Patients With Metastatic Pancreatic Adenocarcinoma

Condition: Metastatic Pancreatic Cancer
Intervention: Drug: vacc. w/ Poly-ICLC & peptide-pulsed dendritic cells
Sponsors: Medical University of South Carolina; Medical University of South Carolina; Oncovir, Inc.
Recruiting - verified April 2012
CONtrolling Disease Using Inexpensive IT - Hypertension in Diabetes

Conditions: Hypertension; Diabetes Mellitus
Intervention: Other: Self-monitoring-nurse-primary care provider feedback loop
Sponsors: University of Massachusetts, Worcester; University of Massachusetts, Worcester; Reliant Medical Group; University of Massachusetts, Amherst
Recruiting - verified February 2012
Measuring Patient Expectations for Thyroid Surgery

Condition: Thyroid Cancer
Intervention: Behavioral: patient interviews
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012
Improving Outcomes for Individuals With Serious Mental Illness and Diabetes

Conditions: Diabetes Mellitus; Bipolar Disorder; Depression; Psychotic Disorders; Schizophrenia
Intervention: Behavioral: Targeted Training in Illness Management (TTIM)
Sponsors: National Institute of Mental Health (NIMH); National Institute of Mental Health (NIMH)
Recruiting - verified May 2012
FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Condition: Pancreatic Neoplasms
Interventions: Drug: oxaliplatin; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: fluorouracil; Other: laboratory biomarker analysis; Other: flow cytometry; Other: immunohistochemistry staining method; Other: pharmacological study; Drug: PF-04136309
Sponsors: Washington University School of Medicine; Washington University School of Medicine; National Cancer Institute (NCI)
Recruiting - verified March 2012
Short Course Radiation Therapy With Proton Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: Capecitabine; Drug: Hydroxychloroquine; Radiation: Proton Radiation Therapy
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified December 2011
Difference in GC-induced Adrenal Insufficiency in RA Related to Polymorphisms in the Glucocorticoid Receptor Gene

Condition: Rheumatoid Arthritis
Intervention: Other: No intervention
Sponsors: Rigshospitalet, Denmark; Rigshospitalet, Denmark
Recruiting - verified April 2012
Ketogenic Diet With Concurrent Chemoradiation for Pancreatic Cancer

Condition: Pancreatic Neoplasms
Intervention: Dietary Supplement: Ketogenic diet
Sponsors: University of Iowa; University of Iowa; National Institutes of Health (NIH); Nutricia North America; The Holden Comprehensive Cancer Center
Recruiting - verified August 2011
Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer

Conditions: Thyroid Cancer; Metastases
Intervention: Drug: TSH stimulation
Sponsors: Institut Gustave Roussy; Institut Gustave Roussy
Recruiting - verified July 2011
Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: pazopanib hydrochloride; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC
Not yet recruiting - verified July 2011
Observational Program of Zemplar in Patients With End Stage Chronic Kidney Disease and Parathyroid Disorder on Hemodialysis in the Russian Federation

Condition: Secondary Hyperparathyroidism
Intervention:
Sponsors: Abbott; Abbott; Almedis
Recruiting - verified January 2012
Use of an In Vivo Optical Probe to Discriminate Benign From Malignant Thyroid Nodules

Conditions: Cancer; Thyroid
Intervention:
Sponsors: Boston Medical Center; Boston Medical Center; Fraunhofer USA
Recruiting - verified December 2011
Effect of Carum Carvi on Thyroid Hormones and TSH Level

Condition: Thyroid Cancer Patients
Interventions: Drug: Carum Cravi; Drug: Placebo
Sponsors: Mashhad University of Medical Sciences; Mashhad University of Medical Sciences; Pharmaceutical Research Center
Recruiting - verified October 2011
Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes

Conditions: Nonalcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis; Type 2 Diabetes
Intervention: Drug: Liraglutide-metformin vs insulin-metformin
Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); Centre hospitalier de l'Université de Montréal (CHUM); Centre de Recherche du Centre Hospitalier de l'Université de Montréal; Diabete Quebec; Radiological Society of North America Research and Education Foundation; Canadian Heads of Academic Radiology-GE Healthcare Development Award
Recruiting - verified July 2011
A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy

Conditions: Diabetic Nephropathy; Chronic Kidney Disease
Interventions: Drug: Atrasentan; Drug: Placebo
Sponsors: Abbott; Abbott
Recruiting - verified December 2011
Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery

Conditions: Recurrent Thyroid Cancer; Stage IVA Follicular Thyroid Cancer; Stage IVA Papillary Thyroid Cancer; Stage IVB Follicular Thyroid Cancer; Stage IVB Papillary Thyroid Cancer; Stage IVC Follicular Thyroid Cancer; Stage IVC Papillary Thyroid Cancer
Interventions: Drug: pazopanib hydrochloride; Radiation: iodine I 131
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI); National Comprehensive Cancer Network; GlaxoSmithKline
Recruiting - verified February 2012
Redifferentiation Therapy Using Alpha Lipoic Acid in Thyroid Cancer

Conditions: Thyroid; Cancer
Intervention: Drug: alpha-lipoic acids
Sponsors: Asan Medical Center; Asan Medical Center
Recruiting - verified July 2011
A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma

Conditions: Ovarian Carcinoma; Relapse
Interventions: Drug: Oxaliplatin; Drug: oxaliplatin
Sponsors: Jules Bordet Institute; Jules Bordet Institute
Recruiting - verified November 2011
Chemotherapy for Patients With Locally Advanced Pancreatic Cancer (LAPC) With Additional Chemo-radiotherapy (CRT) for Patients With Borderline Resectable Tumours

Condition: Pancreatic Cancer
Intervention: Drug: Oxaliplatin, irinotecan, 5-FU & leucovorin
Sponsors: Odense University Hospital; Odense University Hospital
Not yet recruiting - verified June 2011
Effects of Controlled Ovarian Hyperstimulation (COH) With Letrozole and Gonadotropin

Conditions: Infertility; Breast Cancer
Intervention: Procedure: Random Peri-Areolar Fine Needle Aspiration (RPFNA)
Sponsors: University of Kansas; University of Kansas
Recruiting - verified July 2011
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Conditions: Cardiovascular Disease; Diabetes Mellitus, Type 2
Interventions: Drug: Dulaglutide; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Progression of Diabetic Retinopathy Post Bariatric Surgery (BS)

Conditions: Obesity; Diabetes Mellitus
Intervention:
Sponsors: New York University School of Medicine; New York University School of Medicine
Recruiting - verified July 2011
Liraglutide Treatment to Patients With Severe Renal Insufficiency

Conditions: Type 2 Diabetes Mellitus; End-stage Renal Disease
Intervention: Drug: Liraglutide
Sponsors: Rigshospitalet, Denmark; Bo Feldt-Rasmussen; Novo Nordisk; The GCP unit at Copenhagen University Hospital
Recruiting - verified September 2011
Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis

Conditions: Diabetes Mellitus Type 1 and 2; Diabetes Mellitus Complications; Gastroparesis; Gastrointestinal Motility Disorder
Interventions: Drug: RM-131; Drug: Placebo
Sponsors: Rhythm Pharmaceuticals, Inc.; Rhythm Pharmaceuticals, Inc.
Recruiting - verified March 2012
Search for Predictors of Therapeutic Response in Ovarian Carcinoma

Conditions: Carcinoma of the Ovary; Fallopian Tube Cancer; Peritoneal Serous-type Advanced Stage
Intervention: Other: blood samples
Sponsors: Centre Francois Baclesse; Centre Francois Baclesse
Recruiting - verified February 2012
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer

Condition: Pancreatic Cancer
Intervention: Drug: dasatinib
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified February 2012
Safety Study of MGA271 in Refractory Cancer

Conditions: Prostate Cancer; Pancreatic Cancer; Melanoma; Renal Cell Carcinoma; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Bladder Cancer; Non-small Cell Lung Cancer; Glioblastoma
Intervention: Biological: MGA271
Sponsors: MacroGenics; MacroGenics
Recruiting - verified December 2011
Biospecimens for Identification of Diseases of the Pancreas.

Conditions: Pancreatic Cancer; Chronic Pancreatitis; Type II Diabetes; Pancreatic Cysts; Control
Intervention: Procedure: Blood Draw
Sponsors: University of Michigan; University of Michigan
Recruiting - verified January 2012
BRAF V600E Mutations In Papillary Thyroid Carcinoma

Condition: Papillary Thyroid Carcinoma
Intervention: Genetic: BRAF V600E POSITIVITY
Sponsors: Bezmialem Vakif University; Bezmialem Vakif University
Recruiting - verified August 2011
IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients

Condition: Thyroid Cancer
Intervention: Radiation: I131 1.1 GBq
Sponsors: University College, London; University College, London; Cancer Research UK
Not yet recruiting - verified July 2011
Bevacizumab as Adjunctive Treatment to Laser Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

Condition: Proliferative Diabetic Retinopathy
Interventions: Procedure: Panretinal photocoagulation; Procedure: Procedure: Panretinal Photocoagulation (PRP) Drug: Intravitreous injection of Bevacizumab
Sponsors: Instituto do Coracao; Instituto do Coracao; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Recruiting - verified January 2011
Effects of Gum Chewing on Recovery of Bowel Function Following Abdominal Surgery for Endometrial and Ovarian Cancer

Condition: Paralytic Ileus
Intervention: Behavioral: Gum chewing
Sponsors: Chiang Mai University; Chiang Mai University
Recruiting - verified January 2012
Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer

Condition: Carcinoma, Pancreatic Ductal
Interventions: Drug: Targeted Therapy Tailored Treatment; Drug: Standard Chemotherapy
Sponsors: Grupo Hospital de Madrid; Sofia Perea, Director Clinical Trials Unit.
Recruiting - verified March 2012
Exploratory CSII Trial on Erectile Dysfunction in T2DM Patients

Conditions: Diabetes Mellitus, Type 2; Erectile Dysfunction
Interventions: Drug: Insulin; Drug: Insulin
Sponsors: Jothydev's Diabetes and Research Centre; Jothydev's Diabetes and Research Centre
Recruiting - verified February 2012
Multicenter Research Study to Build a Repository to Study Chronic Diseases in Indiana

Condition: Diabetes Mellitus Type II
Intervention:
Sponsors: Fairbanks Institute; Fairbanks Institute; Indiana University School of Medicine; Richard M. Fairbanks Foundation; BioCrossroads; Regenstrief Institute, IU Center for Aging Research
Recruiting - verified June 2011
HYPAZ: Hypertension Induced by Pazopanib

Conditions: Renal Cell Carcinoma; Soft Tissue Sarcoma; Glioblastoma; Ovarian Cancer; Cervical Cancer; Breast Cancer; Non-small Cell Lung Cancer; Small Cell Lung Cancer; Pancreatic Cancer; Melanoma; Gastrointestinal Cancer
Intervention: Drug: Pazopanib
Sponsors: Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; University of Cambridge; GlaxoSmithKline; Cambridge Experimental Cancer Medicine Centre
Recruiting - verified June 2011
Type 1 Diabetes and Eating Disorder Diurnal Glucose Patterns

Conditions: Type I Diabetes Mellitus Without Complication; Eating Disorder
Intervention:
Sponsors: Park Nicollet Institute; Park Nicollet Institute; Park Nicollet Foundation; Melrose Institute; International Diabetes Center at Park Nicollet
Not yet recruiting - verified February 2012
SOM 230 and Gemcitabine in Advanced Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: SOM 230 LAR; Drug: Gemcitabine
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Novartis Pharmaceuticals
Recruiting - verified April 2012
Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others

Conditions: Thyroid Cancer; Papillary Microcarcinoma
Interventions: Behavioral: Focus groups; Behavioral: Focus groups
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012
Cryopreservation of Ovarian Cortex in Girls With Turner Syndrome

Conditions: Turner Syndrome; Ovarian Insufficiency
Intervention: Procedure: Ovariectomy
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris; Groupe Hospitalier Pitie-Salpetriere; Cochin Hospital
Recruiting - verified July 2011
Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy

Conditions: Breast Neoplasms; Peritoneal Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms
Interventions: Other: ²¹²Pb-TCMC-Trastuzumab; Biological: trastuzumab
Sponsors: Areva Med LLC; Areva Med LLC
Recruiting - verified January 2012
Genetic Expression Alteration Affect on Lateral Neck Node Metastasis of Thyroid Papillary Microcarcinoma : Microarray Analysis

Condition: Papillary Thyroid Microcarcinoma
Intervention:
Sponsors: Yonsei University; Yonsei University
Not yet recruiting - verified June 2011
A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis

Conditions: Secondary Hyperparathyroidism; End-Stage Renal Disease
Intervention: Drug: Paricalcitol
Sponsors: Abbott; Abbott
Recruiting - verified May 2012
Distinction Between Lung Cancer and Gynecological Cancers by Canine Scent Detection

Conditions: Lung Cancer; Breast Cancer; Ovarian Cancer
Intervention: Other: exhalation analysis of breath sample
Sponsors: Schillerhoehe Hospital; Schillerhoehe Hospital; Robert Bosch Gesellschaft für Medizinische Forschung mbH
Recruiting - verified November 2011
Safety and Pharmacokinetics of Intraoperative Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) With Cisplatin to Treat Platinum-sensitive Recurrent Ovarian Cancer

Condition: Ovarian Cancer
Intervention: Procedure: Cisplatin administered intraoperatively as hyperthermic intraperitoneal chemoperfusion
Sponsors: University Hospital, Bonn; University Hospital, Bonn
Recruiting - verified June 2011
Trial Assessing Roux-en-Y Anastomosis of the Pancreatic Stump to Prevent Pancreatic Fistula Following Distal Pancreatectomy

Conditions: Pancreatic Cancer; Pancreatic Cystic Lesions; Chronic Pancreatitis; Pancreatic Neuroendocrine Tumors; Pancreatic Pseudocysts
Interventions: Procedure: Stapling closure of the pancreatic stump; Procedure: Roux-en-Y anastomosis of the pancreatic stump
Sponsors: Wakayama Medical University; Wakayama Medical University; Osaka University; Nara Medical University; Kyoto Prefectural University of Medicine; Kansai Rosai Hospital
Recruiting - verified June 2011
Serum Sclerostin Levels, Cardiovascular Parameters and Carpal Tunnel Syndrome in Maintenance Hemodialysis Patients

Conditions: Chronic Kidney Disease; Renal Osteodystrophy; Left Ventricular Hypertrophy
Intervention:
Sponsors: RFM Renal Treatment Services; RFM Renal Treatment Services
Not yet recruiting - verified June 2011
Retinal Laser by Multi-spot Photocoagulator and Driving Eligibility

Condition: Proliferative Diabetic Retinopathy
Intervention: Procedure: Pan retinal Photocoagulation
Sponsors: Moorfields Eye Hospital NHS Foundation Trust; Moorfields Eye Hospital NHS Foundation Trust; Insulin Dependant Diabetes Trust
Not yet recruiting - verified June 2011
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Conditions: Recurrent Ovarian Cancer; Fallopian Tube Carcinoma; Primary Peritoneal Carcinoma
Intervention: Biological: Chimeric monoclonal antibody (TRC105) to CD105
Sponsors: Tracon Pharmaceuticals Inc.; Tracon Pharmaceuticals Inc.
Recruiting - verified March 2012
The Predictive Factors of Vision Recovery in Patients With Pituitary Tumor

Condition: Pituitary Adenomas
Intervention:
Sponsors: Huashan Hospital; Huashan Hospital
Recruiting - verified June 2011
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma

Conditions: Pancreatic Cancer; Adenocarcinoma; Pancreatic Neoplasms
Intervention: Drug: FOLFIRINOX, IPI-926
Sponsors: University of California, San Francisco; University of California, San Francisco; Infinity Pharmaceuticals, Inc.
Recruiting - verified March 2012
Diagnostic Utility of [18F]-FDG-PET/CT and [124I]-PET/CT for Detection of Recurrence in Differentiated Thyroid Carcinoma

Conditions: Thyroid Cancer; Recurrence
Intervention:
Sponsors: Korean Association of Endocrine Surgeons; Korean Association of Endocrine Surgeons
Recruiting - verified January 2011
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease

Condition: Cushing's Disease
Interventions: Drug: SOM230 LAR 30 mg; Drug: SOM230 LAR 10 mg
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET

Condition: Islet Cell Tumor
Interventions: Drug: Everolimus; Drug: Pasireotide + Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Assessment Of Stromal Response To Nab-Paclitaxel In Combination With Gemcitabine In Pancreatic Cancer

Condition: Pancreatic Cancer
Intervention: Drug: Gemcitabine plus nab-paclitaxel
Sponsors: Grupo Hospital de Madrid; Grupo Hospital de Madrid
Recruiting - verified September 2011
123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors

Conditions: Pheochromocytoma; Neuroblastoma; Paraganglioma; Medullary Thyroid Carcinoma; Carcinoid Tumors
Intervention: Drug: 123I-meta-iodobenzylguanidine
Sponsors: Vancouver Coastal Health; Vancouver Coastal Health
Not yet recruiting - verified June 2011
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Conditions: Anxiety Disorder; Fallopian Tube Cancer; Fatigue; Nausea and Vomiting; Neurotoxicity; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Other: medical chart review; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: fatigue assessment and management; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
GLP-1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Diabetic Patients With Aortocoronary Bypass

Conditions: Coronary Artery Disease; Left Ventricular Dysfunction; Type 2 Diabetes Mellitus
Intervention: Drug: Exenatide
Sponsors: Charles University, Czech Republic; Charles University, Czech Republic; Eli Lilly and Company
Recruiting - verified June 2011
Impact of c242T Polymorphism of p22phox in Diabetic type1 Nephropathy

Conditions: Type 1 Diabetes Mellitus; Diabetic Nephropathy
Intervention:
Sponsors: University Hospital, Grenoble; University Hospital, Grenoble
Recruiting - verified December 2011
RLY5016 in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)

Conditions: Chronic Kidney Disease; Hypertension; Hyperkalemia
Interventions: Drug: RLY5016 + Losartan; Drug: RLY5016 + ACEi and/or ARB + Spironolactone; Drug: RLY5016 + Losartan; Drug: RLY5016 + ACEi and/or ARB + Spironolactone
Sponsors: Relypsa, Inc.; Relypsa, Inc.
Recruiting - verified March 2012
Oral Glucose Tolerance Testing (OGTT) on Patients Taking Somatostatin Analogs

Condition: Acromegaly
Intervention: Other: Oral Glucose Tolerance Test (OGTT)
Sponsors: Cedars-Sinai Medical Center; Cedars-Sinai Medical Center
Recruiting - verified June 2011
Vaccine Therapy in Treating Patients With Metastatic Solid Tumors

Conditions: Malignant Solid Tumour; Breast Cancer; Malignant Tumor of Colon; GIST; Ovarian Cancer
Intervention: Biological: HER-2 vaccine
Sponsors: Ohio State University Comprehensive Cancer Center; Ohio State University Comprehensive Cancer Center
Recruiting - verified February 2012
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Conditions: Neoplasms; Neoplasm Metastasis; Pancreatic Cancer
Interventions: Drug: LY2157299; Drug: Gemcitabine; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012
Trial of Neoadjuvant Short Course IMRT Followed by Surgery and IORT for Resectable Pancreatic Cancer

Condition: Pancreatic Neoplasms
Interventions: Radiation: neoadjuvant short course IMRT; Radiation: IORT
Sponsors: University Hospital Heidelberg; University Hospital Heidelberg; German Cancer Research Center
Not yet recruiting - verified June 2011
Online Wound Electronic Medical Record (OWEMR) to Decrease Amputations in Diabetics

Conditions: Wounds; Diabetes Complications; Diabetic Foot; Foot Ulcer
Intervention: Other: Online Wound Electronic Medical Record
Sponsors: New York University School of Medicine; New York University School of Medicine; Agency for Healthcare Research and Quality (AHRQ)
Recruiting - verified March 2012
Informed Consent for Whole Genome Sequencing: Ideals and Norms Referenced by Early Participants

Conditions: Coronary Artery Disease; Proteus Syndrome; Coffin - Sins Syndrome; Familial Isolated Hyperparathyroidism; Dubouitz Syndrome
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified March 2012
Neurogenic Inflammation in Diabetes

Conditions: Diabetes Mellitus; Polyneuropathies; Arthropathy, Neurogenic
Interventions: Other: Intracutaneous injection of Candida albicans antigen.; Procedure: Punch skin biopsy; Other: Temperature measurement.
Sponsors: Maastricht University Medical Center; Maastricht University Medical Center
Not yet recruiting - verified June 2011
Secretin-Assisted Computed Tomography Scan and Magnetic Resonance Imaging in Improving Pancreatic Tumor Conspicuity

Condition: Pancreas Cancer
Intervention: Drug: Secretin Synthetic Human (RG1068)
Sponsors: University Hospital Case Medical Center; University Hospital Case Medical Center; Repligen Corporation
Recruiting - verified June 2011
Early (4 Days) Versus Standard Drainage of the Abdominal Cavity After Pancreaticoduodenectomy

Conditions: Pancreatic Disease; Pancreatic Neoplasms
Interventions: Procedure: Drain removal at D4; Procedure: Standard drain removal
Sponsors: Centre Hospitalier Universitaire, Amiens; Centre Hospitalier Universitaire, Amiens
Recruiting - verified December 2011
Quality of Life in Greek Hemodialysis Patients Receiving Zemplar Intravenous

Conditions: Chronic Kidney Disease; Secondary Hyperparathyroidism
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified May 2012
The Observational Study of Growth Hormone-secreting Pituitary Tumors

Conditions: Acromegaly; Pituitary Tumor
Intervention:
Sponsors: Huashan Hospital; Huashan Hospital; National Natural Science Foundation of China
Recruiting - verified June 2011
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial

Conditions: Acute Ischemic Stroke; Diabetes; Hyperglycemia
Interventions: Drug: IV insulin to maintain target glucose concentration of 80-130 mg/dL; Drug: Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL
Sponsors: University of Virginia; University of Virginia; Neurological Emergencies Treatment Trials Network (NETT); Medical University of South Carolina; Medical Automation Systems, an Alere Company; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2012
Pelvic Floor Disorders in Survivors of Gynecologic Malignancies

Conditions: Uterine Cancer; Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Cervical Cancer; Vulvar Cancer
Intervention: Other: Survey
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified June 2011
Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: paclitaxel; Other: pharmacological study; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group
Recruiting - verified May 2012
Effect of Growth Hormone on Early Brain Development in Girls With Turner Syndrome

Condition: Turner Syndrome
Intervention: Drug: somatotropin
Sponsors: University of North Carolina, Chapel Hill; Marsha Davenport, MD; Pfizer
Recruiting - verified January 2012
INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Drug: Carboplatin; Drug: Pegylated Lipoxomal Doxorubicin (PLD); Drug: Trabectedin
Sponsors: Mario Negri Institute for Pharmacological Research; Mario Negri Institute for Pharmacological Research; PharmaMar; Averion International Corporation
Recruiting - verified September 2011
Primary Prevention of Cardiovascular Disease (CVD) in Pre-diabetic & Pre-hypertensive Subjects

Conditions: Pre-diabetes; Pre-hypertension
Interventions: Drug: Metformin+Enalapril+Simvastatin; Drug: Placebo tablet
Sponsors: Ramathibodi Hospital; Ramathibodi Hospital; Ubon Ratchathani Public Health Office, Thailand; National Health Security Office, Thailand; The Government Pharmaceutical Organization
Not yet recruiting - verified May 2011
Efficacy and Safety of Gabapentin/B Complex Versus Pregabaline in Diabetic Peripheral Neuropathy Pain Management

Condition: Diabetic Peripheral Neuropathic Pain
Interventions: Drug: Gavindo®; Drug: Pregabaline
Sponsors: Merck KGaA; Merck KGaA; Merck S.A. de C.V., Mexico
Recruiting - verified January 2012
Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers

Condition: Hereditary Breast and Ovarian Cancer Syndrome
Intervention: Behavioral: Inquiry Based Stress Reduction (IBSR) program
Sponsors: Sheba Medical Center; Sheba Medical Center
Recruiting - verified June 2011
Long-term Beneficial Metabolic Effects of Adrenalectomy in Subclinical Cushing's Syndrome of Adrenal Incidentaloma

Condition: Cushing Syndrome
Intervention: Procedure: surgery
Sponsors: Samsung Medical Center; Samsung Medical Center; Asan Medical Center; Severance Hospital; Konkuk University Medical Center
Recruiting - verified June 2011
Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum Resistant Ovarian Cancer

Condition: Non-Small Cell Lung Cancer, Ovarian Cancer
Intervention: Drug: DNIB0600A
Sponsors: Genentech; Genentech
Recruiting - verified October 2011
Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism

Condition: Polycystic Ovary Syndrome
Intervention: Drug: folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive
Sponsors: BC Women's Hospital & Health Centre; BC Women's Hospital & Health Centre; Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Recruiting - verified March 2012
Prevention of Contrast Induced Nephropathy by Erythropoietin

Conditions: Diabetes; Chronic Kidney Insufficiency
Interventions: Drug: Epoetin beta; Drug: Saline 0.9%
Sponsors: Western Galilee Hospital-Nahariya; Western Galilee Hospital-Nahariya
Not yet recruiting - verified May 2011
Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma

Condition: Pancreatic Cancer
Interventions: Drug: Gemcitabine; Drug: Capecitabine; Radiation: Stereotactic Body Radiation Therapy (SBRT)
Sponsors: University of Pittsburgh; University of Pittsburgh
Recruiting - verified August 2011
New Treatment Option for Pancreatic Cancer

Condition: Pancreatic Cancer
Intervention: Drug: Vitamin C
Sponsors: University of Kansas; Jeanne Drisko, MD, CNS, FACN; Lotte and John Hecht Memorial Foundation; University of Kansas
Recruiting - verified September 2011
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Condition: Metastatic Pancreatic Adenocarcinoma
Interventions: Drug: ON 01910.Na; Drug: Gemcitabine; Drug: Gemcitabine
Sponsors: Onconova Therapeutics, Inc.; Onconova Therapeutics, Inc.; Academic Oncology Gastrointestinal Cancer Consortium (AGICC)
Recruiting - verified March 2012
Effects of Vitamin D Supplementation in Subjects With New Onset of Type 1 Diabetes

Condition: Type 1 Diabetes
Intervention: Drug: Cholecalciferol
Sponsors: Medical University of Graz; Medical University of Graz; Medical University of Vienna
Recruiting - verified February 2012
FOLFIRINOX in Patients With Inoperable Pancreatic Cancer

Condition: Adenocarcinoma of Pancreas
Intervention: Drug: Irinotecan, Oxaliplatin, Leucovorin, 5-FU
Sponsors: University of Oklahoma; University of Oklahoma
Recruiting - verified February 2012
Hormone Treatment in Growth Hormone and Testosterone Deficient Patients

Condition: Hormone Deficiency
Interventions: Drug: Growth hormone treatment; Drug: Testosterone treatment
Sponsors: Max-Planck-Institute of Psychiatry; Max-Planck-Institute of Psychiatry
Not yet recruiting - verified July 2011
Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Drug: NGR-hTNF; Drug: Pegylated liposomal doxorubicin; Drug: Doxorubicin
Sponsors: MolMed S.p.A.; MolMed S.p.A.
Recruiting - verified December 2011
A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004 AM1)

Condition: Ovarian Cancer
Interventions: Drug: MK-1775; Drug: Placebo; Drug: paclitaxel; Drug: carboplatin
Sponsors: Merck; Merck
Recruiting - verified May 2012
Carboplatin and Pegylated Liposomal Doxorubicin With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Drug: Panitumumab; Drug: pegylated liposomal doxorubicin (PLD); Drug: Carboplatin
Sponsors: WiSP Wissenschaftlicher Service Pharma GmbH; WiSP Wissenschaftlicher Service Pharma GmbH
Not yet recruiting - verified July 2011
Therapeutic Education in Very Young Children With Diabetes Mellitus

Conditions: Type 1 Diabetes; Diabetes Mellitus
Intervention: Other: Educational tool
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris
Recruiting - verified November 2011
The InsuPad in Daily Life Study

Condition: Type 1 Diabetes Mellitus With Diabetic Neuralgia
Intervention: Device: InsuPad
Sponsors: Insuline Medical Ltd.; Insuline Medical Ltd.; FIDAM GmbH
Recruiting - verified May 2012
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Conditions: Hematological Malignancies; Certain Lysosomal Storage and Peroxisomal Enzyme Deficiency Disorders; Hurler Syndrome (MPS I); Krabbe Disease (Globoid Leukodystrophy); X-linked Adrenoleukodystrophy; Primary Immunodeficiency Diseases; Bone Marrow Failure; Beta-thalassemia
Intervention: Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified April 2012
Evaluation of Molecular Markers in Adrenal Tumors

Condition: Adrenal Gland Neoplasms
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012
Risk Education and Assessment for Cancer Heredity

Conditions: Breast Cancer; Ovarian Cancer; Genetic Predisposition
Intervention: Behavioral: BRCA1/BRCA2 Genetic Counseling
Sponsors: University of Utah; University of Utah; National Cancer Institute (NCI); Huntsman Cancer Institute
Recruiting - verified November 2011
Stereotactic Body Radiotherapy for Unresectable Pancreatic Cancer

Condition: Pancreatic Cancer
Intervention: Radiation: Stereotactic Body Radiotherapy
Sponsors: St. John's Mercy Research Institute, St. Louis; St. John's Mercy Research Institute, St. Louis
Recruiting - verified July 2011
Evaluation of VLER-Indiana Health Information Exchange Demonstration Project

Conditions: Primary Prevention; Diabetes Mellitus; Asthma; Cardiovascular Diseases; Heart Failure; Mental Health; Osteoporosis
Intervention:
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; Regenstrief Institute, IU Center for Aging Research
Not yet recruiting - verified March 2012
Trial of an Internet-based Platform for Managing Chronic Diseases at a Distance

Conditions: Ischemic Heart Disease; Heart Failure; Chronic Kidney Disease; Diabetes; Chronic Obstructive Pulmonary Disease
Intervention: Behavioral: iCDM
Sponsors: Simon Fraser University; Simon Fraser University; Canadian Institutes of Health Research (CIHR); Michael Smith Foundation for Health Research
Recruiting - verified April 2011
Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease

Conditions: Chronic Kidney Disease; Diabetes
Interventions: Drug: Febuxostat; Drug: Sugar pill
Sponsors: University of Utah; University of Utah; Takeda Pharmaceutical Company Limited
Recruiting - verified October 2011
The Effects of Iodized Salt on Cognitive Development in Ethiopia

Conditions: Iodine Deficiency; Goiter; Cretinism
Intervention: Other: Iodized salt
Sponsors: McGill University; McGill University; MicroNutrient Initiative; Ethiopian Health and Nutrition Research Institute (EHNRI)
Recruiting - verified February 2012
One Week Comparison Study of PTH and PTHrP Infusions

Conditions: Osteoporosis; Hypercalcemia of Malignancy; Hyperparathyroidism; Bone Diseases, Endocrine
Interventions: Drug: Parathyroid Hormone-related Protein (1-36); Drug: parathyroid hormone (1-34); Drug: PTH (1-34) and PTHrP (1-36)
Sponsors: University of Pittsburgh; University of Pittsburgh
Not yet recruiting - verified January 2012
Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer

Condition: Ovarian Cancer
Intervention: Drug: DMUC5754A
Sponsors: Genentech; Genentech
Recruiting - verified July 2011
Safety and Efficacy of Cryoablation for Abdominal Pain Associated With Pancreatic Cancer

Conditions: Pain; Pancreatic Cancer
Intervention: Procedure: Cryoablation using Galil Medical systems and needles
Sponsors: Galil Medical; Galil Medical
Recruiting - verified April 2012
Blood Test for Ovarian Cancer Associated Auto Antibodies

Condition: Ovarian Cancer
Intervention:
Sponsors: Eventus Diagnostics Ltd; Eventus Diagnostics Ltd
Not yet recruiting - verified March 2012
Coupling of Neural Activity and Retinal Blood Flow in Diabetes

Condition: Diabetic Retinopathy
Intervention:
Sponsors: Medical University of Vienna; Medical University of Vienna
Not yet recruiting - verified April 2011
Study To Evaluate Efficacy, Safety And Tolerability Of Lyrica In Patients With Painful Diabetic Peripheral Neuropathy

Condition: Diabetic Neuropathy, Painful
Interventions: Drug: Pregabalin; Drug: Placebo matched with pregabalin
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel

Condition: Ovarian Cancer Recurrent
Interventions: Drug: Ombrabulin (AVE8062); Drug: Placebo; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012
Safety and Efficacy of LCI699 in Cushing's Disease Patients

Condition: Cushing Disease
Intervention: Drug: LCI699
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Primary Hyperparathyroidism (PHPT): Early Effect of Vitamin D

Conditions: Primary Hyperparathyroidism; Hypercalcemia; Vitamin D Deficiency; Osteoporosis; Osteopenia
Interventions: Dietary Supplement: Placebo; Dietary Supplement: Vitamin D3
Sponsors: Columbia University; Columbia University; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified October 2011
Search Allelic Imbalance of Expression of BRCA Genes in Hereditary Risk of Breast and/or Ovarian Cancer

Condition: Hereditary Breast and Ovarian Cancer Syndrome
Interventions: Genetic: blood collection; Genetic: blood collection
Sponsors: Centre Francois Baclesse; Centre Francois Baclesse
Recruiting - verified February 2012
Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)

Condition: Ovarian Neoplasms
Interventions: Drug: BIBF 1120 (low) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min; Drug: BIBF 1120 (high) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min; Drug: BIBF 1120 (medium) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012
Preoperative Chemoradiotherapy With Gemcitabine for Resectable Pancreatic Carcinoma

Condition: Resectable Pancreatic Carcinoma
Intervention: Radiation: chemoradiotherapy with Gemcitabine
Sponsors: National Cancer Center, Korea; National Cancer Center, Korea
Recruiting - verified March 2011
Relationship Between Vitamin D Biomarkers and Survival in Blood Samples From Patients With Advanced Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Genetic: polymorphism analysis; Other: immunologic technique; Other: laboratory biomarker analysis; Other: medical chart review
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Trial of Vaccine Therapy in Recurrent Platinum Resistant Ovarian Cancer Patients

Condition: Recurrent Epithelial Ovarian Cancer
Intervention: Biological: DC-006 vaccine
Sponsors: Oslo University Hospital; Oslo University Hospital
Recruiting - verified January 2012
Iscador Qu as Supportive Treatment in Pancreatic Cancer (Union for International Cancer Control, UICC Stages II-IV)

Condition: Pancreas Cancer
Intervention:
Sponsors: IFAG AG; IFAG AG; Hiscia Society for Cancer Research; IFAG Basel AG, both Switzerland
Recruiting - verified October 2011
Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment

Condition: Ovarian Epithelial Cancer Recurrent
Intervention: Procedure: maximal cytoreductive surgery
Sponsors: UNICANCER; UNICANCER
Recruiting - verified June 2011
Diabetic Treatment Adherence

Condition: Endocrine System Diseases
Interventions: Drug: Metformin; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Agency for Healthcare Research and Quality (AHRQ)
Recruiting - verified March 2012
Pharmacodynamic Comparison of Truncal Blocks in Patients With or Without Metabolic Disease (Kidney Failure, Diabetes)

Conditions: Renal Insufficiency; Diabetes
Intervention: Procedure: Truncal block
Sponsors: Centre Hospitalier Universitaire de Nīmes; Centre Hospitalier Universitaire de Nīmes
Recruiting - verified February 2012
Effect of Diabetes Education During Retinal Ophthalmology Visits on Diabetes Control

Conditions: Diabetes; Diabetic Retinopathy
Intervention: Behavioral: Diabetes Education
Sponsors: Diabetic Retinopathy Clinical Research Network; Diabetic Retinopathy Clinical Research Network; National Eye Institute (NEI); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified April 2012
YF476 in Patients With Type II Gastric Carcinoids Associated With Zollinger-Ellison Syndrome

Condition: Carcinoid
Intervention: Drug: YF476
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified October 2011
PET/CT Scanning for the Follow-up of Antibiotic Treatment of Infectious Osteoarthritis in the Diabetic Foot

Conditions: Diabetic Foot; Osteoarthritis
Interventions: Procedure: Bone scintigraphy; Procedure: Leukoscan; Procedure: PET / CT
Sponsors: Centre Hospitalier Universitaire de Nīmes; Centre Hospitalier Universitaire de Nīmes
Not yet recruiting - verified July 2011
Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy

Conditions: Thyroid Nodule; Goiter; Thyroiditis; Graves Disease
Interventions: Procedure: Robot-assisted thyroidectomy; Procedure: Open thyroidectomy
Sponsors: Centre Hospitalier Universitaire de Nīmes; Centre Hospitalier Universitaire de Nīmes
Recruiting - verified September 2011
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions

Conditions: Marfan Syndrome; Turner Syndrome; Ehlers-Danlos Syndrome; Loeys-Dietz Syndrome; FBN1, TGFBR1, TGFBR2, ACTA2 or MYH11 Genetic Mutation; Bicuspid Aortic Valve Without Known Family History; Bicuspid Aortic Valve With Family History; Bicuspid Aortic Valve With Coarctation; Familial Thoracic Aortic Aneurysm and Dissections; Shprintzen-Goldberg Syndrome; Other Aneurysms and Dissections of the Thoracic Aorta Not Due to Trauma, <50yo; Other Congenital Heart Disease
Intervention:
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified May 2012
A Trial in Adults With Type 1 Diabetes Mellitus Evaluating the Effects of Fenofibrate Versus Placebo on Macular Thickness and Volume

Conditions: Type 1 Diabetes Mellitus; Retinopathy; Diabetic Nephropathy
Interventions: Drug: Fenofibrate; Drug: Inert lactose placebo
Sponsors: University of Sydney; University of Sydney; Abbott; University of Melbourne; St Vincents Hospital, Melbourne; Melbourne Health; Royal Prince Alfred Hospital, Sydney, Australia
Not yet recruiting - verified March 2011
Genetics of Obesity, Diabetes, and Heart Disease in African Diaspora Populations

Conditions: Diabetes; Cardiovascular Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified September 2011
Effect of a Medium Chain Triglyceride Supplemented Diet on Cognitive Function and Brain Activation in Type 1 Diabetes.

Conditions: Hypo-unawareness; Type 1 Diabetes.
Intervention: Dietary Supplement: Medium chain triglycerides
Sponsors: Yale University; Yale University; Juvenile Diabetes Research Foundation
Recruiting - verified January 2012
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer

Condition: Thyroid Cancer
Interventions: Drug: lenvatinib 24 mg administered orally, once a day; Drug: Placebo 24mg administered orally, once a day
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012
Adrenal Hyperplasia Among Young People With PCOS

Conditions: Adrenal Hyperplasia; Polycystic Ovarian Syndrome; Oligomenorrhea; Obesity; Hyperandrogenism
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified January 2012
Revival of Stem Cells in Addison's Study

Condition: Adrenal Failure
Intervention: Drug: depot tetracosactide
Sponsors: Newcastle University; Newcastle University
Recruiting - verified June 2011
Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer

Conditions: Ovarian Carcinoma; Fallopian Tube Cancer; Primary Peritoneal Cancer
Interventions: Biological: OC-DC vaccine; Drug: Bevacizumab; Drug: cyclophosphamide 300 mg/m2/d for 3 days; Drug: fludarabine 30 mg/m2/d for 3 days; Drug: ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cells
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified June 2011
BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Ovarian Cancer (OC)

Conditions: Ovarian Neoplasms; Peritoneal Neoplasms
Interventions: Drug: BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min; Drug: BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min; Drug: BIBF 1120+ PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012
A Comparative Study of Robotic Thyroidectomy Using Transaxillary Approach Versus Conventional Open Thyroidectomy

Condition: Papillary Thyroid Carcinoma
Intervention:
Sponsors: Yonsei University; Yonsei University
Recruiting - verified January 2012
RENEWING HEALTH - RegioNs of Europe WorkINg Together for HEALTH

Conditions: Type 2 Diabetes; Coronary Artery Disease; Heart Failure; Atrial Fibrillation; Other Arrhythmias
Intervention: Behavioral: Health coaching
Sponsors: South Karelia, Social and Health Care; South Karelia, Social and Health Care
Recruiting - verified November 2011
Vaccine Therapy in Treating Patients With Stage III-IV Ovarian Cancer

Conditions: Stage III Ovarian Epithelial Cancer; Stage III Ovarian Germ Cell Tumor; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor
Interventions: Other: enzyme-linked immunosorbent assay; Other: flow cytometry; Other: laboratory biomarker analysis; Other: immunoenzyme technique; Biological: pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012
A Comprehensive Longitudinal Cohort Study in Type 2 Diabetes With High Risk of Cardiovascular Diseases in China

Condition: Type 2 Diabetes
Intervention:
Sponsors: China Cardiometabolic Registries; China Cardiometabolic Registries; Merck; Gerontological Society of China
Not yet recruiting - verified February 2011
Ranibizumab in Diabetic Vitrectomy

Conditions: Diabetic Retinopathy; Retinal Neovascularisation
Interventions: Drug: Ranibizumab; Drug: Saline
Sponsors: Moorfields Eye Hospital NHS Foundation Trust; Moorfields Eye Hospital NHS Foundation Trust; Novartis
Recruiting - verified May 2011
Trial of Adjuvant FANG™ Vaccine for High Risk Stage IIIc Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Biological: FANG; Drug: standard of care observational follow-up
Sponsors: Gradalis, Inc.; Gradalis, Inc.
Recruiting - verified May 2012
Bevacizumab With or Without Fosbretabulin Tromethamine in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: fosbretabulin tromethamine
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
An Easy Sonographic Scoring System for Predicting Malignant Thyroid Nodules

Condition: Thyroid Cancer
Intervention:
Sponsors: Far Eastern Memorial Hospital; Far Eastern Memorial Hospital
Recruiting - verified September 2011
Role of Cyberknife Stereotactic Radiation Therapy (SBRT) Followed by Gemcitabine for Patients With Locally Advanced Pancreatic Cancer

Conditions: Pancreatic Cancer; Unresectable Pancreatic Cancer
Intervention: Radiation: stereotactic body radiotherapy
Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); Centre hospitalier de l'Université de Montréal (CHUM); Centre de Recherche du Centre Hospitalier de l'Université de Montréal
Recruiting - verified December 2011
Study of Heart Effects When Growth Hormone (GH) is Used for Growth Hormone Deficiency (GHD) Following Cure of Acromegaly

Condition: Acromegaly
Intervention: Procedure: echocardiogram
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified May 2012
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Biological: IMM-101; Drug: Gemcitabine
Sponsors: Immodulon Therapeutics Ltd; Immodulon Therapeutics Ltd
Recruiting - verified March 2012
Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer

Conditions: Cholangiocarcinoma; Pancreatic Cancer
Intervention: Device: Endoscopic bipolar radiofrequency probe (ENDOHPB)
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University; EMcision Limited
Recruiting - verified January 2012
Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment

Conditions: Locally Advanced or Metastatic Medullary Thyroid Cancer; Medullary Thyroid Cancer
Intervention: Behavioral: Patient outreach
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified November 2011
Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients

Conditions: Invasive Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer
Intervention: Drug: Propranolol (Inderal)
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011
Safety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer

Condition: Metastatic Pancreatic Cancer
Interventions: Drug: Gemcitabine+erlotinib; Drug: Gemcitabine+erlotinib+capecitabine
Sponsors: Spanish Cooperative Group for Gastrointestinal Tumour Therapy; Spanish Cooperative Group for Gastrointestinal Tumour Therapy; Hoffmann-La Roche
Recruiting - verified February 2012
Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas

Condition: Pancreatic Cancer
Interventions: Biological: ganitumab; Drug: capecitabine; Drug: gemcitabine hydrochloride; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Epidemiological Study of the Prevalence of Age-Related Macular Degeneration in Portugal

Conditions: Age-Related Macular Degeneration; Other Ocular Disease Such as: Diabetic Retinopathy, Glaucoma, Cataract, Etc.
Intervention:
Sponsors: Association for Innovation and Biomedical Research on Light and Image; Association for Innovation and Biomedical Research on Light and Image
Recruiting - verified September 2011
Genetic Association of Diabetic Retinopathy-1

Conditions: Diabetes; Diabetic Retinopathy
Intervention:
Sponsors: Taipei Veterans General Hospital,Taiwan; Taipei Veterans General Hospital,Taiwan; Yen Tjing Ling Medical Foundation
Recruiting - verified December 2011
Complementary and Integrative Therapy for Diabetic Neuropathy

Conditions: Diabetes Mellitus, Type 2; Diabetic Neuropathy
Intervention: Other: inpatient integrative treatment
Sponsors: Universität Duisburg-Essen; Universität Duisburg-Essen
Recruiting - verified January 2012
Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer

Condition: Resectable Pancreatic Cancer
Intervention: Drug: Abraxane plus Gemcitabine
Sponsors: Pancreatic Cancer Research Team; Pancreatic Cancer Research Team; Celgene Corporation
Recruiting - verified November 2011
Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: intraperitoneal chemotherapy; Genetic: gene expression analysis; Genetic: protein analysis; Other: flow cytometry; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2012
Outcome of Second Generation Drug-eLuting Stents in Patients With Diabetes Mellitus

Conditions: Coronary Artery Disease; Diabetes Mellitus
Interventions: Device: Taxus Element stent; Device: Integrity Resolute stent; Device: Xience Prime stent
Sponsors: Policlinico Casilino ASL RMB; Policlinico Casilino ASL RMB; Azienda Ospedaliera - Universitaria di Modena
Recruiting - verified August 2011
Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial

Conditions: Histologically or Cytologically Confirmed Pancreatic Ca; Unresectable or Borderline Resectable Pancreatic Ca
Interventions: Drug: Gemcitabine; Procedure: Intra Arterial Catheterization and Embolization; Device: Indwelling Intraarterial Catheter
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified December 2011
Vitamin D Repletion in Primary Hyperparathyroidism

Conditions: Primary Hyperparathyroidism; Vitamin D Deficiency
Interventions: Dietary Supplement: 50,000 IU Vitamin D3; Dietary Supplement: 12,000 IU Vitamin D3; Dietary Supplement: Placebo
Sponsors: Columbia University; Columbia University; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting - verified October 2011
VTX-2337 and Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: TLR8 agonist VTX-2337; Drug: pegylated liposomal doxorubicin hydrochloride; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Effect of Autonomic Neuropathy on the Efficacy of a DPP-IV Inhibitor (Galvus) Therapy

Condition: Diabetes Mellitus
Intervention: Drug: Vildagliptin
Sponsors: University Hospital, Toulouse; University Hospital, Toulouse; Institute of Molecular Medicine of Rangueil (I2MR); Faculty of Medicine, Toulouse; Novartis Pharmaceuticals
Recruiting - verified October 2011
Panitumumab and Gemcitabine in Relapsed Ovarian Cancer

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
Intervention: Biological: Panitumumab
Sponsors: Women and Infants Hospital of Rhode Island; Women and Infants Hospital of Rhode Island; Amgen
Recruiting - verified March 2012
The Role of Elastography in the Diagnosis of Thyroid Nodules

Conditions: Thyroid Nodule; Thyroid Neoplasms
Intervention: Other: Elastography
Sponsors: Centre Hospitalier Universitaire de Nīmes; Centre Hospitalier Universitaire de Nīmes
Recruiting - verified November 2011
Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors or Advanced Pancreatic Cancer

Conditions: Adenocarcinoma of the Pancreas; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: dovitinib lactate; Drug: gemcitabine hydrochloride; Drug: capecitabine; Other: laboratory biomarker analysis; Other: enzyme-linked immunosorbent assay; Other: pharmacological study
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; Novartis Pharmaceuticals
Recruiting - verified April 2012
Safety and Pharmacokinetics of CBX129801 in Patients With Type 1 Diabetes

Conditions: Type 1 Diabetes; Diabetes Mellitus; Peripheral Diabetic Neuropathy
Interventions: Drug: CBX129801; Drug: Placebo
Sponsors: Cebix Incorporated; Cebix Incorporated
Recruiting - verified February 2012
Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study

Conditions: Hypertension; Diabetes; Death From Cardiovascular Disease; Myocardial Infarction; Stroke
Intervention:
Sponsors: Imperial College London; Imperial College London; Pfizer
Not yet recruiting - verified December 2011
High Intensity Focused Ultrasound (HIFU) for Parathyroid Adenoma

Condition: Parathyroid Adenomas
Intervention: Device: High Intensity Focused Ultrasound
Sponsors: Oxford University Hospitals NHS Trust; Oxford University Hospitals NHS Trust; Theraclion
Recruiting - verified June 2011
Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors

Conditions: Advanced Solid Malignant Tumors; Advanced Ovarian Cancer
Intervention: Drug: U3-1565
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified March 2012
A Study of RO5185426 (Vemurafenib) in Patients With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation

Condition: Neoplasms
Intervention: Drug: RO5185426
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
The Effect of Guided Imagery and Music Therapy on Post-Operative Recovery After Gynecological Oncology Surgery

Conditions: Ovarian Cancer; Uterine Cancer
Interventions: Behavioral: Guided imagery and music therapy; Behavioral: White Noise; Other: No intervention
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012
MK-2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
Intervention: Drug: MK-2206
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Recruiting - verified February 2012
Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer

Conditions: Bladder Cancer; Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Liver Cancer; Lung Cancer; Pancreatic Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions: Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: veliparib; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); University of Pittsburgh; National Cancer Institute (NCI)
Recruiting - verified August 2011
The Diagnostic Accuracy of the Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and the Hypothalamic-Pituitary-Adrenal Axis

Conditions: Adult Growth Hormone Deficiency; Hypothalamic-pituitary Disorders
Interventions: Procedure: Glucagon stimulation test and insulin tolerance test; Procedure: glucagon stimulation test and insulin tolerance test
Sponsors: The Cleveland Clinic; The Cleveland Clinic; Massachusetts General Hospital; Allegheny Endocrinology Associates; Oregon Health and Science University
Recruiting - verified January 2011
Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: ICM plus Olaparib; Drug: ICM without Olaparib
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified September 2011
Study to Evaluate Cinacalcet HCl in Pediatric Subjects With Chronic Kidney Disease

Conditions: Chronic Kidney Disease; Hyperparathyroidism, Secondary; Secondary Hyperparathyroidism
Intervention: Drug: Cinacalcet HCl
Sponsors: Amgen; Amgen
Recruiting - verified April 2012
Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation (PRP) and PRP (Monotherapy) in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy (PDR).

Conditions: High Risk Proliferative Diabetic Retinopathy; Diabetes Mellitus Type I; Diabetes Mellitus Type II
Interventions: Procedure: Panretinal Photocoagulation (PRP); Drug: Intravitreous injection of pegaptanib
Sponsors: Association for Innovation and Biomedical Research on Light and Image; Association for Innovation and Biomedical Research on Light and Image
Recruiting - verified September 2011
Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis® Monotherapy Compared With Lucentis® Plus Panretinal Photocoagulation (PRP) and PRP in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy

Condition: High Risk Proliferative Diabetic Retinopathy
Interventions: Procedure: Panretinal Photocoagulation (PRP); Drug: Intravitreous injection of ranibizumab
Sponsors: Association for Innovation and Biomedical Research on Light and Image; Association for Innovation and Biomedical Research on Light and Image
Recruiting - verified January 2011
Examination of Pregabalin Access for Treatment of Indicated Pain Disorders: the ExPAND Study

Conditions: Fibromyalgia; Painful Diabetic Peripheral Neuropathy
Interventions: Other: prior authorization; Other: no prior authorization; Other: prior authorization; Other: no prior authorization
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Pediatric Chronic Kidney Disease Safety and Efficacy

Conditions: Chronic Kidney Disease; Hyperparathyroidism; Hyperparathyroidism, Secondary; Kidney Disease; Secondary Hyperparathyroidism
Interventions: Drug: cinacalcet capsule; Drug: placebo capsule; Drug: cinacalcet tablet; Drug: placebo tablet
Sponsors: Amgen; Amgen
Recruiting - verified April 2012
Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients With Relapsed Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Conditions: Fallopian Tube Cancer; Peritoneal Cavity Cancer; Recurrent Ovarian Epithelial Cancer
Interventions: Drug: everolimus; Drug: carboplatin; Drug: pegylated liposomal doxorubicin hydrochloride; Other: laboratory biomarker analysis
Sponsors: Fox Chase Cancer Center; Fox Chase Cancer Center; National Cancer Institute (NCI)
Recruiting - verified September 2011
Gemcitabine Pharmacokinetics

Condition: Pancreatic Cancer
Intervention: Drug: Gemcitabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer

Conditions: Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Primary Peritoneal Neoplasm
Interventions: Biological: KHK2866; Drug: Gemcitabine and Carboplatin; Drug: paclitaxel; Drug: pegylated liposomal doxorubicin
Sponsors: Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin Pharma, Inc.
Recruiting - verified February 2012
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers

Conditions: Mesothelioma; Pancreatic Cancer; Ovarian Cancer; Non-small Cell Lung Cancer
Intervention: Drug: Amatuximab
Sponsors: Morphotek; Morphotek
Recruiting - verified January 2012
Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: Hydroxychloroquine; Drug: Hydroxychloroquine
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Massachusetts General Hospital
Recruiting - verified March 2012
Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction

Condition: Graves Ophthalmopathy
Interventions: Drug: Botulinum Toxin Type A; Drug: Saline injection
Sponsors: University of Toronto; University of Toronto; Allergan
Not yet recruiting - verified December 2010
Sonographic and Laboratory Evaluation of the Thyroid Gland in Patients With Systemic Sclerosis

Conditions: Systemic Sclerosis; Hashimoto Thyroiditis; Thyroid Nodules
Intervention:
Sponsors: Meir Medical Center; Meir Medical Center
Recruiting - verified March 2012
A Trial of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer

Condition: Thyroid Cancer
Interventions: Drug: Everolimus; Drug: Pasireotide; Drug: Everolimus and Pasireotide
Sponsors: Emory University; Emory University; Novartis
Recruiting - verified April 2012
Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer

Condition: Metastatic Pancreatic Cancer
Interventions: Biological: bavituximab; Drug: Gemcitabine
Sponsors: Peregrine Pharmaceuticals; Peregrine Pharmaceuticals
Recruiting - verified May 2012
Thyroid Cancer Among Chornobyl Clean-up Workers in Ukraine: Pilot Studyy

Condition: Thyroid Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified April 2012
Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma

Condition: Non-functioning Pituitary Adenoma
Intervention: Drug: Pasireotide LAR
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified March 2012
Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs

Condition: Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System
Interventions: Drug: Pasireotide LAR followed by Pasireotide LAR + Everolimus; Drug: Everolimus followed by Pasireotide LAR + Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012
Tissue Biomarker for Pegvisomant Action

Condition: Acromegaly
Intervention: Drug: Pegvisomant
Sponsors: Cedars-Sinai Medical Center; Cedars-Sinai Medical Center
Recruiting - verified February 2012
Narrow Band Imaging (NBI): A Novel Imaging Modality in Laparoscopic and Robotic Surgery

Conditions: Endometrial Cancer; Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer
Intervention: Other: Narrow Band Imaging (NBI)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2012
Glutathione in Diabetic Nephropathy

Conditions: Diabetic Nephropathy; Proteinuria; Oxidative Stress
Interventions: Drug: N-acetylcysteine placebo + silibin placebo; Drug: N-acetylcysteine active + silibin placebo; Drug: N-acetylcysteine placebo + silibin active; Drug: N-acetylcysteine active + silibin active; Drug: N-acetylcysteine active + high-dose silibin active
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified April 2012
Characterization of Ovarian Cancer Stem Cell

Condition: Ovarian Cancer
Intervention: Procedure: surgery or debulking surgery
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital
Recruiting - verified May 2011
Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment

Conditions: Diabetic Retinopathy; Macular Oedema
Intervention: Drug: Ranibizumab
Sponsors: Novartis; Novartis
Recruiting - verified April 2012
To Study Polycystic Ovary Syndrome in Taiwanese Women

Conditions: Polycystic Ovary Syndrome; Metabolic Syndrome; Cardiovascular Disease
Intervention:
Sponsors: Taipei Medical University WanFang Hospital; Taipei Medical University WanFang Hospital
Recruiting - verified October 2011
Comparative Study of 1000 Centistoke Versus 5000 Centistoke Silicone Oil for Repair of Complex Retinal Detachments

Conditions: Retinal Detachment; Vitrectomy; Proliferative Vitreoretinopathy; Diabetic Retinopathy
Interventions: Procedure: 1000 centistoke silicone oil; Procedure: 5000 centistoke silicone oil
Sponsors: Mid Atlantic Retina; Mid Atlantic Retina
Recruiting - verified February 2012
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer

Condition: Adrenal Cortex Neoplasms
Intervention: Drug: Axitinib
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI); Pfizer Pharmaceuticals, Inc.
Recruiting - verified July 2011
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes

Conditions: Renal Insufficiency, Chronic; Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Bardoxolone Methyl: 20 mg
Sponsors: Reata Pharmaceuticals, Inc.; Reata Pharmaceuticals, Inc.
Recruiting - verified May 2012
Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids

Conditions: Endometrial Cancer; Ovarian Cancer
Interventions: Drug: Ridaforolimus; Drug: Paclitaxel; Drug: carboplatin
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Merck
Recruiting - verified April 2012
Cancer Screening Program for Women at High Risk for Developing Ovarian Cancer

Conditions: Ovarian Diseases; Ovarian Neoplasms
Interventions: Other: Laboratory Tumor Marker Analysis; Other: Transvaginal Ultrasound; Other: Health Status Questionnaire
Sponsors: Swedish Medical Center; Swedish Medical Center; Fred Hutchinson Cancer Research Center; The Marsha Rivkin Center for Ovarian Cancer Research
Recruiting - verified May 2012
Study to Assess Patient Management Practices and Quality of Life With Paricalcitol Capsules in the Treatment of Secondary Hyperparathyroidism in Stage 3-5 Chronic Kidney Disease Patients Not Yet on Dialysis

Conditions: Secondary Hyperparathyroidism; Chronic Kidney Disease
Intervention:
Sponsors: Abbott; Abbott; Pharma Consulting Group
Recruiting - verified March 2012
Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection

Conditions: Anal Cancer; Breast Cancer; Esophageal Cancer; Gastric Cancer; Head and Neck Cancer; Lung Cancer; Nonneoplastic Condition; Ovarian Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: vorinostat; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012
Comparing Parenteral Nutrition vs Best Supportive Nutritional Care in Patients With Pancreatic Cancer

Condition: Pancreatic Cancer
Intervention: Drug: SMOF Kabiven
Sponsors: National Center for Tumor Diseases, Heidelberg; National Center for Tumor Diseases, Heidelberg; University of Heidelberg
Recruiting - verified April 2012
Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
Interventions: Drug: carboplatin; Drug: carboplatin
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Institutes of Health (NIH)
Recruiting - verified November 2011
Study of Intratumoral Hypoxia Using Pre-operative Administration of Pimonidazole

Condition: Pancreatic Cancer
Intervention: Drug: Pimonidazole hydrochloride
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified October 2011
DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study

Conditions: Pleuropulmonary Blastoma; Cystic Nephroma; Ovarian Sertoli-Leydig Cell Tumors; Ocular Medulloepithelioma; Nasal Chondromesenchymal Hamartoma
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified August 2011
Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission

Conditions: Fallopian Tubes; Ovarian Cancer; Peritoneal Cancer
Intervention: Biological: Globo-H-GM2-sTn-TF-Tn-KLH conjugate, plus the immunological adjuvant QS-21
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2012
Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients

Conditions: Depression; PCOS
Interventions: Dietary Supplement: Inositol; Dietary Supplement: Placebo
Sponsors: AGUNCO Obstetrics and Gynecology Centre; AGUNCO Obstetrics and Gynecology Centre; Centro Clinico Colle Cesarano Tivoli Rome Italy
Recruiting - verified June 2011
Perioperative Morbidity in Gyneco-oncology According to the Procedure : Coelioscopy Versus Robot-assisted Coelioscopy

Conditions: Cervical Cancer; Uterus Cancer; Ovarian Cancer
Intervention: Procedure: gynecologic surgery
Sponsors: Centre Oscar Lambret; Centre Oscar Lambret; CRG : Groupe Francophone de Chirurgie Robotique en Gynécologie
Recruiting - verified December 2011
Adrenalectomy Versus Follow-up in Patients With Subclinical Cushings Syndrome

Condition: Adrenal Tumour With Mild Hypercortisolism
Intervention: Procedure: Adrenalectomy
Sponsors: Region Skane; Region Skane
Recruiting - verified January 2012
Whole Body Diffusion MRI for Non-invasive Lesion Detection and Therapy Follow-up: Study With Patients With Ovarian Cancer and Peritoneal Metastasis

Conditions: Ovarian Cancer; Peritoneal Metastasis
Intervention: Procedure: intravenous contrast administration
Sponsors: Universitaire Ziekenhuizen Leuven; Universitaire Ziekenhuizen Leuven
Recruiting - verified September 2011
Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer

Conditions: Testicular Cancer; Germ Cell Cancer
Intervention: Drug: Everolimus
Sponsors: Hannover Medical School; Hannover Medical School; Novartis
Recruiting - verified November 2010
Mycophenolate Mofetil, Carnitine and PDE5 Inhibitor, Three Potential Treatments for Resistant Proteinuria Slowing Diabetic Nephropathy Deterioration

Conditions: Diabetic Nephropathy; Chronic Kidney Disease
Intervention: Drug: Mycophenolate Mofetil (MMF) ,phosphodiesterase 5 inhibitors , CARNITINE
Sponsors: The Nazareth Hospital, Israel; The Nazareth Hospital, Israel; Western Galilee Hospital-Nahariya
Not yet recruiting - verified March 2012
A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)

Conditions: Solid Tumor; Anaplastic Thyroid Cancer
Interventions: Drug: Cisplatin and Crolibulin; Drug: Cisplatin
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified August 2011
Elastography Interest in the Management of Thyroid Nodules

Condition: Thyroid Nodules
Intervention: Device: Medical ultrasound device (ShearWave system)
Sponsors: University Hospital, Grenoble; AdministrateurCIC
Recruiting - verified February 2012
A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: carboplatin; Drug: Paclitaxel
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
A Phase II Study to Assess the Efficacy and Safety of Preoperative Chemo With Radiation Therapy for Patients With Borderline Unresectable Adenocarcinoma of the Pancreas

Condition: Pancreatic Cancer
Interventions: Drug: Gemcitabine; Radiation: Radiation therapy; Procedure: pancreaticoduodenectomy
Sponsors: University of Arkansas; University of Arkansas
Recruiting - verified November 2011
Combination With Gemcitabine in Advanced Pancreatic Cancer

Condition: Pancreatic Neoplasms
Intervention: Drug: BAY86-9766+Gemcitabine
Sponsors: Bayer; Bayer
Recruiting - verified May 2012
Olaparib in Combination With Carboplatin for Refractory or Recurrent Women's Cancers

Conditions: Mixed Muellerian Cancer; Cervical Cancer; Ovarian Cancer; Breast Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer; Endometrial Cancer; Carcinosarcoma
Interventions: Drug: Carboplatin; Drug: Olaparib; Drug: Treatment Effect
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified August 2011
Computer-Guided Glucose Management Systems in Treating Patients With Hyperglycemia Who Have Undergone Blood and Bone Marrow Transplant

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Disseminated Neuroblastoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; High Risk Metastatic Gestational Trophoblastic Tumor; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Small Lymphocytic Lymphoma
Intervention: Other: computer-assisted intervention
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012
Statins in Children With Type 1 Diabetes and Hypercholesterolemia

Conditions: Diabetes Mellitus, Insulin-Dependent; Hypercholesterolemia
Interventions: Drug: Atorvastatin; Drug: Atorvastatin Placebo
Sponsors: Nemours Children's Clinic; Nemours Children's Clinic; Pfizer; Medtronic; Quest Diagnostics
Recruiting - verified May 2012
RO4929097 in Treating Patients With Previously Treated Metastatic Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); University of Colorado, Denver; National Cancer Institute (NCI)
Recruiting - verified July 2011
Everolimus and Octreotide With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

Conditions: Islet Cell Tumor; Pancreatic Cancer
Interventions: Biological: bevacizumab; Drug: everolimus; Drug: octreotide acetate
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Exercise Training in Patients With Coronary Heart Disease and Type 2 Diabetes

Conditions: Coronary Artery Disease; Diabetes Mellitus, Type 2; Atherosclerosis
Interventions: Behavioral: Exercise; Behavioral: Control
Sponsors: Oslo University Hospital; Oslo University Hospital
Recruiting - verified October 2010
Post-Authorisation Safety Study of Samsca (Tolvaptan) Used in Routine Medical Practice

Conditions: SIADH; Non-SIADH Hyponatremia; Non-Hyponatremia
Intervention: Drug: Tolvaptan
Sponsors: Otsuka Frankfurt Research Institute GmbH; Otsuka Frankfurt Research Institute GmbH
Recruiting - verified November 2011
Differential Diagnosis Value of PSV of Thyroid Superior Artery Using Color Flow Doppler Sonography in Transient Thyrotoxicosis

Conditions: Thyrotoxicosis; Peak Systolic Velocity of Superior Thyroid Artery; Thyroiditis; Graves Disease
Intervention:
Sponsors: Huashan Hospital; xiaolong zhao; zhongda hospital of southeast university; Fudan University
Recruiting - verified November 2011
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia

Conditions: Hyponatremia; Dilutional Hyponatremia; Inappropriate ADH Syndrome
Interventions: Drug: tolvaptan; Other: Fluid Restriction
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified April 2012
Topical Application of Latanoprost in Diabetic Retinopathy

Condition: Diabetic Retinopathy
Intervention: Drug: Latanoprost
Sponsors: University of Aarhus; Aarhus University Hospital
Recruiting - verified November 2011
Hsp90 Inhibitor STA-9090 as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Conditions: Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IV Pancreatic Cancer
Interventions: Drug: Hsp90 inhibitor STA-9090; Other: laboratory biomarker analysis
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified November 2011
Studies of Disorders With Increased Susceptibility to Fungal Infections

Conditions: Primary Immune Deficiency; Candida; Autoimmune Polyendocrinopathy Candidiasis Ectodermal; Chronic Mucocutaneous Candidiasis (CMC); Fungal Infection
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2011
Systematic Treatment After Successful Surgical Treatment for Primary Hyperparathyroidism With Strontium Ranelate

Condition: Cured Primary Hyperparathyroidism, Concommitant Osteopenia or Osteoporosis
Interventions: Drug: Strontium Ranelate + Ca/Vitamin-D; Drug: Placebo
Sponsors: Medical University of Vienna; Medical University of Vienna; National Bank of Austria
Recruiting - verified April 2010
GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Conditions: Adenocarcinoma of the Pancreas; Advanced Solid Tumors; Cancer; Cancer of Pancreas; Cancer of the Pancreas; Metastases; Metastatic Cancer; Metastatic Pancreatic Cancer; Pancreas Cancer; Pancreatic Cancer; Bone Metastases; Endocrine Cancer; Oncology; Oncology Patients; Solid Tumors; Advanced Malignancy
Interventions: Drug: AMG 479; Drug: Placebo; Drug: AMG 479; Drug: gemcitabine
Sponsors: Amgen; Amgen; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2012
Safety and Efficacy Study of ONGLYZA (Saxagliptin) Under Conditions of Actual Use

Condition: Type 2 Diabetes Mellitus
Intervention:
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified January 2012
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy

Conditions: Melanoma; Ovarian Cancer; Sarcoma; BONE; CNS-SPINAL CD/MEMBR,NOS; LYMPH NODES; SOFT TISSUE
Interventions: Radiation: IGIMRT using a single dose of 24 Gy; Radiation: IGIMRT 27 Gy in 3 fractions
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; University of Pisa
Recruiting - verified March 2012
Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab

Conditions: Fallopian Tubes Cancer; Ovarian Cancer; Peritoneal Cancer
Intervention: Biological: bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Genentech
Recruiting - verified February 2012
Evaluation of Blood-retinal Barrier Functional Alterations by Optical Coherence Tomography

Condition: Diabetic Retinopathy
Intervention:
Sponsors: Association for Innovation and Biomedical Research on Light and Image; Association for Innovation and Biomedical Research on Light and Image; Fundação para a Ciência e a Tecnologia; Instituto Financeiro para o Desenvolvimento Regional
Recruiting - verified September 2011
Pancreatic Intraepithelial Neoplasia (PanIN) and the Association With Recurrence of Pancreatic Adenocarcinoma

Condition: Pancreatic Cancer
Intervention:
Sponsors: Columbia University; Columbia University; Cold Spring Harbor Laboratory
Recruiting - verified February 2012
Impact of Vitamin D on Diabetic Kidney Disease in African Americans

Condition: Diabetic Kidney Disease
Interventions: Drug: Vitamin D3; Drug: Vitamin D3
Sponsors: Medical University of South Carolina; Medical University of South Carolina
Recruiting - verified October 2010
Preventing Renal Functional Abnormalities With Calorie Restriction in Subjects With Abdominal Obesity and Type 2 Diabetes at Increased Renal and Cardiovascular Risk

Condition: Diabetes Mellitus
Interventions: Other: Diet; Other: No intervention
Sponsors: Mario Negri Institute for Pharmacological Research; Mario Negri Institute for Pharmacological Research; Istituto Superiore di Sanita
Recruiting - verified June 2011
Trientine Hydrochloride for the Prevention of Macular Edema Associated With Pan-retinal Photocoagulation for Severe Non-proliferative and Proliferative Diabetic Retinopathy

Condition: Diabetic Retinopathy
Interventions: Drug: Trientine Hydrochloride; Drug: Oral placebo capsules
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified June 2011
Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors

Conditions: Neuroendocrine Tumors; Pancreatic Neoplasms; Advanced Disease; Sunitinib
Intervention: Drug: Sutent
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris
Recruiting - verified March 2010
Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT)

Conditions: Chronic Kidney Disease; Secondary Hyperparathyroidism
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified December 2011
The Effect of Pharmacological Antilipolysis on the Metabolic Effects of Ghrelin

Conditions: Metabolism; Insulin Resistance; Hypopituitarism
Interventions: Drug: Acipimox; Drug: Ghrelin; Other: Placebo
Sponsors: University of Aarhus; University of Aarhus
Not yet recruiting - verified March 2012
Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer

Conditions: Healthy, no Evidence of Disease; Hereditary Breast/Ovarian Cancer - BRCA1; Hereditary Breast/Ovarian Cancer - BRCA2
Interventions: Other: questionnaire administration; Other: survey administration; Other: counseling intervention; Other: educational intervention
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified May 2012
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer

Condition: Head and Neck Cancer
Interventions: Drug: cediranib maleate; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); University of Chicago; National Cancer Institute (NCI)
Recruiting - verified October 2010
Thymus Transplantation Safety-Efficacy

Conditions: Complete DiGeorge Anomaly; DiGeorge Syndrome; DiGeorge Anomaly; Complete DiGeorge Syndrome
Interventions: Biological: Thymus Transplantation; Procedure: Blood Draw
Sponsors: Duke University; M. Louise Markert; National Institutes of Health (NIH); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified February 2012
Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer

Conditions: Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Carcinoma; Primary Peritoneal Carcinoma
Intervention: Drug: Lenalidomide, Liposomal Doxorubicin, Bevacizumab
Sponsors: New Mexico Cancer Care Alliance; New Mexico Cancer Care Alliance; Celgene Corporation
Recruiting - verified December 2011
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Condition: Diabetic Nephropathies
Interventions: Drug: PF-00489791; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Characterization of Metabolic Biomarkers in Varying Subjects

Conditions: Obesity; Type 2 Diabetes
Intervention:
Sponsors: CPL Associates; CPL Associates; VascuFlo Inc.
Recruiting - verified June 2011
Evaluation of SJG-136 for Cisplatin- Refractory /Resistant Epithelial Ovarian

Condition: Ovarian Carcinoma
Intervention: Drug: SJG-136
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI)
Recruiting - verified March 2012
Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: wild-type reovirus; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2012
The Clinical,Radiologic,Pathologic and Molecular Marker Characteristics of Pancreatic Cysts Study

Conditions: Pancreatic Cysts; Pancreatic Cancer
Intervention:
Sponsors: Johns Hopkins University; Johns Hopkins University; The Lustgarten Foundation
Recruiting - verified March 2012
Predictors of Ovarian Insufficiency in Young Breast Cancer Patients

Conditions: Breast Cancer; Ovarian Insufficiency; Ovarian Failure
Intervention:
Sponsors: University of California, San Diego; University of California, San Diego; University of Pennsylvania; American Cancer Society; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified August 2011
A Multi-site, Individually Randomized, Controlled Translation Trial of Integrated and Comprehensive Care Strategies to Reduce Cardiovascular Disease (CVD) Risk Among 1,120 Type 2 Diabetes Mellitus(T2DM) Patients in South Asia

Conditions: Type 2 Diabetes Mellitus; Hypertension; Dyslipidaemia
Interventions: Other: Care Coordinator + Decision Support Software; Other: Usual care
Sponsors: Public Health Foundation of India; Public Health Foundation of India; National Heart, Lung and Blood Institute, USA; United Health Group, USA; All India Institute of Medical Sciences, New Delhi; Madras Diabetes Research Foundation, Chennai; Aga Khan University
Recruiting - verified September 2011
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Clear Cell Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified November 2011
A Phase I Study of MGAH22 in Patients With Refractory HER2 Positive Cancers

Conditions: Non-Small Cell Lung Neoplasms; Prostate Neoplasms; Bladder Neoplasms; Ovarian Neoplasms; Breast Neoplasms
Intervention: Drug: MGAH22
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012
Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer

Conditions: Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer
Interventions: Drug: Gemcitabine; Drug: Vinorelbine
Sponsors: The Catholic University of Korea; The Catholic University of Korea; Korean Cancer Study Group
Recruiting - verified February 2012
Cancer Stem Cells and Inhibition of Hedgehog Pathway Signaling in Advanced Pancreas Cancer: A Pilot Study of GDC-0449 in Combination With Gemcitabine

Condition: Pancreatic Cancer
Interventions: Drug: GDC-0449; Drug: Gemcitabine
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012
Epithelial Ovarian Cancer- Staging and Response to Chemotherapy Evaluated by PET/CT

Conditions: Epithelial Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer
Intervention:
Sponsors: Turku University Hospital; Turku University Hospital
Recruiting - verified January 2012
Intravitreal Bevacizumab (Avastin®) Versus Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema

Conditions: Diabetic Retinopathy; Macular Edema
Interventions: Drug: bevacizumab; Drug: dexamethasone
Sponsors: University of Sydney; University of Sydney; National Health and Medical Research Council, Australia
Recruiting - verified February 2012
Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease

Conditions: Hyperparathyroidism; Chronic Kidney Disease
Interventions: Drug: sevelamer carbonate; Drug: placebo
Sponsors: Phelps, Kenneth R., M.D.; Phelps, Kenneth R., M.D.
Recruiting - verified June 2011
Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer

Conditions: Recurrent Colon Cancer; Recurrent Gastric Cancer; Recurrent Pancreatic Cancer; Recurrent Rectal Cancer; Stage III Colon Cancer; Stage III Gastric Cancer; Stage III Pancreatic Cancer; Stage III Rectal Cancer; Stage IV Colon Cancer; Stage IV Gastric Cancer; Stage IV Pancreatic Cancer; Stage IV Rectal Cancer
Interventions: Other: laboratory biomarker analysis; Other: enzyme-linked immunosorbent assay; Other: flow cytometry; Other: immunoenzyme technique; Biological: modified vaccinia virus ankara vaccine expressing p53
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified December 2011
TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: AMG 386 Placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012
A Study of Gemcitabine Plus OMP-21M18 as 1st-line Treatment in Subjects With Pancreatic Cancer

Condition: Pancreatic Cancer
Intervention: Drug: OMP-21M18
Sponsors: OncoMed Pharmaceuticals, Inc.; OncoMed Pharmaceuticals, Inc.; Novotech (Australia) Pty Ltd
Recruiting - verified December 2010
Phase II of Carbo/Pralatrexate in Rec. Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
Interventions: Drug: carboplatin; Drug: pralatrexate
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Dana-Farber Cancer Institute; Brigham and Women's Hospital; National Comprehensive Cancer Network
Recruiting - verified April 2012
Short Non-coding RNA Biomarkers of Predisposition to Ovarian Cancer

Condition: Ovarian Cancer
Intervention:
Sponsors: University of Virginia; University of Virginia
Recruiting - verified May 2011
The Natural History of Reproductive and Overall Health in Girls and Women With a Pre-Mutation in the FMR1 Gene; Creation of a Patient Registry

Conditions: Fragile X Syndrome; FMR1 Premutation; Primary Ovairan Insufficiency; Premature Ovarian Failure; Premature Menopause
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified July 2011
Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy

Condition: Gastric Cancers
Intervention:
Sponsors: University of Chicago; University of Chicago
Recruiting - verified August 2011
Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer

Conditions: Non-Small-Cell Lung Carcinoma; Liver Cancer; Adrenal Cancer
Intervention: Radiation: stereotactic body radiation therapy
Sponsors: Wake Forest University; Wake Forest University
Recruiting - verified October 2011
ROGYcare: The Impact of a Cancer Survivorship Care Plan on Patient Reported Outcomes and Health Care Providers

Conditions: Ovarian Cancer; Endometrium Cancer
Intervention: Other: SCP care
Sponsors: University of Tilburg; Lonneke van de Poll-Franse; Comprehensive Cancer Centre South (CCCS); Dutch Cancer Society
Recruiting - verified August 2011
A Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) for the Treatment of Chronic Renal Anaemia in Patients With Diabetic Nephropathy

Condition: Anemia
Intervention: Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin

Condition: Thyroid Neoplasm
Intervention: Drug: Valproic Acid
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011
Comparison of Metal and Plastic Stents for Preoperative Biliary Decompression

Conditions: Obstructive Jaundice; Pancreatic Cancer
Interventions: Procedure: Metal stent placement in the bile duct; Procedure: Plastic stent
Sponsors: University of Alabama at Birmingham; Shyam Varadarajulu; University of Virginia
Recruiting - verified October 2011
Trial of High Dose Topotecan With Carboplatin in Patients With Relapsed Ovarian Carcinoma

Conditions: Ovarian Cancer; Relapses
Intervention: Drug: Topotecan
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris
Recruiting - verified July 2011
Changes in Performance Status and Symptom Distress in Older Patients With Advanced Ovarian Epithelial Cancer Undergoing Surgery and/or Chemotherapy

Condition: Ovarian Cancer
Interventions: Other: Palliative Performance Scale version 2 (PPSv2); Other: McCorkle Symptom Distress Scale (SDS); Other: Geriatric Assessment; Other: Medical Records Abstraction
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
AXP107-11 in Combination With Standard Gemcitabine (Gemzar® ) Therapy for Treatment in Patients With Pancreatic Cancer

Condition: Adenocarcinoma
Intervention: Drug: AXP107-11
Sponsors: Axcentua Pharmaceuticals AB; Axcentua Pharmaceuticals AB
Recruiting - verified June 2011
A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Insulin Lispro; Drug: Insulin Glargine
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012
Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Insulin Lispro; Drug: Insulin Glargine
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified March 2012
Chemoradiation With Gemcitabine in Combination With Panitumumab for Patients With Locally Advanced Pancreatic Cancer

Condition: Pancreatic Cancer
Intervention: Drug: Panitumumab
Sponsors: VU University Medical Center; VU University Medical Center; Amgen
Recruiting - verified February 2012
A Phase II Study Using Short-Term Cultured, CD8+-Enriched Autologous Tumor-infiltrating Lymphocytes Following a Lymphocyte Depleting Regimen in Metastatic Digestive Tract Cancers

Conditions: Metastatic Colorectal Cancer; Metastatic Gastric Cancer; Metastatic Pancreatic Cancer; Metastatic Hepatocellular Carcinoma; Metastatic Cholangiocarcinoma
Interventions: Drug: CD8+ young TIL; Drug: Aldesleukin; Drug: Cyclophosphamide; Drug: Fludarabine
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012
Noninvasive Methods in Diagnosing Coronary Heart Disease in Diabetic Patients

Condition: Type 2 Diabetes
Intervention: Other: Diagnostic
Sponsors: Norwegian University of Science and Technology; Norwegian University of Science and Technology; Volda Hospital
Recruiting - verified December 2011
Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema

Conditions: Anti- VGF Inhibitor; Diabetic Macular Edema; Diabetic Retinopathy
Intervention: Drug: pega
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision

Conditions: Pancreatic Neoplasms; Pancreatic Cancer
Interventions: Drug: Gemcitabine and cisplatin; Drug: Gemcitabine / Cisplatin
Sponsors: Emory University; Emory University
Recruiting - verified May 2012
Study of External Beam Radiotherapy to Thyroid Carcinoma

Condition: Thyroid Cancer
Intervention: Radiation: External Beam Radiotherapy
Sponsors: National Cancer Center, Korea; National Cancer Center, Korea
Recruiting - verified April 2012
Evaluation of Single Nucleotide Polymorphisms (SNPs) in Patients With and Without Diabetic Macular Edema

Conditions: Diabetic Retinopathy; Diabetic Macular Edema
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Eye Institute (NEI)
Recruiting - verified June 2011
Combination Chemotherapy With or Without Metformin Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: cisplatin; Drug: epirubicin hydrochloride; Drug: gemcitabine hydrochloride; Drug: metformin hydrochloride
Sponsors: IRCCS San Raffaele; IRCCS San Raffaele
Recruiting - verified July 2010
Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer

Condition: Pancreatic Cancer
Intervention: Drug: Vidaza
Sponsors: University of Oklahoma; University of Oklahoma; Celgene Corporation
Recruiting - verified March 2012
Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity

Conditions: Pleural Metastases; Breast Cancer; Colon Cancer; Ovarian Cancer; Uterine Cancer; Renal Cell Cancer; Thymic Cancer
Intervention: Procedure: Surgical debulking and Intrathoracic Hyperthermic Chemotherapy
Sponsors: St. Luke's-Roosevelt Hospital Center; St. Luke's-Roosevelt Hospital Center
Recruiting - verified September 2011
Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Operable Adenocarcinoma of the Pancreas

Conditions: Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer
Intervention: Drug: siG12D LODER
Sponsors: Silenseed Ltd; Silenseed Ltd
Recruiting - verified February 2012
Diabetes Peripheral Neuropathy and Small-fibre Nerve Damage: A Comparative Study

Conditions: Diabetes Mellitus; Peripheral Neuropathy; Small Fibre Neuropathy; Autonomic Neuropathy
Intervention:
Sponsors: Haukeland University Hospital; Haukeland University Hospital; Aarhus University Hospital
Recruiting - verified July 2011
Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)

Condition: Ovarian Cancer
Interventions: Drug: EC145; Drug: Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®); Drug: placebo; Drug: EC20
Sponsors: Endocyte; Endocyte
Recruiting - verified March 2012
Registry Study - Whipple at the Splenic Artery

Condition: Pancreas Cancer
Intervention: Procedure: Whipple at the Splenic Artery (WATSA)
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified February 2012
Miami Healthy Heart Initiative a Behavioral Study on Cardiovascular Risk Factors

Conditions: Diabetes; Heart Disease; Hypertension
Intervention: Behavioral: CARIÑO Project
Sponsors: University of Miami; University of Miami; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified August 2011
Trial Comparing Metabolic Efficiency of Islet Graft to Intensive Insulin Therapy for Type 1 Diabetes's Treatment

Condition: Diabetes Mellitus, Type 1
Intervention: Procedure: human pancreatic islet transplantation
Sponsors: University Hospital, Grenoble; University Hospital, Grenoble
Recruiting - verified March 2012
Gemcitabine, Cisplatin, Epirubicin, and Capecitabine in Treating Patients With Stage I-II Resectable Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: cisplatin; Drug: epirubicin hydrochloride; Drug: gemcitabine hydrochloride; Procedure: adjuvant therapy
Sponsors: IRCCS San Raffaele; IRCCS San Raffaele
Recruiting - verified July 2010
Effective Treatment of Sleep Apnea in Prediabetes to Reduce Cardiometabolic Risk

Conditions: Diabetes; Sleep Apnea
Interventions: Device: CPAP mask; Drug: Placebo
Sponsors: University of Chicago; University of Chicago
Recruiting - verified July 2010
A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving Selective Vitamin D Receptor Activator's for Prevention and Treatment of Secondary Hyperparathyroidism

Conditions: Secondary Hyperparathyroidism; End Stage Renal Disease
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified March 2012
Safety Study of MGAH22 in HER2-positive Carcinomas

Conditions: Breast Cancer; Gastric Cancer; Bladder Cancer; Ovarian Cancer; Non-small Cell Lung Cancer
Intervention: Biological: MGAH22
Sponsors: MacroGenics; MacroGenics; Green Cross Corporation; National Cancer Institute (NCI)
Recruiting - verified April 2012
Cincalcet and Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism

Conditions: Hyperparathyroidism; Arterial Stiffness
Intervention: Drug: Cinacalcet
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified June 2010
Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer

Condition: Thyroid Cancer
Intervention: Drug: sorafenib with everolimus
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012
Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer

Conditions: Breast Cancer; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Other: questionnaire administration; Procedure: evaluation of cancer risk factors; Procedure: quality-of-life assessment; Procedure: study of high risk factors
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Renal Effect of Pentoxyphylline in High Risk Patients Undergoing Angiography

Conditions: Contrast Induced Nephropathy; Diabetes Mellitus
Interventions: Drug: pentoxyphylline; Drug: placebo; Drug: pentoxiphylline; Drug: placebo
Sponsors: Meir Medical Center; Meir Medical Center
Not yet recruiting - verified May 2011
Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Intervention: Biological: Monoclonal antibody Hu3S193
Sponsors: Recepta Biopharma; Recepta Biopharma
Recruiting - verified September 2011
Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice

Conditions: Secondary Hyperparathyroidism; End-Stage Renal Disease
Interventions: Drug: Paricalcitol; Drug: Calcitriol
Sponsors: Abbott; Abbott; North America Pediatric Renal Trials and Collaborative Studies (NAPRTCS)
Recruiting - verified January 2012
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly

Condition: Acromegaly
Interventions: Drug: Pasireotide (SOM230); Drug: octreotide LAR 30mg or lanreotide ATG 120mg
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified November 2011
Autologous OC-DC Vaccine in Ovarian Cancer

Conditions: Chemotherapy; Tumor; Ovarian Cancer
Intervention: Biological: OCDC
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified May 2012
WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian Cancer

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Carcinoma
Interventions: Drug: Hyperthermic intraperitoneal chemotherapy with Carboplatin; Other: Isotonic saline (perfusate); Procedure: Surgery; Drug: Carboplatin; Drug: Paclitaxel
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2012
Rapid Gastric and Pancreas Cancer Staging Utilizing Peritoneal Lavage

Conditions: Gastric Cancer; Pancreatic Cancer
Intervention: Procedure: Diagnostic peritoneal lavage
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

Conditions: Brain and Central Nervous System Tumors; Breast Cancer; Colorectal Cancer; Kidney Cancer; Lung Cancer; Melanoma (Skin); Ovarian Cancer; Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: cediranib maleate; Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Princess Margaret Hospital, Canada; National Cancer Institute (NCI)
Recruiting - verified June 2011
Cardiovascular Intervention Improvement Telemedicine Study

Conditions: Cardiovascular Disease; Hypertension; Diabetes; Hyperlipidemia
Intervention: Behavioral: Pharmacist CVD
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified April 2012
Neoadjuvant Therapy for Ovarian Cancer

Conditions: Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer
Intervention: Drug: Carboplatin, paclitaxel, and bevacizumab
Sponsors: Columbia University; Columbia University; Genentech
Recruiting - verified October 2011
Local Invasion of Pancreatic Cancer

Condition: Pancreatic Cancer
Intervention:
Sponsors: Columbia University; Columbia University
Recruiting - verified February 2012
Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas

Condition: Pancreatic Cancer
Interventions: Drug: Hydroxychloroquine; Drug: Gemcitabine
Sponsors: University of Pittsburgh; University of Pittsburgh; National Institutes of Health (NIH)
Recruiting - verified January 2012
A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women

Condition: Epithelial Ovarian Cancer
Interventions: Procedure: CA125 assay on Abbott Architect i1000SR platform; Procedure: HE4 assay on Architect i1000SR platform; Procedure: Transvaginal Ultrasound
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; The Marsha Rivkin Center for Ovarian Cancer Research; Canary Foundation; Swedish Medical Center; Beckman Research Institute; Cedars-Sinai Medical Center; Stanford University; Fox Chase Cancer Center
Recruiting - verified February 2012
EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: EGEN-001; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2012
Cediranib and Olaparib in Combination for Recurrent Ovarian or Triple-Negative Breast Cancer

Conditions: Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer
Interventions: Drug: cediranib; Drug: olaparib
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Massachusetts General Hospital; Beth Israel Deaconess Medical Center; University of Chicago; National Cancer Institute (NCI)
Recruiting - verified April 2012
Randomized Study With Oxaliplatin in 2nd Line Pancreatic Cancer

Condition: Pancreatic Neoplasms
Interventions: Drug: Leucovorin; Drug: OXALIPLATIN; Drug: Capecitabine; Drug: 5-Fluorouracil
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified February 2012
A Study in Patients With Diabetic Kidney Disease

Conditions: Diabetic Kidney Disease; Diabetic Nephropathy; Diabetic Glomerulosclerosis
Interventions: Drug: LY2382770; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012
A Phase 1 Study in Patients With Advanced Cancer

Conditions: Advanced Cancer; Non Small Cell Lung Cancer; Colorectal Cancer; Ovarian Cancer
Intervention: Drug: LY2606368
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified November 2011
Genetic Modifiers of Cystic Fibrosis Related Diabetes

Condition: Cystic Fibrosis Related Diabetes
Intervention:
Sponsors: Johns Hopkins University; Johns Hopkins University; Cystic Fibrosis Foundation; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University of Minnesota - Clinical and Translational Science Institute; Vanderbilt University; Northwestern University; Emory University
Recruiting - verified June 2011
Biobehavioral Influences and the Ovarian Tumor Microenvironment

Condition: Ovarian Neoplasms
Intervention:
Sponsors: Washington University School of Medicine; Washington University School of Medicine; University of Iowa
Recruiting - verified October 2011
Tissue Characterisation by Endoscopic GI-elastography

Conditions: Disorder of Upper Gastrointestinal Tract; Pancreatic Nodule; Secondary and Unspecified Malignant Neoplasm of Retroperitoneal Lymph Nodes; Secondary and Unspecified Malignant Neoplasm of Mediastinal Lymph Nodes
Intervention:
Sponsors: Haukeland University Hospital; Haukeland University Hospital; University of Bergen
Recruiting - verified May 2011
A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse

Condition: Ovarian Cancer Recurrent
Intervention: Drug: Lenalidomide
Sponsors: ARCAGY/ GINECO GROUP; ARCAGY/ GINECO GROUP
Recruiting - verified February 2011
Aldosterone and the Metabolic Syndrome

Conditions: Metabolic Diseases; Diabetes Mellitus; Endocrine System Diseases; Glucose Metabolism Disorders
Interventions: Drug: Renin-Angiotensin-Aldosterone System (RAAS) Activation; Drug: Administration of Aliskiren, Spironolactone, or Placebo; Drug: Increased Dose, Combination, or Placebo
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified August 2011
Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies

Conditions: Sarcoma; Endocrine Tumors; Neuroblastoma; Retinoblastoma; Renal Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified December 2011
Clinical and Genetic Studies in Familial Non-medullary Thyroid Cancer

Condition: Non-Medullary Thyroid Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified December 2011
Molecular and Clinical Profile of Diabetes Mellitus and Its Complications

Conditions: Diabetes Mellitus, Type 2; Diabetic Nephropathy; Obesity
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified October 2011
Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Breast Cancer
Interventions: Drug: Fludarabine; Drug: Cyclophosphamide; Drug: Cyclosporine; Biological: Natural killer cells; Drug: IL-2; Drug: Methylprednisolone; Drug: Methylprednisolone; Drug: Interleukin-2
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2012
Central Compartment Neck Dissection With Thyroidectomy

Condition: Indeterminate Thyroid Nodules
Interventions: Procedure: Total Thyroidectomy + CLND; Procedure: Total thyroidectomy - CLND; Procedure: Hemi-thyroidectomy + CLND; Procedure: Hemi-thyroidectomy - CLND
Sponsors: University of Alberta; University of Alberta; Dalhousie University
Recruiting - verified July 2011
Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer

Conditions: Estrogen Receptor-negative Breast Cancer; Hereditary Breast/Ovarian Cancer - BRCA1; Hereditary Breast/Ovarian Cancer - BRCA2; Male Breast Cancer; Progesterone Receptor-negative Breast Cancer; Recurrent Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Triple-negative Breast Cancer
Interventions: Other: immunohistochemistry staining method; Genetic: gene expression analysis; Drug: veliparib; Drug: cisplatin; Drug: vinorelbine tartrate; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Family and Personal History of Malignancy in Intraductal Papillary Mucinous Neoplasm (IPMN)

Conditions: Pancreatic Cancer; Neoplasm
Intervention:
Sponsors: Columbia University; Columbia University
Recruiting - verified February 2012
Stool Testing for Pancreatic Cancer

Condition: Pancreatic Cancer
Intervention:
Sponsors: Columbia University; Columbia University; Mayo Clinic
Recruiting - verified February 2012
Pancreatic Cancer Genetics

Condition: Pancreatic Cancer
Intervention:
Sponsors: Columbia University; Columbia University
Recruiting - verified January 2012
Use of PET Imaging to Distinguish Malignant From Benign IPMN

Conditions: Neoplasm; Pancreatic Cancer
Intervention:
Sponsors: Columbia University; Columbia University; National Center for Research Resources (NCRR)
Recruiting - verified February 2012
Pancreatic Cancer Registry for High Risk Individuals

Condition: Pancreatic Cancer
Intervention:
Sponsors: Columbia University; Columbia University
Recruiting - verified January 2012
Validation of a Mouse Model of Pancreatic Carcinogenesis

Condition: Pancreatic Cancer
Intervention:
Sponsors: Columbia University; Columbia University
Recruiting - verified February 2012
Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: gemcitabine hydrochloride; Drug: liposome-encapsulated doxorubicin citrate; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Innsbruck Universitaetsklinik
Recruiting - verified April 2010
Effect of Angiotensin Converting Enzyme Inhibitor, Lisinopril, on Renal Blood Flow and Its Correlation With Proteinuria Reduction in Subjects With Type 2 Diabetes and Kidney Disease

Condition: Type 2 Diabetes
Interventions: Drug: ACEI or ARB; Drug: Lisinopril
Sponsors: University of Virginia; University of Virginia
Recruiting - verified December 2011
MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed by Surgery

Condition: Pancreatic Cancer
Interventions: Drug: Notch signaling pathway inhibitor MK0752; Drug: gemcitabine hydrochloride; Other: imaging biomarker analysis; Other: laboratory biomarker analysis; Other: pharmacological study; Radiation: fludeoxyglucose F 18
Sponsors: Cancer Research UK; Cancer Research UK
Recruiting - verified February 2012
First-line Treatment of Weekly Paclitaxel With Carboplatin and Bevacizumab in Ovarian Cancer

Conditions: Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer
Interventions: Drug: Carboplatin; Drug: Paclitaxel; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genentech
Recruiting - verified January 2012
Collection of Tissue Samples From Patients With Stage III or Stage IV Ovarian Epithelial Cancer

Condition: Ovarian Cancer
Intervention:
Sponsors: Vanderbilt University; Vanderbilt University; National Cancer Institute (NCI); Celgene Corporation
Recruiting - verified April 2012
Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease

Condition: Diabetic Nephropathies
Interventions: Drug: Moxonidine; Drug: Placebo
Sponsors: Baker IDI Heart and Diabetes Institute; Baker IDI Heart and Diabetes Institute
Recruiting - verified March 2010
Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and Pancreatic Function Following Surgery

Condition: Pancreatic Cancer
Intervention: Drug: Synthetic Human Secretin
Sponsors: Columbia University; Columbia University
Not yet recruiting - verified January 2012
Comparison of Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) to Endoscopic Pancreatic Function Test (ePFT) in Diagnosing Pancreatic Exocrine Insufficiency

Condition: Pancreatic Cancer
Intervention: Drug: Synthetic Human Secretin
Sponsors: Columbia University; Columbia University
Not yet recruiting - verified July 2011
Secretin-enhanced Magnetic Resonance Imaging (S-MRI) for Pancreatic Cancer Detection

Conditions: Pancreatic Cancer; Intraductal Papillary Mucinous Neoplasm
Intervention: Drug: Secretin
Sponsors: Columbia University; Columbia University
Recruiting - verified February 2012
Diurnal Variation of Exogenous Peptides (GH Puls/Jurgita I)

Condition: Growth Hormone Deficiency
Intervention: Drug: Norditropin SimpleXx (growth hormone)
Sponsors: Aarhus University Hospital; Aarhus University Hospital; Novo Nordisk
Recruiting - verified June 2011
Corticosteroid Therapy for Glucocorticoid Insufficiency Related to Traumatic Brain Injury

Conditions: Traumatic Brain Injury; Trauma; Adrenal Insufficiency; Pneumonia
Interventions: Drug: Placebo; Drug: Hydrocortisone Fludrocortisone; Other: No treatment
Sponsors: Nantes University Hospital; Nantes University Hospital; Société Française d'Anesthésie et de Réanimation (SFAR)
Recruiting - verified December 2011
The Role of Meat-borne Carcinogens in Pancreatic Cancer

Condition: Pancreas Cancer
Intervention: Drug: PhiP
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; University of Arkansas; Lawrence Livermore National Laboratory
Not yet recruiting - verified October 2011
Seprafilm™ for the Prevention of Intraperitoneal Adhesions and Improved Delivery of Therapy in Women Undergoing Staging and Intraperitoneal Chemotherapy for Advanced Ovarian Cancer

Condition: Epithelial Ovarian Cancer
Intervention: Procedure: Seprafilm™
Sponsors: University of British Columbia; University of British Columbia; Genzyme
Recruiting - verified November 2011
Irinotecan and Bevacizumab for Recurrent Ovarian Cancer

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma
Intervention: Drug: Irinotecan and Bevacizumab
Sponsors: New York University School of Medicine; New York University School of Medicine; Genentech
Recruiting - verified March 2012
MLN8237 in Patients With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

Conditions: Ovarian Carcinoma; Fallopian Tube Cancer; Peritoneal Cancer; Breast Carcinoma
Interventions: Drug: MLN8237 + Paclitaxel; Drug: MLN8237+Paclitaxel vs. Paclitaxel alone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified December 2011
The Influence of Adalimumab on Cardiovascular and Metabolic Risk in Psoriasis

Conditions: Psoriasis; Cardiovascular Diseases; Diabetes Mellitus, Type 2
Interventions: Drug: Adalimumab treatment arm; Drug: Fumaric acid esters treatment group; Other: Narrow band UVB radiation
Sponsors: Medical University of Vienna; Medical University of Vienna
Recruiting - verified January 2012
Sentinel Lymphnode in Patients With Papillary Thyroid Carcinoma and in Patients With Suspected Thyroid Neoplasia

Conditions: Thyroid Neoplasms; Thyroid Cancer
Intervention: Procedure: Histological investigation of the SN
Sponsors: Region Skane; Region Skane
Recruiting - verified January 2012
Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer

Conditions: Bladder Cancer; Cervical Cancer; Colorectal Cancer; Endometrial Cancer; Gastrointestinal Complications; Long-term Effects Secondary to Cancer Therapy in Adults; Ovarian Cancer; Prostate Cancer; Radiation Toxicity; Sarcoma; Testicular Germ Cell Tumor; Vaginal Cancer
Interventions: Other: questionnaire administration; Procedure: gastrointestinal complications management/prevention; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Royal Marsden NHS Foundation Trust
Recruiting - verified March 2010
A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal Cancers

Conditions: Breast Cancer; Lung Cancer; Renal Cancer; Adrenal Cancer
Intervention: Drug: F-18 Paclitaxel (FPAC)
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Not yet recruiting - verified September 2011
Use of Topical Lidocaine to Reduce Pain in Patients With Diabetic Neuropathy

Condition: Diabetic Peripheral Neuropathy
Interventions: Other: Skin biopsy; Other: Skin biopsy
Sponsors: Albany Medical College; Albany Medical College; Endo Pharmaceuticals
Recruiting - verified December 2010
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: carboplatin; Drug: oxaliplatin; Drug: paclitaxel; Procedure: quality-of-life assessment
Sponsors: University College, London; University College, London; National Cancer Institute (NCI); Gynecologic Oncology Group
Recruiting - verified December 2011
Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy

Conditions: Cognitive/Functional Effects; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: systemic chemotherapy; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified October 2011
Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer

Condition: Pancreatic Cancer
Intervention: Drug: Gemcitabine and Pazopanib
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas

Condition: Metastatic Pancreatic Cancer
Intervention: Drug: Gemcitabine, nab-Paclitaxel, GDC-0449
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; Stand Up To Cancer; Genentech; Celgene Corporation
Recruiting - verified March 2012
Long-Term Therapy Outcomes When Treating Chronic Kidney Disease Patients With Paricalcitol in German and Austrian Clinical Practice

Conditions: Kidney Insufficiency; Secondary Hyperparathyroidism
Intervention: Drug: Zemplar (paricalcitol)
Sponsors: Abbott; Abbott
Recruiting - verified March 2012
Cohort Study in Type 2 Diabetes in China

Condition: Type 2 Diabetes
Intervention:
Sponsors: China Cardiometabolic Registries; China Cardiometabolic Registries; Roche Pharma AG; VitalStrategic Research Institute; Chinese College of Cardiovascular Physicians; China Endocrinologist Association
Recruiting - verified February 2010
Predictive Factors of Clinical, Laboratory and Imaging Findings Routinely Used in Diagnosing Thyroid Cancer

Condition: Thyroid Cancer
Intervention:
Sponsors: National Cancer Institute, Naples; National Cancer Institute, Naples
Recruiting - verified February 2012
Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: bortezomib; Drug: carboplatin; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011
Study of S1 Efficacy as Second Line Treatment on Gemcitabine-refractory Patients With Inoperable or Advanced Pancreatic Cancers

Condition: Pancreatic Cancer
Intervention:
Sponsors: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences; The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Recruiting - verified January 2012
Immunotherapy Study for Surgically Resected Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Biological: HyperAcute-Pancreas Immunotherapy; Drug: Gemcitabine; Radiation: 5FU Chemoradiation
Sponsors: NewLink Genetics Corporation; NewLink Genetics Corporation
Recruiting - verified May 2012
Self-Management and Resourceful Transition of Type 2 Diabetes With Stage 3 Kidney Disease

Conditions: Diabetes Mellitus, Type 2; Renal Insufficiency, Chronic
Interventions: Behavioral: Computer assisted education and motivational interviewing.; Behavioral: Group talks/social chat
Sponsors: University of Colorado, Denver; University of Colorado, Denver; Robert Wood Johnson Foundation; National Center for Research Resources (NCRR)
Recruiting - verified July 2011
Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III)

Conditions: Pancreatic Cancer Stage II; Pancreatic Cancer Stage III
Interventions: Drug: Neoadjuvant gemcitabine, capecitabine, and docetaxel; Drug: Gemcitabine, capecitabine, docetaxel followed by radiotherapy
Sponsors: Columbia University; Columbia University
Recruiting - verified October 2011
Observation of Histological Changes in Parathyroid Adenomas Following High Intensity Focused Ultrasound (HIFU) Treatment Procedure

Condition: Primary Parathyroid Adenomas
Intervention: Device: Ultrasonic ablation device
Sponsors: Theraclion; Theraclion
Recruiting - verified April 2012
Randomized Trial of Restrictive Versus Liberal Perioperative Fluid Management for Patients Undergoing Pancreatic Resection

Condition: Pancreatic Cancer
Interventions: Other: restrictive perioperative fluid management; Other: Liberal perioperative fluid management
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified May 2012
Endoscopic Ethanol Ablation of Communicating Pancreatic Cystic Neoplasms

Conditions: Neoplasms, Cystic, Mucinous, and Serous; Pancreatic Neoplasms; Ultrasonography, Interventional
Intervention: Procedure: EUS and/or ERCP with ethanol injections of pancreatic cyst
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified July 2011
Stereotactic Radiation Therapy, Nelfinavir Mesylate, Gemcitabine Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Locally Advanced Pancreatic Cancer

Conditions: Adenocarcinoma of the Pancreas; Pancreatic Cancer; Stage III Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride; Drug: leucovorin calcium; Drug: fluorouracil; Drug: nelfinavir mesylate; Radiation: stereotactic body radiation therapy; Radiation: hypofractionated radiation therapy; Procedure: therapeutic conventional surgery; Other: pharmacological study; Genetic: polymorphism analysis; Other: pharmacogenomic studies; Genetic: protein expression analysis
Sponsors: University of Nebraska; University of Nebraska; National Cancer Institute (NCI)
Recruiting - verified August 2011
Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic or Colorectal Cancer

Conditions: Pancreatic Cancer; Colorectal Cancer
Intervention: Biological: Cancer macrobead placement in abdominal cavity
Sponsors: The Rogosin Institute; The Rogosin Institute
Recruiting - verified April 2012
Naltrexone and Hypoglycemia in Type 1 Diabetes

Conditions: Type 1 Diabetes; Hypoglycemia Unawareness
Interventions: Drug: Naltrexone; Drug: Naltrexone
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); American Diabetes Association
Recruiting - verified August 2011
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck

Conditions: Ovarian Cancer; Non Small Cell Lung Cancer; Prostate Cancer; Colorectal Cancer; Gastric Cancer; Esophageal Cancer; Cancer of Head and Neck
Interventions: Drug: LY2523355; Drug: pegfilgrastim
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified December 2011
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

Conditions: Stomach Cancer; Gastro-Esophageal(GE) Junction Cancer; Gastric (Stomach) Cancer; Esophageal Cancer; Gastrointestinal Stromal Tumor (GIST)
Interventions: Procedure: Blood draw; Procedure: Tissue tumor biopsy
Sponsors: Stanford University; Stanford University; State of California; National Institutes of Health (NIH)
Recruiting - verified June 2010
Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders

Conditions: Mucopolysaccharidosis; Hurler Syndrome; Hunter Syndrome; Maroteaux-Lamy Syndrome; Sly Syndrome; Alpha Mannosidosis; Fucosidosis; Aspartylglucosaminuria; Adrenoleukodystrophy (ALD); Globoid Cell Leukodystrophy (GLD); Krabbe Disease; Metachromatic Leukodystrophy (MLD); Sphingolipidoses; Peroxisomal Disorders
Interventions: Drug: Campath-1H; Drug: Cyclophosphamide; Drug: Busulfan; Procedure: Allogeneic stem cell transplantation
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Aleglitazar; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified March 2012
Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors

Condition: Ovarian Cancer
Interventions: Biological: bleomycin sulfate; Drug: carboplatin; Drug: cisplatin; Drug: etoposide phosphate; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Correlation of Albuminuria With Arterial Stiffness

Conditions: Diabetes Mellitus; Hypertension; Albuminuria; Arterial Stiffness
Intervention:
Sponsors: Istanbul University; Istanbul University
Recruiting - verified June 2011
Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi

Conditions: Cancer of Bile Duct; Pancreatic Cancer
Interventions: Device: PTFE Covered ComVi [full covered] Biliary Stent; Device: PTFE Covered ComVi [full covered] Biliary Stent
Sponsors: Taewoong Medical Co., Ltd.; Taewoong Medical Co., Ltd.
Recruiting - verified August 2011
Phase 2A Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer

Conditions: Metastatic Pancreatic Cancer; Metastatic Colorectal Cancer
Intervention: Drug: NPC-1C
Sponsors: Neogenix Oncology, Inc.; Neogenix Oncology, Inc.
Recruiting - verified January 2012
M. D. Anderson Symptom Inventory - Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Behavioral: Interview; Behavioral: Survey
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genentech
Recruiting - verified April 2012
Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Carcinoma
Interventions: Drug: Pazopanib; Drug: Doxil
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; GlaxoSmithKline
Recruiting - verified November 2011
A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Condition: Ovarian Cancer
Intervention: Drug: BSI-201
Sponsors: Sanofi-Aventis; Sanofi-Aventis; BiPar Sciences
Recruiting - verified June 2011
Gemcitabine, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery

Condition: Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: gemcitabine hydrochloride; Procedure: quality-of-life assessment; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Wales Cancer Trials Unit
Recruiting - verified May 2011
Collection of Biospecimen & Clinical Information in Patients w/ Gastrointestinal Cancers

Conditions: Gastrointestinal Neoplasms; Gynecologic Cancers; Gynecologic Cancers Cervical Cancer; Gastric (Stomach) Cancer; Gastro-Esophageal(GE) Junction Cancer; Gastrointenstinal Stromal Tumor (GIST); Colon/Rectal Cancer; Colon/Rectal Cancer Colon Cancer; Colon/Rectal Cancer Rectal Cancer; Colon/Rectal Cancer Anal Cancer; Anal Cancer; Hepatobiliary Cancers; Hepatobiliary Cancers Liver; Pancreatic Cancer
Interventions: Procedure: Blood Draw; Procedure: Frozen Tumor Specimens
Sponsors: Stanford University; Stanford University; Caring for Carcinoid Foundation; GI Cancer Research Gift Fund
Not yet recruiting - verified May 2010
PD 0332991 in Treating Patients With Refractory Solid Tumors

Conditions: Adult Solid Tumor; Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum; Adult Central Nervous System Germ Cell Tumor; Adult Teratoma; Benign Teratoma; Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; Familial Testicular Germ Cell Tumor; HER2-negative Breast Cancer; HER2-positive Breast Cancer; Male Breast Cancer; Ovarian Immature Teratoma; Ovarian Mature Teratoma; Ovarian Monodermal and Highly Specialized Teratoma; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Recurrent Colon Cancer; Recurrent Extragonadal Germ Cell Tumor; Recurrent Extragonadal Non-seminomatous Germ Cell Tumor; Recurrent Extragonadal Seminoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Melanoma; Recurrent Ovarian Germ Cell Tumor; Recurrent Rectal Cancer; Stage III Extragonadal Non-seminomatous Germ Cell Tumor; Stage III Extragonadal Seminoma; Stage III Malignant Testicular Germ Cell Tumor; Stage III Ovarian Germ Cell Tumor; Stage IV Breast Cancer; Stage IV Colon Cancer; Stage IV Extragonadal Non-seminomatous Germ Cell Tumor; Stage IV Extragonadal Seminoma; Stage IV Melanoma; Stage IV Ovarian Germ Cell Tumor; Stage IV Rectal Cancer; Testicular Immature Teratoma; Testicular Mature Teratoma
Interventions: Drug: PD-0332991; Other: pharmacological study
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified February 2012
Low Dose Radiation to Improve T-Cell Infiltration in Pancreatic Cancer

Condition: Primarily Resectable Pancreatic Cancer
Interventions: Radiation: neoadjuvant Photonradiation; Radiation: neoadjuvant Photonradiation; Radiation: neoadjuvant Photonradiation
Sponsors: German Cancer Research Center; German Cancer Research Center; University of Heidelberg
Recruiting - verified April 2012
Vitamin D Status in Males in Jerusalem Area and Its Correlation to Parathyroid Hormone (PTH) Level and Bone Mineral Density

Conditions: Vitamin D Deficiency; Secondary Hyperparathyroidism; Osteomalacia
Intervention: Drug: 25 OH vitamin D
Sponsors: Clalit Health Services; Clalit Health Services
Recruiting - verified December 2009
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine

Conditions: Pancreatic Cancer; Ductal Adrenocarcinoma; Exocrine Pancreatic Cancer
Intervention: Drug: PCI-27483
Sponsors: Pharmacyclics; Pharmacyclics
Recruiting - verified January 2012
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery

Condition: Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: erlotinib hydrochloride; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Early Increase in Blood Flow (EIBS) in the Duodenum in Patients With Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Procedure: Endoscopic Ultrasound (EUS); Device: EUS/4D-ELF
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified February 2012
ABT-888 and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Conditions: Ovarian Cancer; Primary Peritoneal Cavity Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: topotecan hydrochloride; Drug: veliparib; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified January 2012
Ultrasonic Measurements of the Clitoris in Fetuses

Condition: Ambiguous Genitalia
Intervention:
Sponsors: Meir Medical Center; Meir Medical Center
Recruiting - verified March 2012
Temsirolimus and Bevacizumab in Treating Patients With Locally Advanced, Recurrent, Metastatic, or Progressive Endometrial Cancer, Ovarian Epithelial Cancer, Liver Cancer, Islet Cell Cancer, or Carcinoid Tumor

Conditions: Endometrial Cancer; Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Liver Cancer; Lung Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2012
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms

Conditions: Neuroendocrine Neoplasms; Thyroid Neoplasms; Parathyroid Neoplasms; Adrenal Neoplasm; Neuroblastoma
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified June 2011
Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes

Conditions: Coronary Artery Disease; Diabetes Mellitus Type 2
Intervention: Drug: Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere
Sponsors: Mayo Clinic; Mayo Clinic; University of Nebraska; Astellas Pharma US, Inc.; Lantheus Medical Imaging
Recruiting - verified January 2012
Safety Study of PLX108-01 in Patients With Solid Tumors

Conditions: Solid Tumors; Mucoepidermal Carcinoma (MEC) of the Salivary Gland; Pigmented Villo-nodular Synovitis (PVNS); Gastrointestinal Stromal Tumors (GIST); Anaplastic Thyroid Carcinoma (ATC); Solid Tumors With Documented Malignant Pleural or Peritoneal Effusions; Malignant Peripheral Nerve Sheath Tumor (MPNST); Neurofibromatosis Type I (NF-1); Melanoma; Schwannomatosis
Intervention: Drug: PLX3397
Sponsors: Plexxikon; Plexxikon
Recruiting - verified May 2012
Trial of LBH589 in Metastatic Thyroid Cancer

Condition: Thyroid Carcinoma
Intervention: Drug: LBH589
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison; Novartis Pharmaceuticals
Recruiting - verified December 2011
Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer

Condition: Ovarian Cancer
Intervention: Drug: topotecan and erlotinib
Sponsors: New York University School of Medicine; New York University School of Medicine; OSI Pharmaceuticals
Recruiting - verified February 2012
Can Ultrasound Predict Nerve Injury Following Posterior Tibial Nerve Block in Patients With Peripheral Neuropathy?

Condition: Diabetic Neuropathy
Intervention: Procedure: Nerve conduction study and Ultrasound of the PTN
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified November 2011
Pemetrexed and Carboplatin in Recurrent Platinum Sensitive Ovarian Cancer

Conditions: Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer
Interventions: Drug: Carboplatin; Drug: Pemetrexed
Sponsors: Montefiore Medical Center; Montefiore Medical Center
Recruiting - verified July 2011
Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment

Condition: Nonalcoholic Steatohepatitis
Interventions: Drug: placebo; Drug: pioglitazone; Dietary Supplement: Vitamin E
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified February 2012
Neuropsychologic, Neuroradiologic, Endocrinologic, and Genetic Aspects of Klinefelter Syndrome

Condition: Klinefelter Syndrome
Intervention:
Sponsors: University of Aarhus; University of Aarhus; Aarhus University Hospital
Recruiting - verified March 2012
Diabetes and Periodontal Therapy Trial

Conditions: Chronic Periodontitis; Type 2 Diabetes
Interventions: Procedure: Non-surgical periodontal treatment; Other: Delayed non-surgical periodontal therapy
Sponsors: Stony Brook University; Stony Brook University; University of Alabama at Birmingham; University of Minnesota - Clinical and Translational Science Institute; The University of Texas Health Science Center, Houston; University of Texas; National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting - verified December 2011
Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients

Conditions: Diabetes Mellitus, Type 2; Atherosclerosis; Prediabetic State
Interventions: Drug: ACZ885 (Canakinumab); Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Intravitreal Ranibizumab for VH Due to PDR (N)

Conditions: Vitreous Hemorrhage; Proliferative Diabetic Retinopathy
Interventions: Drug: Ranibizumab; Behavioral: Saline
Sponsors: Diabetic Retinopathy Clinical Research Network; Diabetic Retinopathy Clinical Research Network; National Eye Institute (NEI)
Recruiting - verified February 2012
Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess

Condition: Pancreatic Cancer
Interventions: Drug: Pasireotide (SOM230); Other: placebo
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Novartis Pharmaceuticals
Recruiting - verified December 2011
Comparing Three Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Metastatic Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel; Procedure: quality-of-life assessment
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI); Grupo Español de Investigación en Cáncer de Ovario; Cancer Research UK; Southwestern Oncology Group (SWOG)
Recruiting - verified March 2012
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel; Drug: veliparib
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer

Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Liver Cancer; Pancreatic Cancer; Periampullary Adenocarcinoma; Small Intestine Cancer
Interventions: Drug: erlotinib hydrochloride; Drug: gemcitabine hydrochloride; Drug: oxaliplatin; Other: laboratory biomarker analysis
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified November 2011
Lysophosphatidic Acid Assay in Patients With Ovarian Cancer or Who Are at Risk for Ovarian Cancer

Conditions: brca1 Mutation Carrier; brca2 Mutation Carrier; Ovarian Cancer
Interventions: Other: diagnostic laboratory biomarker analysis; Other: liquid chromatography; Other: mass spectrometry; Procedure: screening method
Sponsors: National Cancer Institute (NCI); Women and Infants Hospital of Rhode Island; National Cancer Institute (NCI)
Recruiting - verified September 2009
Vitamin E δ-Tocotrienol Administered to Subjects With Resectable Pancreatic Exocrine Neoplasia

Condition: Pancreatic Neoplasms
Intervention: Drug: Vitamin E δ-Tocotrienol
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI)
Recruiting - verified January 2012
Increasing Vitamin Intake and Physical Activity

Conditions: Heart Diseases; Diabetes Mellitus, Type 2; Behavior; Motivation
Intervention: Behavioral: Intervention Group (IG)
Sponsors: Freie Universität Berlin; Freie Universität Berlin; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2011
Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer

Conditions: Pancreatic Cancer; Periampullary Adenocarcinoma
Interventions: Drug: capecitabine; Drug: vorinostat; Radiation: Radiotherapy; Procedure: Surgery to remove tumor
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI); National Comprehensive Cancer Network
Recruiting - verified January 2012
RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction

Conditions: Biliary Tract Neoplasms; Pancreatic Neoplasms; Stents
Interventions: Device: Patency of Steel Stent.; Device: Patency of Nitinol Stent, Wallflex®.
Sponsors: Stockholm South General Hospital; Stockholm South General Hospital
Recruiting - verified September 2009
A Study of Combination of Temsirolimus (Torisel®) and Pegylated Liposomal Doxorubicin (PLD, Doxil®/Caelyx®) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer

Conditions: Advanced/Recurrent Breast Cancer; Endometrial Cancer; Ovarian Cancer
Intervention: Drug: Temsirolimus/PLD
Sponsors: Radboud University; Radboud University
Recruiting - verified April 2012
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients

Conditions: Chronic Allograft Nephropathy; Chronic Kidney Disease; Chronic Renal Failure; Disordered Mineral Metabolism; End Stage Renal Disease; Hyperparathyroidism; Hypophosphatemia; Kidney Disease; Kidney Transplantation; Post Renal Transplantation
Interventions: Drug: Cinacalcet; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified January 2012
Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma

Condition: Ovarian Neoplasms
Interventions: Drug: Vorinostat; Drug: Vorinostat
Sponsors: Gynecologic Oncology Associates; Gynecologic Oncology Associates; Merck
Recruiting - verified June 2011
Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease

Conditions: Von Hippel-Lindau Disease; Hemangioblastoma; Renal Cell Carcinoma; Pheochromocytoma; Pancreatic Neuroendocrine Tumor
Intervention: Other: 89Zr bevacizumab PET scan
Sponsors: University Medical Centre Groningen; University Medical Centre Groningen; VHL Family Alliance
Recruiting - verified April 2012
Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244

Condition: Thyroid Cancer
Intervention: Biological: AZD6244
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Genzyme; AstraZeneca
Recruiting - verified January 2012
High Blood Pressure and Sleep Apnea in Diabetic Macular Edema

Condition: Diabetic Retinopathy
Interventions: Behavioral: high blood pressure treatment; Behavioral: sleep apnea treatment; Behavioral: diabetic macular edema treatment
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris
Recruiting - verified September 2011
Effect of Cinnamon Extract on Insulin Resistance in Polycystic Ovary Syndrome

Conditions: Polycystic Ovary Syndrome; Insulin Resistance
Interventions: Dietary Supplement: Cinnamon Supplementation; Dietary Supplement: Placebo (wheat flour)
Sponsors: Pennington Biomedical Research Center; Pennington Biomedical Research Center
Recruiting - verified May 2012
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Conditions: Diabetes Mellitus, Type 2; Acute Coronary Syndrome
Interventions: Drug: Alogliptin; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2012
C-VISA BikDD: Liposome in Advanced Pancreatic Cancer

Condition: Pancreatic Cancer
Intervention: Genetic: BikDD Nanoparticle
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Not yet recruiting - verified May 2012
Prevention of Cystic Fibrosis Diabetes

Conditions: Cystic Fibrosis; Prediabetes
Intervention: Drug: sitagliptin phosphate
Sponsors: Emory University; Emory University; Ohio State University; Children's Healthcare of Atlanta; Merck; FDA Office of Orphan Products Development
Recruiting - verified January 2012
Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients

Conditions: Pancreatic Cancer; Venous Thromboembolism
Intervention: Drug: Dalteparin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Eisai Inc.
Recruiting - verified February 2012
Tarceva With Chemoradiation and Adjuvant Chemotherapy for Resectable Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: Erlotinib; Drug: capecitabine; Radiation: Radiation Therapy; Drug: gemcitabine; Drug: erlotinib
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; Genentech
Recruiting - verified April 2012
Anterior Pituitary Hormone Replacement in Traumatic Brain Injury

Conditions: Growth Hormone Deficiency; Traumatic Brain Injury
Interventions: Drug: Human Growth Hormone; Drug: Placebo
Sponsors: The University of Texas, Galveston; The University of Texas, Galveston; The Moody Foundation
Recruiting - verified December 2011
Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer; Psychosocial Effects of Cancer and Its Treatment
Interventions: Other: communication intervention; Other: educational intervention; Other: internet-based intervention; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: assessment of therapy complications; Procedure: management of therapy complications; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Exercise-facilitated Neurorehabilitation in Diabetic Neuropathy

Condition: Diabetic Neuropathy
Interventions: Behavioral: Exercise; Behavioral: Exercise
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified April 2012
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine or Ovarian Cancer

Conditions: Ovarian Cancer; Sarcoma
Interventions: Drug: carboplatin; Drug: ifosfamide; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Develop and Validate a Self-Administered Instrument That Will Screen for Eating Disorder Symptoms in Persons Aged 12 and Older With Type 1 Diabetes.

Conditions: Type 1 Diabetes; Eating Disorder
Intervention:
Sponsors: Park Nicollet Institute; Park Nicollet Institute; International Diabetes Center at Park Nicollet; Park Nicollet Eating Disorder Institute; Park Nicollet Foundation
Recruiting - verified February 2012
Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome

Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Intervention: Dietary Supplement: Lactobacillus rhamnosus GG
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI)
Recruiting - verified November 2011
Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease

Conditions: Graves Disease; Hyperthyroidism
Intervention: Drug: Potassium Iodine
Sponsors: University of Massachusetts, Worcester; University of Massachusetts, Worcester
Recruiting - verified October 2011
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Conditions: Pancreatic Neoplasm; Pituitary Neoplasm; Nelson Syndrome; Ectopic ACTH Syndrome
Intervention: Drug: Pasireotide LAR
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified November 2011
Trial of Simvastatin and Gemcitabine in Pancreatic Cancer Patients

Condition: Pancreatic Cancer
Interventions: Drug: Gemcitabine+simvastatin; Drug: Gemcitabine+Placebo
Sponsors: Samsung Medical Center; Samsung Medical Center
Recruiting - verified January 2012
Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries

Conditions: Metabolic Diseases; Endocrine System Diseases; Heart Disease; Vascular Diseases; Diabetes; Cardiovascular Disease; Glucose Metabolism Disorders; Hypertension
Intervention: Drug: omega-3 acid ethyl esters
Sponsors: Denver Health and Hospital Authority; Denver Health and Hospital Authority; National Heart, Lung, and Blood Institute (NHLBI); GlaxoSmithKline
Recruiting - verified July 2011
Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy

Conditions: Pituitary Adenomas; Prolactinomas; Cushing's Disease
Intervention: Drug: Lapatinib
Sponsors: Cedars-Sinai Medical Center; Cedars-Sinai Medical Center
Recruiting - verified November 2011
RAD001 for Patients With Radioiodine Refractory Thyroid Cancer

Condition: Thyroid Cancer
Intervention: Drug: RAD001
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Massachusetts General Hospital; M.D. Anderson Cancer Center; Novartis
Recruiting - verified June 2011
High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors

Condition: Testicular Cancer
Interventions: Drug: Bevacizumab; Drug: Gemcitabine; Drug: Docetaxel; Drug: Melphalan; Drug: Carboplatin; Drug: Mesna; Drug: Ifosfamide; Drug: Etoposide; Procedure: Stem Cell Transplant
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Gestational Diabetes and Sleep-Disordered Breathing

Condition: Gestational Diabetes Mellitus
Intervention: Other: Determining a change in heart rate variability post delivery of the baby
Sponsors: Christiana Care Health Services; Christiana Care Health Services
Recruiting - verified October 2011
Safety and Efficacy of Intravitreal Ranibizumab as a Preoperative Adjunct Treatment Before Vitrectomy Surgery in Proliferative Diabetic Retinopathy (PDR) Compared to Vitrectomy Alone

Condition: Diabetic Retinopathy
Interventions: Drug: ranibizumab and vitrectomy; Procedure: vitrectomy without preoperative ranibizumab
Sponsors: University of Debrecen; Attila Vajas; Semmelweis University
Recruiting - verified January 2012
Intra-ductal Confocal Endomicroscopy for Characterization of Pancreas and Bile Duct Tumor

Conditions: Pancreas Neoplasms; Bile Duct Diseases
Intervention: Procedure: Endoscopic Retrograde Cholangio-Pancreatography (ERCP)
Sponsors: Institut Paoli-Calmettes; Institut Paoli-Calmettes
Recruiting - verified September 2011
Comparison of Iodine-124 (I-124) and Iodine-131 (I-131) Radiopharmacokinetics

Condition: Thyroid Cancer
Intervention: Radiation: Radioactive Iodine 124
Sponsors: Washington Hospital Center; Washington Hospital Center; Genzyme; IBA
Recruiting - verified August 2011
Lovaza® and Microvascular Function in Type 2 Diabetes

Conditions: Hypertriglyceridemia; Diabetic Neuropathy
Intervention: Drug: omega-3-acie ethyl esters
Sponsors: Eastern Virginia Medical School; Eastern Virginia Medical School; GlaxoSmithKline
Recruiting - verified July 2011
Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI)

Condition: Pancreatic Cancer
Intervention: Drug: Superparamagnetic Iron Oxide Magnetic Resonance Imaging
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified April 2012
Administration of Kisspeptin to Healthy Subjects and Subjects With Reproductive Disorders

Conditions: Healthy; Hypogonadotropic Hypogonadism
Interventions: Drug: kisspeptin 112-121; Drug: GnRH
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified August 2011
N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy

Conditions: Diabetic Nephropathies; Proteinuria; Oxidative Stress
Interventions: Dietary Supplement: N-acetylcysteine; Dietary Supplement: silibin; Dietary Supplement: high-dose silibin; Dietary Supplement: N-acetylcysteine placebo; Dietary Supplement: silibin placebo
Sponsors: The University of Texas Health Science Center at San Antonio; The University of Texas Health Science Center at San Antonio; National Center for Complementary and Alternative Medicine (NCCAM); Department of Veterans Affairs
Recruiting - verified August 2011
The Pancreatic Adenocarcinoma Gene Environment Risk Study - A Study of Patients at Risk or Having Pancreatic Disease

Condition: Pancreatic Cancer
Interventions: Biological: blood and urine specimen collection; Other: questionnaire; Biological: collection of biological waste
Sponsors: University of Pittsburgh; University of Pittsburgh
Recruiting - verified January 2012
Vorinostat, Carboplatin and Gemcitabine Plus Vorinostat Maintenance in Women With Recurrent, Platinum-Sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
Interventions: Drug: Vorinostat; Device: Carboplatin; Drug: Gemcitabine
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Massachusetts General Hospital; Merck
Recruiting - verified February 2012
Topic Ketorolac Added to Panphotocoagulation in Proliferative Diabetic Retinopathy

Conditions: Proliferative Diabetic Retinopathy; Macular Edema
Interventions: Drug: Tromethamine ketorolac; Drug: Alcohol polivinilico
Sponsors: Hospital Juarez de Mexico; Hospital Juarez de Mexico
Recruiting - verified March 2010
rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors

Condition: Advanced Malignant Thyroid Tumors
Interventions: Drug: rAd-p53 gene; Procedure: surgery; Drug: p53 gene therapy; Radiation: p53 gene therapy with radioactive iodine
Sponsors: Shenzhen SiBiono GeneTech Co.,Ltd; Shenzhen SiBiono GeneTech Co.,Ltd
Recruiting - verified February 2010
Topic Antiinflammatory Therapy Added to Selective Photocoagulation in Macular Edema

Conditions: Diabetic Retinopathy; Macular Edema
Interventions: Drug: Tromethamine ketorolac; Drug: Nepafenac; Drug: Polietilenglicol 400, propilenglicol, HP guar
Sponsors: Hospital Juarez de Mexico; Hospital Juarez de Mexico
Recruiting - verified February 2012
Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer

Conditions: Non-melanomatous Skin Cancer; Pancreatic Cancer; Small Intestine Cancer; Testicular Germ Cell Tumor
Interventions: Genetic: in situ hybridization; Genetic: protein expression analysis; Other: immunologic technique
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012
Laboratory Study in Predicting Tumor Response to Chemotherapy in Patients With Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Other: flow cytometry; Other: immunohistochemistry staining method
Sponsors: National Cancer Institute (NCI); Southeastern Gynecologic Oncology, LLP - Northside
Recruiting - verified July 2009
Studying DNA in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer

Condition: Ovarian Cancer
Interventions: Genetic: DNA methylation analysis; Genetic: microarray analysis; Genetic: polymerase chain reaction; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Scottish Gynaecological Cancer Study Group
Recruiting - verified July 2009
Tumor Marker YKL-40 in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Intervention: Other: diagnostic laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Conditions: Breast Cancer; Hypercalcemia of Malignancy; Colon Cancer; Endocrine Cancer; Head and Neck Cancer; Kidney Cancer; Lung Cancer; Lymphoma; Metastatic Cancer; Multiple Myeloma; Parathyroid Neoplasms; Renal Cancer; Thyroid Cancer; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Non-Small Cell Lung Cancer
Intervention: Drug: denosumab
Sponsors: Amgen; Amgen
Recruiting - verified April 2012
Role of Indicator Test (Neuropad) in Detecting Diabetic Neuropathy

Condition: Diabetic Neuropathy
Intervention:
Sponsors: Tameside Hospital NHS Foundation Trust; Tameside Hospital NHS Foundation Trust
Recruiting - verified May 2009
Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure

Conditions: Congestive Heart Failure; Type II Diabetes Mellitus
Interventions: Drug: vildagliptin; Drug: placebo of vildagliptin
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Anesthesia Management of Retroperitoneal Adrenalectomies

Condition: Adrenal Tumors
Intervention:
Sponsors: Kliniken Essen-Mitte; Kliniken Essen-Mitte
Recruiting - verified May 2009
Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer

Condition: Adenocarcinoma
Interventions: Drug: zoledronic acid; Drug: zoledronic acid; Drug: zoledronic acid; Drug: zoledronic acid
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011
The Luveris In Vitro Fertilization Trial

Conditions: Infertility; Hypothalamic Amenorrhea; Hyperprolactinemia
Interventions: Drug: Luveris fixed dose; Drug: Luveris increasing dose
Sponsors: University Reproductive Associates; University Reproductive Associates; EMD Serono
Recruiting - verified April 2012
Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Radiation: Accelerated Short Course Radiation; Drug: Capecitabine
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Massachusetts General Hospital
Recruiting - verified October 2011
Paclitaxel-Loaded Polymeric Micelle and Carboplatin as First-Line Therapy in Treating Patients With Advanced Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel-loaded polymeric micelle
Sponsors: National Cancer Institute (NCI); Asan Medical Center
Recruiting - verified December 2009
Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: everolimus; Other: placebo
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2011
ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: erlotinib [Tarceva]; Drug: capecitabine [Xeloda]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer

Condition: Pancreas Cancer
Intervention: Drug: Lapatinib and Capecitabine
Sponsors: Georgetown University; Georgetown University; GlaxoSmithKline
Recruiting - verified October 2011
Assessment of Screening Modalities for Gynecologic Cancers

Conditions: Ovarian Cancer; Endometrial Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)

Conditions: Solid Tumors; Ovarian Cancer
Interventions: Drug: OSI-906; Drug: Paclitaxel
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified May 2012
Sex Differences in Early Brain Development; Brain Development in Turner Syndrome

Condition: Turner Syndrome
Intervention:
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; National Institute of Mental Health (NIMH)
Recruiting - verified December 2011
Outcomes From Home in Patients Recovering From Major Gynecologic Cancer Surgery: Measuring Symptoms and Health-related Quality of Life

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer; Uterine Cancer; Vaginal Cancer; Vulvar Cancer
Intervention: Behavioral: online platform "STAR" (Symptom Tracking and Reporting for Patients)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Institutes of Health (NIH)
Recruiting - verified January 2012
Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer

Condition: Pancreatic Cancer
Intervention: Drug: irinotecan, oxaliplatin and cetuximab
Sponsors: New Mexico Cancer Care Alliance; New Mexico Cancer Care Alliance
Recruiting - verified December 2011
A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer

Condition: Pancreatic Cancer
Intervention: Drug: Gemcitabine (Gemzar), docetaxel (Taxotere), and capecitabine (Xeloda)
Sponsors: Columbia University; Columbia University
Recruiting - verified October 2011
Study for Inoperable Non-Metastatic Pancreatic CA (Stage IVA) With Neoadjuvant GTX, and Radiation With Gemzar

Condition: Pancreatic Cancer Stage IVA
Interventions: Drug: Gemcitabine, docetaxel, and capecitabine; Radiation: Radiation therapy with gemcitabine
Sponsors: Columbia University; Columbia University
Recruiting - verified October 2011
Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease

Conditions: Type 2 Diabetes Mellitus; Vascular Disease
Interventions: Drug: Spironolactone; Drug: hydrochlorothiazide + potassium; Other: placebo
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital; National Institutes of Health (NIH)
Recruiting - verified June 2011
Renal Osteodystrophy: A Fresh Approach

Condition: Renal Osteodystrophy
Intervention:
Sponsors: University of Kentucky; University of Kentucky
Recruiting - verified June 2011
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: immunological adjuvant OPT-821; Biological: polyvalent antigen-KLH conjugate vaccine
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Evaluation of Exenatide in Patients With Diabetic Neuropathy

Conditions: Type 2 Diabetes Mellitus; Diabetic Peripheral Neuropathy
Interventions: Drug: Exenatide; Drug: Glargine
Sponsors: University of Michigan; University of Michigan; Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Recruiting - verified August 2011
Intravitreal Adalimumab in Refractory Diabetic Retinopathy, Choroidal Neovascularization or Uveitis: A Pilot Study

Conditions: Uveitis; Diabetic Retinopathy; Choroidal Neovascularization
Intervention: Drug: adalimumab
Sponsors: Rafic Hariri University Hospital; Rafic Hariri University Hospital; American University of Beirut Medical Center
Recruiting - verified September 2009
A Comparison of Islet Cell Transplantation With Medical Therapy for the Treatment of Diabetic Eye Disease

Conditions: Diabetic Retinopathy; Diabetic Macular Edema
Interventions: Procedure: islet cell transplant; Other: Medical therapy
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified November 2011
Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer

Conditions: Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer
Intervention: Other: Enteral feeding
Sponsors: Queensland Centre for Gynaecological Cancer; Queensland Centre for Gynaecological Cancer; Cancer Australia; The University of Queensland
Recruiting - verified June 2011
Cancer Screening and Prevention Program for High Risk Women

Conditions: Ovarian Cancer; Breast Cancer
Intervention: Other: screening
Sponsors: New York University School of Medicine; New York University School of Medicine; Lynne Cohen Foundation for Ovarian Cancer Research
Recruiting - verified November 2011
EMD 525797 in Colorectal & Ovarian Cancer Patients With Liver Metastases

Condition: Colorectal and Ovarian Cancer Patients With Liver Metastasis
Intervention: Biological: EMD525797
Sponsors: Merck KGaA; Merck KGaA
Recruiting - verified February 2012
Preoperative Bexarotene Treatment for Cushing's Disease

Condition: Cushing's Disease
Intervention: Drug: Bexarotene
Sponsors: University of Virginia; University of Virginia
Recruiting - verified May 2011
A Study for Patients With Pancreatic Cancer

Condition: Pancreatic Neoplasms
Interventions: Drug: LY2603618; Drug: Gemcitabine
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012
Genetics of Type 2 Diabetes in West Africans

Conditions: Nephropathy; Retinopathy; Hypertension; Obesity; Diabetes
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified January 2012
Collecting Blood and Tissue Samples From Family Members of Patients With Pancreatic Diseases, Pancreatic Cancer, and Melanoma

Condition: Familial Pancreatic Cancer
Interventions: Other: biologic sample preservation procedure; Other: medical chart review; Other: survey administration
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified September 2011
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders

Conditions: Islet Cell Tumor; Pancreatic Cancer; Pancreatic Disease
Interventions: Other: medical chart review; Other: survey administration; Other: biospecimen collection
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified September 2011
Prospective Analysis of Hypersensitivity Reactions to Oxaliplatin

Conditions: Colorectal Cancer; Esophageal Cancer; Gastric Cancer; Small Bowel Cancer; Pancreatic Cancer
Intervention:
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Sanofi-Aventis
Recruiting - verified February 2012
Acarbose Cardiovascular Evaluation Trial

Conditions: Coronary Heart Disease; Acute Coronary Syndrome; Impaired Glucose Tolerance; Type 2 Diabetes Mellitus (T2DM)
Interventions: Drug: Acarbose; Drug: Matching Placebo
Sponsors: University of Oxford; University of Oxford; Bayer
Recruiting - verified September 2011
Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer

Condition: Ovarian Cancer
Intervention: Biological: DTA-H19
Sponsors: BioCancell Therapeutics Israel Ltd.; BioCancell Therapeutics Israel Ltd.
Recruiting - verified February 2012
Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity

Conditions: Ovarian Cancer; Peritoneal Cavity Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI); National Comprehensive Cancer Network
Recruiting - verified December 2011
Home-Based Walking Study

Conditions: Cardiovascular; Diabetes; Orthostatic Hypotension; Type 2 Diabetes
Intervention: Behavioral: Home-based walking program (Aerobic Exercise)
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified November 2011
Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: erlotinib hydrochloride; Drug: gemcitabine hydrochloride
Sponsors: University of California, Davis; University of California, Davis; National Cancer Institute (NCI)
Recruiting - verified March 2012
Autologous Hematopoietic Stem Cell Transplantation for Early Onset Type 1 Diabetes

Condition: Type 1 Diabetes Mellitus
Intervention: Procedure: Immunosuppression and autologous stem cell transplantation
Sponsors: Shanghai Jiao Tong University School of Medicine; Shanghai Jiao Tong University School of Medicine
Recruiting - verified March 2010
Sex Steroids, Sleep, and Metabolic Dysfunction in Women

Conditions: Polycystic Ovary Syndrome; Obstructive Sleep Apnea; Obesity
Interventions: Drug: Progesterone; Drug: testosterone; Drug: glucocorticoid; Device: continuous positive airway pressure; Drug: Estrogens
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified February 2012
Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Conditions: Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer
Intervention: Procedure: Tumor collection
Sponsors: Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute; Massachusetts General Hospital; National Cancer Institute (NCI)
Recruiting - verified July 2011
Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod

Conditions: Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer
Interventions: Drug: GM-CSF; Biological: Dendritic Cell/Tumor Fusion Vaccine; Drug: imiquimod
Sponsors: Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Massachusetts General Hospital; National Cancer Institute (NCI)
Recruiting - verified October 2011
Less Invasive Detection and Treatment of Very Early Coronary Artery Disease in Patients With Diabetes Mellitus

Conditions: Type 2 Diabetes; Microvascular Dysfunction
Intervention: Other: Intensive risk factor management
Sponsors: University of Virginia; University of Virginia; National Institutes of Health (NIH); Pfizer; Astellas Pharma Inc
Recruiting - verified May 2011
Proton Radiation Therapy for Pituitary Adenoma

Condition: Pituitary Adenoma
Intervention: Radiation: Proton Radiation Therapy
Sponsors: University of Florida; University of Florida
Recruiting - verified March 2012
Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma

Condition: Thyroid Cancer
Intervention: Procedure: Prophylactic central lymph node dissection
Sponsors: Samsung Medical Center; Samsung Medical Center
Recruiting - verified July 2011
Measurement of Glucose Metabolism in Humans Using Magnetic Resonance at 4 Tesla. Substudy: Hypoglycemia Unawareness

Conditions: Type 1 Diabetes; Hypoglycemia Unawareness
Intervention:
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute
Recruiting - verified August 2011
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking

Conditions: Bladder Cancer; Cervical Cancer; Esophageal Cancer; Gastric Cancer; Head and Neck Cancer; Kidney Cancer; Leukemia; Liver Cancer; Lung Cancer; Pancreatic Cancer; Tobacco Use Disorder
Interventions: Drug: nicotine; Drug: varenicline; Other: placebo
Sponsors: Butler Hospital; Butler Hospital; National Cancer Institute (NCI)
Recruiting - verified March 2012
Etiological Factors of Obesity-Associated Hyperandrogenemia in Peripubertal Girls

Conditions: Obesity; Hyperandrogenemia; Polycystic Ovary Syndrome
Intervention:
Sponsors: University of Virginia; University of Virginia; National Institutes of Health (NIH)
Recruiting - verified May 2012
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer

Conditions: Cancer; Carcinoma; Fallopian Tube Cancer; Gynecological Malignancies; Metastases; Oncology; Ovarian Cancer; Solid Tumors; Tumors
Interventions: Drug: A1: AMG 386 10 mg/kg + Liposomal doxorubicin; Drug: A3: AMG 386 15mg/kg + Liposomal doxorubicin; Drug: B1: AMG 386 10 mg/kg + Topotecan; Drug: B3: AMG 386 15mg/kg + Topotecan
Sponsors: Amgen; Amgen
Recruiting - verified September 2011
Permission to Collect Blood Over Time for Research

Conditions: Pancreatic Cancer; Gastrointestinal Neoplasms; Colon Rectal Cancer Adenocarcinoma; Esophageal Cancer; Gall Bladder Cancer; Gastric (Stomach) Cancer; Gastrooesophageal Cancer; Gastrointestinal Stromal Tumor (GIST); Hepatobiliary Neoplasm; Liver Carcinoma; Gallbladder Carcinoma; Bile Duct Carcinoma; Carcinoma of the Large Intestine; Anal Cancer
Intervention: Procedure: Observation
Sponsors: Stanford University; Stanford University
Recruiting - verified June 2011
Proton Therapy for Resectable Carcinoma of the Pancreas

Condition: Pancreatic Cancer
Intervention: Radiation: Proton Therapy, Capecitabine, Gemcitabine
Sponsors: University of Florida; University of Florida
Recruiting - verified May 2012
Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer

Conditions: Locally Advanced (Unresectable) Pancreatic Cancer; Metastatic Pancreatic Cancer
Interventions: Drug: gemcitabine; Drug: Erlotinib; Radiation: low dose fractionated radiotherapy
Sponsors: Fox Chase Cancer Center; Fox Chase Cancer Center
Recruiting - verified November 2011
Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions

Conditions: WAGR Syndrome; Wilm's Tumor; Aniridia; Urogenital Abnormalities; Mental Retardation
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified June 2011
Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors

Conditions: Cancer; Non-Small Cell Lung Cancer; Endometrial Carcinoma; Ovarian Carcinoma
Interventions: Drug: XL147 (SAR245408),; Drug: paclitaxel; Drug: carboplatin
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified March 2012
Thermal Spread Into the Interstitial Portion of the Fallopian Tubes Using the Ligasure Device at Time of Hysterectomy

Conditions: Cervical Cancer; Ovarian Cancer; Uterine Cancer
Intervention: Device: LigaSure vessel sealing system
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012
A Collection of Clinical and Epidemiologic Data Combined With Tissue and Blood From Patients With a Diagnosis of Neuroendocrine Tumors

Conditions: Gastric Cancer; Pancreatic Cancer
Intervention: Other: questionnaire, Blood specimens
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012
Bevacizumab and Carboplatin for Patients With Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Drug: Bevacizumab; Drug: Carboplatin
Sponsors: Vejle Hospital; Vejle Hospital
Recruiting - verified May 2012
Tranexamic Acid in Surgery of Advanced Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Drug: Tranexamic acid; Drug: 0.9% NaCl solution
Sponsors: University Hospital, Linkoeping; Preben Kjolhede
Recruiting - verified November 2011
IDO Inhibitor Study for Relapsed or Refractory Solid Tumors

Conditions: Breast Cancer; Lung Cancer; Melanoma; Pancreatic Cancer; Solid Tumors
Intervention: Drug: 1-methyl-D-tryptophan
Sponsors: NewLink Genetics Corporation; NewLink Genetics Corporation
Recruiting - verified December 2011
Impaired Wound Healing in Diabetic Foot Ulceration

Conditions: Diabetes Mellitus; Healthy Volunteers
Intervention:
Sponsors: Beth Israel Deaconess Medical Center; Beth Israel Deaconess Medical Center; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified June 2011
Vitamin D, Insulin Resistance, and Cardiovascular Disease

Conditions: Vitamin D Deficiency; Insulin Resistance; Type 2 Diabetes Mellitus; Cardiovascular Disease; Hypertension
Interventions: Drug: Vitamin D3; Drug: Placebo
Sponsors: Washington University School of Medicine; Washington University School of Medicine; National Heart, Lung, and Blood Institute (NHLBI); American Diabetes Association
Recruiting - verified November 2011
Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: Kanglaite Injection plus gemcitabine; Drug: Gemcitabine
Sponsors: KangLaiTe USA; KangLaiTe USA
Recruiting - verified January 2012
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery

Condition: Pancreatic Cancer
Interventions: Biological: GVAX pancreatic cancer vaccine; Drug: cyclophosphamide
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer

Condition: Metastatic Pancreatic Cancer
Intervention: Drug: Ontak
Sponsors: Loyola University; Loyola University; Riveria Country Club Organization; Eisai Inc.
Recruiting - verified September 2011
Chronotherapy With Low-dose Aspirin for Primary Prevention

Condition: Type 2 Diabetes
Interventions: Drug: aspirin; Drug: aspirin
Sponsors: University of Vigo; University of Vigo
Recruiting - verified March 2012
Natural Killer Cells and Bortezomib to Treat Cancer

Conditions: Lung or Prostatic Neoplasms; Colorectal or Kidney Neoplasms; Pancreatic Neoplasms; Leukemia, Myelogenous, Chronic Lymphocytic Leukemia, BCR-ABL Positive; Melanoma; CLL
Intervention: Drug: NK cells +CliniMACs CD3 and CD56 systems
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2012
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer

Condition: Ovarian Neoplasms
Interventions: Drug: AMG 479; Drug: AMG 479 Placebo
Sponsors: Cancer International Research Group; Cancer International Research Group
Recruiting - verified March 2012
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Liver Cancer; Neuroblastoma; Ototoxicity; Ovarian Cancer; Sarcoma
Interventions: Drug: sodium thiosulfate; Procedure: examination
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
De Novo Lipogenesis, Lipid and Carbohydrate Metabolism in Non-alcoholic Fatty Liver Disease

Conditions: Non-alcoholic Fatty Liver Disease; Diabetes
Interventions: Other: Dietary intervention (calorie restricted diet); Other: Dietary intervention (calorie restricted diet)
Sponsors: University of California, San Francisco; University of California, San Francisco; Touro University; American Diabetes Association
Recruiting - verified April 2012
The Effect of TRA-8 on Ovarian Cancer Tissue

Condition: Ovarian Cancer
Intervention:
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham
Recruiting - verified July 2011
Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women

Condition: Polycystic Ovary Syndrome
Interventions: Drug: Orlistat (Alli) and Lifestyle Intervention with exercise and diet; Drug: Loestrin 1/20; Drug: Orlistat (Alli) and Loestrin 1/20
Sponsors: Penn State University; Penn State University; University of Pennsylvania
Recruiting - verified November 2011
Study on the Role of Decompression of Lower Extremity Nerves for the Treatment of Patients With Symptomatic Diabetic Neuropathy With Chronic Nerve Compression

Condition: Painful Diabetic Neuropathy
Intervention: Procedure: Nerve Decompression
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center
Recruiting - verified August 2011
Ovarian Dendritic Cell Vaccine Trial

Condition: Ovarian Cancer
Interventions: Biological: Ontak DC; Biological: DC vaccination; Drug: Ontak
Sponsors: Loyola University; Loyola University
Recruiting - verified September 2011
Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents.Intervention Trial

Conditions: Type 2 Diabetes Mellitus; Cardiovascular Disease
Interventions: Drug: add-on pioglitazone; Drug: add-on sulphonylurea
Sponsors: Italian Society of Diabetology; Italian Society of Diabetology; Associazione Medici Diabetologi (AMD); Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO)
Recruiting - verified August 2011
Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer

Condition: Ovarian Cancer
Intervention: Drug: flutamide
Sponsors: University of Arizona; University of Arizona; National Cancer Institute (NCI)
Recruiting - verified September 2010
International Pediatric Adrenocortical Tumor Registry

Condition: Adrenocortical Tumor
Intervention:
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified April 2012
Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: immunological adjuvant OPT-821; Biological: polyvalent antigen-KLH conjugate vaccine
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified July 2008
Efficacy Study of EUS-guided Ethanol Lavage With Paclitaxel Injection for Cystic Tumors of the Pancreas

Condition: Cystic Tumors of the Pancreas
Intervention: Procedure: Endoscopic ultrasonography-guided ethanol lavage with paclitaxel injection
Sponsors: Asan Medical Center; Asan Medical Center
Recruiting - verified February 2012
RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe

Conditions: Carcinoma; Neuroendocrine; Non Functioning Neuroendocrine Tumors/NET; Non Syndromic Neuroendocrine Tumors/NET; Carcinoids; Non Functioning
Intervention: Drug: Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified January 2012
Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study

Condition: Acromegaly
Intervention:
Sponsors: Ipsen; Ipsen
Recruiting - verified April 2012
Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors

Condition: Growth Hormone Deficiency
Interventions: Drug: Recombinant Human Growth Hormone; Drug: Recombinant human IGF-1
Sponsors: Columbia University; Columbia University; Tercica
Recruiting - verified January 2012
Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children

Conditions: Breast Cancer; Hereditary Breast/Ovarian Cancer (brca1, brca2)
Interventions: Other: counseling intervention; Other: educational intervention; Other: survey administration; Behavioral: psychosocial assessment and care; Behavioral: supportive care
Sponsors: Georgetown University; Georgetown University; National Cancer Institute (NCI); National Human Genome Research Institute (NHGRI)
Recruiting - verified October 2011
Substrate Metabolism and Insulin Sensitivity in Patients With Hyperprolactinemia Before and After Treatment

Conditions: Hyperprolactinemia; Insulin Resistance
Intervention: Other: Cabergoline
Sponsors: University of Aarhus; University of Aarhus; Aarhus University Hospital
Recruiting - verified March 2012
Proton Therapy for Unresectable Cancer (CA) of Pancreas

Condition: Pancreatic Cancer
Intervention: Other: Capecitabine, proton, Gemcitabine
Sponsors: University of Florida; University of Florida
Recruiting - verified March 2012
Improving the Care of Diabetic Patients: A Randomized Trial of a Family Physician Office-Based Chronic Disease Care Model for Patients With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Other: multidisciplinary approach; Other: multifactorial approach - for enhanced care group; Other: reflects current patterns of care
Sponsors: University of Alberta; University of Alberta; Alberta Heritage Foundation for Medical Research
Recruiting - verified November 2011
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy

Condition: Lipodystrophy
Intervention: Drug: metreleptin
Sponsors: Amylin Pharmaceuticals, Inc.; Amylin Pharmaceuticals, Inc.
Recruiting - verified March 2012
Vaccine Therapy and GM-CSF in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery

Condition: Pancreatic Cancer
Interventions: Biological: falimarev; Biological: inalimarev; Biological: sargramostim
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI)
Recruiting - verified August 2011
Sutent Adjunctive Treatment of Differentiated Thyroid Cancer

Conditions: Papillary Thyroid Cancer; Follicular Thyroid Cancer; Differentiated Thyroid Cancer
Intervention: Drug: SU011248, Sutent
Sponsors: Washington Hospital Center; Washington Hospital Center; Pfizer
Recruiting - verified April 2012
ChemoFx® PRO - A Post-Market Data Collection Study

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Uterine Neoplasms; Endometrial Cancer; Vaginal Cancer; Vulvar Cancer; Cervical Cancer; Lung Cancer; Carcinoid Tumor of Lung; Sarcoma of Lung; Mesothelioma; Colorectal Cancer
Intervention:
Sponsors: Precision Therapeutics; Precision Therapeutics
Recruiting - verified June 2011
Effects of Worksite Wellness Interventions on Vascular Function, Insulin Sensitivity and High-Density Lipoprotein in Overweight or Obese Women

Conditions: Atherosclerosis; Diabetes Mellitus; Obesity; Dyslipidemia; Hypertension
Interventions: Behavioral: Exercise; Behavioral: Weight Loss
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified November 2011
Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer

Conditions: brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer; Ovarian Cancer
Interventions: Drug: rucaparib (CO-338; formally AG-014699 or PF-01367338); Genetic: protein expression analysis; Genetic: western blotting; Other: immunohistochemistry staining method; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study
Sponsors: Cancer Research UK; Cancer Research UK
Recruiting - verified April 2012
Computer Tools for Improving Early Diagnosis and Treatment in Healthy Volunteers or Patients With Pancreatic Cancer or Who Are At Risk For Pancreatic Cancer or Who Have a Noncancer Pancreatic Disorder

Condition: Pancreatic Cancer
Interventions: Other: medical chart review; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: biopsy
Sponsors: University of Nebraska; University of Nebraska; National Cancer Institute (NCI)
Recruiting - verified June 2011
Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer

Condition: Adenocarcinoma of the Ovary
Intervention: Biological: OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine
Sponsors: AVAX Technologies; AVAX Technologies
Recruiting - verified January 2011
Probucol Combined With Valsartan in Reducing Proteinuria in Diabetes Nephropathy

Conditions: Type 2 Diabetes Mellitus; Nephropathy
Interventions: Drug: Valsartan; Drug: Placebo; Drug: Probucol
Sponsors: Guangdong General Hospital; Guangdong General Hospital
Recruiting - verified December 2011
Bone Health in Type 1 Diabetes

Conditions: Type 1 Diabetes; Osteoporosis
Intervention:
Sponsors: Creighton University; Creighton University
Recruiting - verified October 2011
Genetics and Markers of Degenerative and Inflammatory Eye Diseases

Conditions: Diabetic Retinopathy; Age-Related Macular Degeneration (AMD); Uveitis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Eye Institute (NEI)
Recruiting - verified January 2012
Substrate Metabolism and Insulin Sensitivity in Acromegalic Patients Before and After Treatment

Conditions: Acromegaly; Growth Hormone; Insulin Resistance
Intervention: Procedure: Transsphenoidal adenomectomy
Sponsors: University of Aarhus; University of Aarhus; Aarhus University Hospital
Recruiting - verified March 2012
Concurrent Chemo-radiotherapy With Capecitabine for Unresectable Locally Advanced Pancreatic Carcinoma

Condition: Pancreatic Cancer
Interventions: Drug: Capecitabine (Xeloda®); Radiation: Localization, simulation and immobilization
Sponsors: National Cancer Center, Korea; National Cancer Center, Korea
Recruiting - verified April 2012
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor

Conditions: Solid Tumor; Adult Central Nervous System Germ Cell Tumor; Adult Rhabdomyosarcoma; Childhood Central Nervous System Germ Cell Tumor; Childhood Soft Tissue Sarcoma; Ewing Sarcoma; Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Ovarian Mixed Germ Cell Tumor; Previously Untreated Childhood Rhabdomyosarcoma; Recurrent Adult Brain Tumor; Recurrent Adult Soft Tissue Sarcoma; Recurrent Childhood Brain Stem Glioma; Recurrent Childhood Cerebellar Astrocytoma; Recurrent Childhood Cerebral Astrocytoma; Recurrent Childhood Ependymoma; Recurrent Childhood Malignant Germ Cell Tumor; Recurrent Childhood Medulloblastoma; Recurrent Childhood Pineoblastoma; Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor; Recurrent Childhood Visual Pathway and Hypothalamic Glioma; Recurrent Childhood Visual Pathway Glioma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Extragonadal Germ Cell Tumor; Recurrent Extragonadal Non-seminomatous Germ Cell Tumor; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Neuroblastoma; Recurrent Ovarian Germ Cell Tumor; Recurrent Wilms Tumor and Other Childhood Kidney Tumors; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: busulfan; Drug: melphalan; Drug: topotecan hydrochloride; Other: laboratory biomarker analysis; Biological: filgrastim; Procedure: autologous hematopoietic stem cell transplantation; Other: pharmacological study; Procedure: autologous bone marrow transplantation
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified November 2011
Glycan Analysis in Diagnosing Cancer in Women With Ovarian Epithelial Cancer and in Healthy Female Participants

Condition: Ovarian Cancer
Intervention:
Sponsors: University of California, Davis; University of California, Davis; National Cancer Institute (NCI)
Recruiting - verified April 2012
Pazopanib in Treating Patients With Advanced Thyroid Cancer

Condition: Head and Neck Cancer
Interventions: Drug: pazopanib hydrochloride; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2011
Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study

Conditions: Epithelial Ovarian Cancer; Fallopian Tube Carcinoma
Intervention: Procedure: Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC)
Sponsors: Cantonal Hospital of St. Gallen; Cantonal Hospital of St. Gallen
Recruiting - verified June 2011
Combination Chemotherapy, Intensity-Modulated Radiation Therapy, and Surgery in Treating Patients With Localized Pancreatic Cancer That Can Be Removed By Surgery

Conditions: Adenocarcinoma of the Pancreas; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride; Drug: docetaxel; Drug: capecitabine; Radiation: intensity-modulated radiation therapy; Drug: oxaliplatin; Procedure: pancreatic surgical procedure; Procedure: therapeutic conventional surgery
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012
Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: Bevacizumab; Drug: Erlotinib; Drug: Capecitabine; Radiation: Radiation Therapy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genentech
Recruiting - verified May 2012
Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer

Condition: Thyroid Cancer
Intervention: Drug: Thyrogen combinated with continuing Liothyronine treatment
Sponsors: Copenhagen University Hospital at Herlev; Copenhagen University Hospital at Herlev; Odense University Hospital
Recruiting - verified June 2011
Trial of Rituximab for Graves' Ophthalmopathy

Condition: Thyroid-associated Ophthalmopathy
Interventions: Drug: Rituximab; Drug: IV saline
Sponsors: Mayo Clinic; Rebecca Bahn; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2012
Thyroid Disease Serum Repository

Condition: Thyroid Disease
Intervention:
Sponsors: University of Arkansas; University of Arkansas
Recruiting - verified February 2012
Pancreatic and Gastrointestinal Tumor Registry and Tissue Collection

Condition: Pancreatic Cancer
Intervention:
Sponsors: University of Alabama at Birmingham; Charles Mel Wilcox, MD; National Cancer Institute (NCI)
Recruiting - verified December 2011
Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract

Conditions: Esophageal Cancer; Bile Duct Neoplasms; Gastric Cancer; Liver Cancer; Melanoma; Pancreatic Cancer; Sarcoma
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Multicenter Trial On The Utility and Impact Of Computed Tomography and Serum CA-125 In the Management of Newly Diagnosed Ovarian Cancer

Condition: Ovarian Cancer
Intervention: Other: CA 125 and CT scan
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Johns Hopkins University; M.D. Anderson Cancer Center
Recruiting - verified January 2012
Spectroscopy With Surface Coils and Decoupling

Conditions: Adrenal Cortical Cancer; Brain Cancer; Breast Cancer; CNS Cancer; Colon Cancer; HEENT Cancer; Hodgkin's Disease; Kaposi's Sarcoma; Liver Cancer; Lung Cancer; Non-Hodgkin's Lymphoma; Ovarian Cancer; Pancreatic Cancer; Prostate Cancer; Rectal Cancer; Renal Cancer; Sarcoma; Squamous Cell Carcinoma; Thyroid Cancer
Interventions: Device: Proton-decoupled 31P MRS at 1.5T; Device: 1H Spectroscopy at 1.5T and 3T
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Columbia University; University of Pennsylvania; St.George's Hospital (England); Royal Marsden NHS Foundation Trust; University Medical Center Nijmegen; Weill Medical College of Cornell University
Recruiting - verified February 2012
An Initial Study of Lithium in Patients With Medullary Thyroid Cancer

Condition: Medullary Thyroid Cancer
Intervention: Drug: Lithium carbonate
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison
Recruiting - verified November 2011
Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers

Conditions: Breast Neoplasms; Ovarian Neoplasms; Colonic Neoplasms; Prostatic Neoplasms; Uterine Cervical Neoplasms; Leukemia; Lymphoma, Non-Hodgkin
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2012
Clinical Outcomes in Hereditary Cancer

Conditions: Breast Cancer; Pancreatic Cancer
Intervention: Other: Genotyping
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified November 2011
Analyzing the Composition of Tears to Identify Cancer

Conditions: Breast Cancer; Ovarian Cancer; Colon Cancer; Benign Disease
Intervention: Other: Tear collection
Sponsors: University of Arkansas; University of Arkansas; Tenenbaum Family Foundation
Recruiting - verified January 2012
Metabolic Causes of Thrombosis in Type 2 Diabetes - Question 4

Condition: Type 2 Diabetes
Intervention: Other: Hyperinsulinemic Hypoglycemic Clamp
Sponsors: University of Maryland; University of Maryland; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified July 2011
Prediction of Thyroid Cancer From Ultrasonographic Characteristics of Thyroid Nodules

Condition: Thyroid Nodule
Intervention: Procedure: Thyroid ultrasonography
Sponsors: Istanbul Science University; Istanbul Science University; Group Florence Nightingale
Recruiting - verified April 2012
Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival & Frozen Tissue Sample

Conditions: Breast Cancer; Stomach Neoplasms; Salivary Gland Neoplasms; Thyroid Cancer
Intervention:
Sponsors: Stanford University; Stanford University
Recruiting - verified April 2012
Nimotuzumab in Adults With Pancreatic Cancer

Condition: Pancreatic Cancer, Advanced or Metastatic
Intervention:
Sponsors: Oncoscience AG; Oncoscience AG; Marienhospital Herne, Abt. für Hämatologie und Onkologie, Herne, Germany; University of Kiel; Gemeinschaftspraxis für Hämatologie und Onkologie, Köln, Germany; Onkologisches Zentrum III, Medizinische Klinik, Mannheim, Germany; Onkologische Gemeinschaftspraxis, Mülheim, Germany; II. Medizinische Klinik u. Poliklinik, Klinikum rechts der Isar, München, Germany; Hämatologisch-Onkologische Schwerpunktpraxis, Münster, Germany; Praxis für Internistische Onkologie und Hämatologie, Recklinghausen, Germany
Recruiting - verified June 2011
VA NEPHRON-D: Diabetes iN Nephropathy Study

Conditions: Kidney Disease; Nephropathy; Type 2 Diabetes
Interventions: Drug: losartan; Drug: lisinopril; Drug: losartan
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2012
Follow-up Evaluation Using CT Scans in Patients Who Have Been Treated For Metastatic Testicular Cancer

Condition: Testicular Germ Cell Tumor
Interventions: Other: biomarker analysis; Procedure: computed tomography
Sponsors: National Cancer Institute (NCI); Royal Marsden NHS Foundation Trust
Recruiting - verified October 2007
Exercise Testing to Screen for Unknown Coronary Artery Disease in Diabetic Patients: Does it Contribute to a Risk Reduction in Very High Risk Patients?

Conditions: Coronary Artery Disease; Diabetes Mellitus
Intervention: Procedure: exercise testing - coronary angiography - revascularization
Sponsors: Azienda Unita' Sanitaria Locale Di Modena; Azienda Unita' Sanitaria Locale Di Modena
Recruiting - verified May 2010
Early Detection of Ovarian Cancer

Condition: Ovarian Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Accuracy of FDG-PET Scanning to Diagnose Malignant Thyroid Nodules

Condition: Thyroid Neoplasms
Intervention: Other: FDG-PET Scan
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified September 2011
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors and Multiple Myeloma

Conditions: Ovarian Cancer; Renal Cancer; Non-small Cell Lung Cancer; Small Cell Lung Cancer; Solid Tumors; Multiple Myeloma
Intervention: Drug: carfilzomib
Sponsors: Onyx Pharmaceuticals; Onyx Therapeutics, Inc.
Recruiting - verified July 2011
How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis

Conditions: Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Endothelial Cells; Vitamin D
Intervention: Drug: doxercalciferol
Sponsors: Duke University; Duke University; Genzyme
Recruiting - verified June 2011
Pancreatic Cancer Genetic Epidemiology (PACGENE) Study

Condition: Pancreatic Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
EBIS: The Eindhoven Breech Intervention Study

Conditions: Breech Presentation; External Cephalic Version; Thyroid Hormones; Stress, Psychological; Congenital Hip Dysplasia
Intervention:
Sponsors: Catharina Ziekenhuis Eindhoven; Catharina Ziekenhuis Eindhoven; University of Tilburg
Recruiting - verified October 2011
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

Conditions: Triple Negative Metastatic Breast Cancer; Advanced Ovarian Cancer; Carboplatin; Paclitaxel
Interventions: Drug: KU-0059436 (AZD2281)(PARP inhibitor); Drug: Carboplatin; Drug: KU-0059436 (AZD2281)(PARP inhibitor); Drug: Paclitaxel; Drug: KU-0059436 (AZD2281)(PARP inhibitor); Drug: Paclitaxel + Carboplatin
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified May 2012
Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer

Conditions: Multiple Endocrine Neoplasia Type 2A; Multiple Endocrine Neoplasia Type 2B
Intervention: Drug: ZACTIMA (Vandetanib)
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified December 2011
Quality of Life Associated With a Low-Risk Screening Program for Ovarian Cancer

Condition: Ovarian Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Detection and Treatment of Endocrine Abnormalities in Childhood Cancer Survivors

Conditions: Hypopituitarism; Hypogonadism; Thyroid Dysfunction; Bone Diseases, Metabolic
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified March 2012
Psychosocial Aspects of Multiple Endocrine Neoplasia (MEN) Syndromes

Condition: Multiple Endocrine Neoplasia
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified November 2011
Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery

Condition: Acromegaly
Intervention:
Sponsors: Ipsen; Ipsen
Recruiting - verified April 2012
Randomized Study Comparing the Effect of Plastic Stents to That of Expandable Metal Stents as Prior to Pancreaticoduodenectomy

Condition: Pancreas Cancer
Intervention: Procedure: Plastic and metalic stent inserion
Sponsors: Karolinska Institutet; Karolinska Institutet
Recruiting - verified September 2007
Preventing ESRD in Overt Nephropathy of Type 2 Diabetes

Condition: Diabetes
Interventions: Drug: Benazepril; Drug: Valsartan; Drug: Benazepril/Valsartan
Sponsors: Mario Negri Institute for Pharmacological Research; Mario Negri Institute for Pharmacological Research; Agenzia Italiana del Farmaco
Recruiting - verified June 2011
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders

Conditions: Hypogonadism; Kallmann Syndrome; Puberty, Delayed; Puberty, Precocious; Hypothalamic Amenorrhea; Anosmia; GnRH Deficiency
Intervention:
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified February 2012
Data Collection for Patients With Low Grade Ovarian Carcinoma

Conditions: Ovarian Cancer; Peritoneum Tumors
Intervention: Behavioral: Data Collection
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified December 2011
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: paclitaxel; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Medical Research Council
Recruiting - verified April 2012
Dry Eye in Women With Turner Syndrome and Women With Premature Ovarian Failure

Conditions: Turner Syndrome; Ovarian Failure, Premature; Sex Chromosome Aberrations; Menopause; Perimenopause
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Eye Institute (NEI)
Recruiting - verified October 2009
Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Conditions: Pancreatic Cancer; Thromboembolism
Interventions: Drug: dalteparin; Drug: gemcitabine hydrochloride; Other: diagnostic laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Hull and East Yorkshire Hospitals NHS Trust
Recruiting - verified April 2007
The Effect of a Diabetes Action Team in Patients Post Infrainguinal Bypass Surgery With and Without Diabetes

Conditions: Type 2 Diabetes; Peripheral Vascular Disease
Interventions: Behavioral: Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive standard diabetes care by their admitting physician; Behavioral: Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive diabetes care under the direction of the Diabetes Action Team; Behavioral: Subjects without diabetes will have their blood glucose levels monitored while in the hospital
Sponsors: University of British Columbia; University of British Columbia; Novo Nordisk
Recruiting - verified December 2011
Baselines in Reproductive Disorders

Conditions: Amenorrhea; Hypogonadotropic Hypogonadism; Kallmann's Syndrome
Intervention: Procedure: Frequent baseline blood sampling
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Institutes of Health (NIH)
Recruiting - verified April 2012
Effect of EGCG on the Body's Response to Insulin

Conditions: Hypertension; Obesity; Type 2 Diabetes; Insulin Resistance
Interventions: Drug: Dietary Supplement: epigallocatechin 3-gallate (EGCG); Procedure: hyperinsulinemic isoglycemic glucose clamp; Procedure: insulin-stimulated brachial artery blood flow; Procedure: assess capillary recruitment in forearm skeletal muscle
Sponsors: University of Maryland; University of Maryland; Office of Dietary Supplements (ODS); National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified December 2011
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors

Conditions: Childhood Germ Cell Tumor; Ovarian Cancer; Teratoma
Interventions: Drug: carboplatin; Drug: etoposide; Drug: ifosfamide; Drug: paclitaxel; Drug: thiotepa; Procedure: autologous hematopoietic stem cell transplantation; Drug: Mesna; Biological: filgrastim
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified January 2012
Metabolic Syndrome in PCOS: Precursors and Interventions

Conditions: Polycystic Ovary Syndrome; Metabolic Syndrome
Interventions: Drug: Metformin; Drug: flutamide; Drug: drospirenone; Other: placebo
Sponsors: Northwestern University; Northwestern University; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2012
Physical and Behavioral Traits of Overweight and Obese Adults

Conditions: Morbid Obesity; Diabetes Mellitus Type 2; Insulin Resistance; Obstructive Sleep Apnea; Mood Disorders
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified January 2012
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Conditions: Metastatic Breast Cancer; Advanced Breast Cancer; Gastrointestinal Stromal Tumor; Hepatocellular Carcinoma; Metastasizing Breast Cancer (F); Metastatic Castration-Resistant Prostrate Cancer; Metastatic Renal Cell Cancer; Non Small Cell Lung Cancer; Pancreatic Islet Cell Carcinoma
Intervention: Drug: sunitinib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Secondary Debulking Surgery +/- Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Procedure: Secondary debulking; Procedure: secondary debulking with intraperitoneal chemotherapy
Sponsors: The Netherlands Cancer Institute; The Netherlands Cancer Institute
Recruiting - verified April 2012
Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Biological: sargramostim; Biological: telomerase peptide vaccine GV1001; Drug: capecitabine; Drug: gemcitabine hydrochloride
Sponsors: National Cancer Institute (NCI); Royal Liverpool University Hospital
Recruiting - verified May 2009
An Imaging Pilot Study of 18F-fluoro-3'-Deoxy-3'-L-fluorothymidine (18F-FLT) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Who Will be Treated With Gemcitabine

Condition: Pancreatic Cancer
Intervention: Procedure: Positron-Emission Tomography (PET) 18F-FLT
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified March 2012
Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Conditions: Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: carcinoembryonic antigen-expressing measles virus; Biological: oncolytic measles virus encoding thyroidal sodium iodide symporter; Genetic: reverse transcriptase-polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified April 2012
Chemoradiation-Induced Nausea and Emesis: Quality of Life

Conditions: Gastric Cancer; Pancreatic Cancer; Cervical Cancer; Vulvar Cancer; Endometrial Cancer; Anal Cancer
Interventions: Behavioral: Interview; Other: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Merck
Recruiting - verified December 2011
HSCT for High Risk Inherited Inborn Errors

Conditions: Adrenoleukodystrophy; Metachromatic Leukodystrophy; Globoid Cell Leukodystrophy; Tay Sachs Disease; Sandhoffs Disease; Wolman Disease; I-Cell Disease; Sanfilippo Syndrome; GM1 Gangliosidosis
Interventions: Drug: Clofarabine; Procedure: Total body Irradiation; Drug: Melphalan
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified October 2011
Pulsatile GnRH in Anovulatory Infertility

Conditions: Hypogonadotropic Hypogonadism; Amenorrhea; Kallmann's Syndrome
Interventions: Drug: synthetic gonadotropin releasing hormone (GnRH); Device: Mini-infusion pump
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified April 2012
Androgen Effect on Klinefelter Syndrome Motor Outcome

Condition: Klinefelter Syndrome
Interventions: Drug: androgen oxandrolone; Other: placebo
Sponsors: Thomas Jefferson University; Thomas Jefferson University; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified July 2011
Scientific Protocol for the Study of Thyroid Cancer and Other Thyroid Disease in Belarus Following the Chernobyl Accident

Conditions: Thyroid Cancer; Thyroid Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012
Family Investigation of Nephropathy and Diabetes (F.I.N.D.)

Conditions: Nephropathy; Diabetes
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2012
Novel Diagnostics With Optical Coherence Tomography: Retinal Imaging

Conditions: Macular Degeneration; Glaucoma; Diabetic Retinopathy.
Intervention:
Sponsors: University of Pittsburgh; University of Pittsburgh
Recruiting - verified July 2011
Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor

Condition: Adrenocortical Carcinoma
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: mitotane; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011
Epidural Analgesia or Patient-Controlled Analgesia in Treating Patients Who Have Undergone Surgery for Gynecologic Cancer

Conditions: Cervical Cancer; Endometrial Cancer; Fallopian Tube Cancer; Ovarian Cancer; Pain; Perioperative/Postoperative Complications; Sarcoma
Interventions: Drug: fentanyl citrate; Drug: hydromorphone hydrochloride; Drug: ropivacaine hydrochloride
Sponsors: National Cancer Institute (NCI); University of California, San Francisco; National Cancer Institute (NCI)
Recruiting - verified September 2007
Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome

Condition: Turner Syndrome
Intervention: Drug: Somatropin
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012
Ghrelin Levels in Pancreatic Cancer Patients

Condition: Pancreatic Cancer
Intervention: Procedure: Blood draw
Sponsors: Dartmouth-Hitchcock Medical Center; Dartmouth-Hitchcock Medical Center
Recruiting - verified June 2010
Trial Comparing Care in Multiple Clinics Versus Care in a Cardiac, Diabetes and Kidney Care Clinic

Conditions: Kidney Diseases; Heart Diseases; Diabetes Mellitus
Intervention: Procedure: The Combined Cardiac Kidney Diabetes Care Clinic
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified February 2012
Interactive Studies of Endstage Diabetic Dialysis Patients

Condition: Diabetes
Interventions: Procedure: High Hemoglobin Concentration; Procedure: Low Hemoglobin Concentration
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified February 2012
Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs)

Condition: Pancreas Neoplasms
Intervention: Drug: celecoxib
Sponsors: Indiana University; Indiana University School of Medicine
Recruiting - verified March 2012
Randall's Plaque Study: Pathogenesis and Relationship to Nephrolithiasis

Conditions: Nephrocalcinosis; Renal Calculi; Hypercalciuria; Hyperparathyroidism; Cystinuria
Intervention: Other: videotape for mapping of renal anatomy and papillary biopsy
Sponsors: Indiana Kidney Stone Institute; Indiana Kidney Stone Institute; Indiana University School of Medicine; University of Chicago
Recruiting - verified April 2012
Adrenal Function in Critical Illness

Condition: Adrenal Insufficiency
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified March 2012
Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma

Conditions: Testicular Cancer; Germ Cell Neoplasm
Intervention: Drug: paclitaxel, gemcitabine, and oxaliplatin
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; Sanofi-Aventis
Recruiting - verified May 2012
Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia

Conditions: Growth Hormone Deficiency; Septo-Optic Dysplasia; Hypopituitarism
Intervention: Drug: Nutropin AQ
Sponsors: Children's Hospital Los Angeles; Children's Hospital Los Angeles; Genentech
Recruiting - verified February 2012
Nitric Oxide (NO) Activity and Diabetic Nephropathy

Condition: Diabetic Nephropathies
Intervention: Drug: Folic Acid
Sponsors: University of Erlangen-Nürnberg Medical School; University of Erlangen-Nürnberg Medical School
Recruiting - verified October 2011
Thyroid and Glucose and Energy Metabolism

Conditions: Thyroid Diseases; Thyroidectomy; Replacement Thyroid Hormone Therapy; Near Total Thyroidectomy
Interventions: Drug: Liothyronine (T3); Drug: Levothyroxine (T4)
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified January 2012
Hormonal Causes of Menstrual-Related Mood Disorders

Conditions: Mood Disorders; Premenstrual Syndrome; PMS; PMDD; Depression; Healthy
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Mental Health (NIMH)
Recruiting - verified September 2011
Surgery for Pancreatic Tumors and Collection of Tumor Tissue for Study

Condition: Pancreatic Neoplasms
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified December 2011
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Myelodysplastic Syndromes; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Disseminated Neuroblastoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; High Risk Metastatic Gestational Trophoblastic Tumor; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Previously Treated Childhood Rhabdomyosarcoma; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage II Ovarian Epithelial Cancer; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Malignant Testicular Germ Cell Tumor; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Ovarian Epithelial Cancer; Stage III Small Lymphocytic Lymphoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Breast Cancer; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Ovarian Epithelial Cancer; Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: pentostatin; Biological: therapeutic allogeneic lymphocytes; Drug: mycophenolate mofetil; Drug: cyclosporine
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Insulin Resistance Intervention After Stroke Trial

Conditions: Stroke; Myocardial Infarction; Diabetes
Interventions: Drug: pioglitazone; Drug: placebo
Sponsors: Yale University; Yale University; National Institute of Neurological Disorders and Stroke (NINDS); Takeda Pharmaceuticals North America, Inc.
Recruiting - verified August 2011
Cisplatin, Metronomic Low-Dose Interferon Alfa, Gemcitabine, and Fever-Range Whole-Body Hyperthermia in Treating Patients With Inoperable or Metastatic Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Biological: recombinant interferon alfa; Drug: cisplatin; Drug: gemcitabine hydrochloride; Procedure: hyperthermia treatment
Sponsors: National Cancer Institute (NCI); The University of Texas Health Science Center, Houston
Recruiting - verified December 2008
Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Procedure: adjuvant therapy; Procedure: conventional surgery; Procedure: neoadjuvant therapy
Sponsors: National Cancer Institute (NCI); Royal College of Obstetricians and Gynecologists
Recruiting - verified May 2007
Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Childhood Chronic Myelogenous Leukemia; Childhood Myelodysplastic Syndromes; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Ovarian Epithelial Cancer; Stage IV Small Lymphocytic Lymphoma
Intervention: Biological: therapeutic allogeneic lymphocytes
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities

Conditions: Healthy; Pituitary Disease; Thyroid Disease
Intervention: Drug: TRH (Thyrotropin Releasing Hormone)
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2012
Research Study in Patients With Advanced Epithelial Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Genetic: comparative genomic hybridization; Genetic: cytogenetic analysis; Genetic: gene rearrangement analysis; Genetic: microarray analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified March 2007
Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: ifosfamide; Procedure: hyperthermia treatment
Sponsors: National Cancer Institute (NCI); Ludwig-Maximilians - University of Munich
Recruiting - verified October 2002
Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer

Conditions: Breast Neoplasms; Ovarian Neoplasms
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011
Clinical Trial to Screen Participants Who Are at High Genetic Risk for Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Other: screening questionnaire administration; Procedure: study of high risk factors
Sponsors: National Cancer Institute (NCI); Massachusetts General Hospital; National Cancer Institute (NCI)
Recruiting - verified April 2008
Cause of Familial Testicular Cancer

Conditions: Testicular Neoplasms; Germinoma
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2011
Turner Syndrome: Genotype and Phenotype

Condition: Turner's Syndrome
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified February 2012
Paclitaxel in Treating Patients With Ovarian Stromal Cancer

Condition: Ovarian Cancer
Intervention: Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Endocrine Studies in Health and Disease

Condition: Endocrine Diseases
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified January 2012
Study of Adrenal Gland Tumors

Condition: Adrenal Gland Neoplasm
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified September 2011
Evaluation of Patients With Endocrine-Related Conditions

Conditions: Endocrine Disease; Glucose Intolerance; Hyperinsulinemia; Impaired Glucose Tolerance; Non Insulin Dependent Diabetes Mellitus; Obesity; Type II Diabetes Mellitus
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified November 2011
Carboplatin With or Without Thalidomide in Treating Patients With Ovarian Epithelial Cancer

Condition: Ovarian Cancer
Interventions: Drug: carboplatin; Drug: thalidomide
Sponsors: National Cancer Institute (NCI); Cancer Research UK
Recruiting - verified November 2011
The Treatment and Natural History of Acromegaly

Conditions: Acromegaly; Pituitary Neoplasm
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified March 2012
Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Children

Conditions: Autoimmune Disease; Congenital Adrenal Hyperplasia; Healthy; Mental Disorder Diagnosed in Childhood; Neurologic Manifestations
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Mental Health (NIMH)
Recruiting - verified September 2011
Evaluation of Women With Endocrine and Reproductive-Related Conditions

Conditions: Endocrine Disease; Infertility
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified June 2011
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders

Conditions: Abnormalities; Craniopharyngioma; Cushing's Syndrome; Endocrine Disease; Pituitary Neoplasm
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified June 2011
Studies of Inherited Diseases of Metabolism

Conditions: Hypercalcemia; Hyperparathyroidism; Multiple Endocrine Neoplasia
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified July 2011
Evaluation of Patients With Thyroid Disorders

Conditions: Hyperthyroidism; Hypothyroidism; Pituitary Neoplasm
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified January 2012
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex

Conditions: Cushing's Syndrome; Hereditary Neoplastic Syndrome; Lentigo; Neoplasm; Testicular Neoplasm
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified June 2011
Studies of Elevated Parathyroid Activity

Conditions: Hyperparathyroidism; Hypocalcemia; Hypoparathyroidism; Parathyroid Neoplasm
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified June 2011
Studies on Tumors of the Thyroid

Conditions: Neoplasm Metastasis; Thyroid Neoplasm; Thyroid Nodule
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified July 2011
Diagnosing and Treating Low Blood Sugar Levels

Conditions: Hypoglycemia; Insulinoma
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified April 2012
Evaluation and Intervention for the Effects of Osteogenesis Imperfecta

Conditions: Dwarfism; Osteogenesis Imperfecta
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified September 2011
Ovarian Follicle Function in Patients With Premature Ovarian Failure

Conditions: Amenorrhea; Hypoaldosteronism; Hypogonadism; Infertility; Premature Ovarian Failure
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified December 2011
Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: topotecan hydrochloride
Sponsors: National Cancer Institute (NCI); Rigshospitalet, Denmark
Recruiting - verified July 2002